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Abstract 
Glatiramer acetate (GA) is approved for the treatment of relapsing-remitting 
multiple sclerosis (MS), and can suppress experimental autoimmune encephalomyelitis 
(EAE), a murine model of human MS. GA treatment is associated with the induction of 
anti-inflammatory TH2 responses and with the antigen specific expansion of regulatory 
T cells that counteract or inhibit pathogenic events in MS and EAE. These T cell 
mediated mechanisms of protection are considered to be a result of modulation of antigen 
presenting cells (APCs) by GA, rather than direct effects on T cells. However, it is 
unknown if GA preferentially targets a specific APC subset or can act through multiple 
APCs in vivo. In addition, GA-modulated innate cells may also exhibit direct antigen 
non-specific suppression of autoreactive cells.  
One objective of this study was to identify the in vivo target cell population of GA 
and to assess the potential of the target cells to antigen non-specifically suppress immune 
responses. Fluorophor-labelled GA bound to monocytes after intravenous injections, 
suggesting that monocytes may be the primary target of GA in vivo. In addition, 
intravenous GA treatment enhanced the intrinsic ability of monocytes to suppress T cell 
proliferation, both in vitro and in vivo. The findings of this study therefore suggest that 
GA-induced monocytes may contribute to GA therapy through direct mechanisms of 
antigen non-specific T cell immunosuppression. 
A further objective of this work was to investigate the potential of an in vivo drug 
targeting approach. This approach was hypothesised to increase the uptake of GA by the 
target cells and substantially improve GA treatment through antigen specific mechanisms 
such as induction of TH2 or regulatory T cells. Targeting antigens to professional APCs 
with an anti-MHC class II antibody resulted in significantly enhanced T cell proliferation 
in vitro. However, no EAE suppression occurred when GA was targeted to MHC class II 
in vivo. In addition, targeting GA specifically to monocytes also failed to suppress EAE. 
These findings suggest that GA treatment may selectively modulate monocytes to 
enhance their ability to inhibit autoreactive T cells, which could be part of the mechanism 
by which GA ameliorates MS. Targeting GA to a specific cell type may not be a 
powerful approach to improve treatment, because increased proliferation of GA specific 
T cells is not sufficient for disease suppression, and conjugation to antibodies may 
functionally reduce GA to a mere antigen devoid of immunomodulatory capacity. 
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The main function of the immune system is to protect the host against harmful 
pathogens, through a combination of innate and adaptive immune responses. The innate 
immune system provides the first line of defence against pathogens. Innate immune 
responses occur rapidly, are not specific to a particular antigen and do not confer 
immunological memory. In contrast, adaptive immune responses are antigen specific and 
show delayed kinetics in comparison to innate immunity. In addition, adaptive immunity 
results in the generation of immunological memory, which confers improved and 
accelerated immune responses against subsequent challenges with the same pathogen. 
The ability to provide effective antigen specific adaptive immune responses 
requires a vast and diverse lymphocyte repertoire. One of the drawbacks of this 
lymphocyte diversity is the presence of self-reactive clones among lymphocytes. In 
normal conditions, self-reactivity is avoided by multiple mechanisms that maintain self-
tolerance. However, when one or several of these regulatory mechanisms fail, 
autoimmune disorders such as multiple sclerosis (MS) can develop. 
This general introduction will briefly summarise the innate and adaptive arms of 
the immune system, and review mechanisms of tolerance and development of 
autoimmunity. Probable causes, pathogenesis and current treatment of MS will be 
introduced, with particular focus on treatment with the current MS therapeutic glatiramer 
acetate (GA). 
 
1.1 Principles of Innate and Adaptive Immunity 
1.1.1 The Innate Immune System 
The innate immune system forms the first line of defence against invading 
pathogens. Components of the innate immune system include physical barriers such as 
the skin, mucosal surfaces and epithelia; chemical mediators such as complement, and a 
variety of immune cells with specialised functions (1). 
Cells of the innate immune system express pattern recognition receptors (PRRs) 
that recognise conserved structures on pathogens and trigger the initial cell-mediated 
innate response (1). The best-defined pattern recognition receptors are Toll-like receptors 
(TLRs), which recognise bacterial or viral components such as lipopolysaccharide (LPS) 
of the gram-negative bacterial cell wall or virus-derived double stranded RNA (2). TLR 
signalling results in the activation of transcription factors that promote the expression of 
CHAPTER 1: GENERAL INTRODUCTION 
 3 
inflammatory cytokines, chemokines or other inflammatory mediators that initiate an 
immediate innate immune response against the pathogen (2).  
An important cellular component of the innate immune system are phagocytes 
that can recognise pathogens through PRRs, followed by the internalisation and 
destruction of the pathogen. Monocytes and macrophages are mononuclear phagocytes 
that are found in the blood or tissue, respectively (3). Neutrophils are polymorphonuclear 
phagocytes that are found in the blood and tissue. In addition to phagocytosis, neutrophils 
also contribute to the elimination of pathogens through the release of cytotoxic granules 
and production of reactive oxygen species (ROS) (4). 
The complement system consists of a cascade of sequentially activated proteins 
(5). Complement promotes phagocytosis and lysis of pathogens through recruitment of 
macrophages and neutrophils. In addition, pathogens or infected host cells can be coated 
by complement proteins, which are then recognised by phagocytes, resulting the 
destruction of the target cells (5). 
In addition to directly attacking pathogens, some innate cells such as monocytes, 
macrophages or dendritic cells (DCs) can also act as antigen presenting cells (APCs) and 
induce adaptive immune responses (6). Priming of adaptive responses is facilitated by 
TLR triggering, which induces maturation of the APCs and renders them able to interact 
with components of the adaptive immune system in a productive manner (1). 
1.1.2 The Adaptive Immune System 
Adaptive immune responses can be sub-divided into humoral and cell-mediated 
responses. The main players in humoral immunity are B cells (7). B cells express cell-
surface immunoglobulins (or B cell receptors) that recognise three-dimensional structures 
of antigens on pathogens or pathogen components. This antigen recognition triggers the 
activation of B cells, which then differentiate into antibody producing plasma cells or 
memory B cells (7). Antibodies specifically bind to antigens, resulting in the formation of 
antigen-antibody complexes that can be recognised and eliminated by cells of the innate 
immune system (7). 
Cellular immunity is mediated by T cells, which express antigen specific T cell 
receptors (TCRs) and combat mostly intracellular pathogens (8). Circulating T cells can 
be activated by APCs in lymphoid organs and differentiate into effector T cells. Based on 
their effector function, T cells can be subdivided into cytotoxic T lymphocytes (CTL, 
also known as CD8 T cells) and T helper cells (TH cells or CD4 T cells). CD8 T cells can 
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eliminate intracellular pathogens by inducing apoptosis of infected host cells through 
granzymes or Fas-FasL interaction (8). CD4 T cells produce cytokines that can further 
enhance CTL responses or promote humoral immunity (9).  
CD8 T cells and CD4 T cells have common progenitors that migrate from the 
bone marrow to the thymus during their development (10). Differentiation of pre-T cells 
into mature T cells in the thymus involves the rearrangement of TCR subunits, which 
determines the antigen specificity of the T cells. Once the rearrangement is complete, a 
functional TCR is expressed on the cell surface, and the T cells can undergo selection and 
maturation to CD4 or CD8 T cells, before they egress from the thymus and enter the 
circulation (10). 
 
1.2 Antigen Presentation to T Cells 
The majority of circulating T cells are naïve cells that have not encountered 
antigen (11). In order to differentiate into effector T cells, they require to be activated by 
APCs. Immature APCs are recruited to sites of infection by chemokines such as 
monocyte chemoattractant protein-1 (MCP-1) or chemokine (C-C motif) ligand 20 
(CCL20) that are produced by resident cells in response to the infection (12). Recruited 
APCs acquire antigen at the infection site and migrate to secondary lymphoid organs, 
such as lymph nodes or the spleen, where they present antigen to T cells (11). 
Concurrently with their migration, the APCs undergo phenotypic maturation, a process 
that is initiated by the activation of TLR signalling pathways by microbial compounds at 
the site of infection (1). 
APCs possess two major mechanisms of antigen presentation (6). Antigens 
derived from intracellular bacteria or viruses are presented on major histocompatibility 
complex (MHC) class I molecules, whereas antigens derived from pathogens that reside 
in the extracellular space or within vesicular compartments are presented on MHC 
class II molecules (13). This dichotomy ensures that the immune system can mount 
appropriate responses to pathogens replicating in different intracellular or extracellular 
compartments. 
The MHC class I (MHCI) antigen presentation pathway acquires antigenic 
peptides within the APC (6). This pathway involves the degradation of pathogen-derived 
proteins by cytosolic proteasome complexes and the subsequent transport of peptides into 
the endoplasmic reticulum (ER), where they are loaded onto newly synthesised MHCI 
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molecules (6). Peptide-loaded MHCI molecules are transported to the cell surface, where 
they can be recognised by TCRs on CD8 T cells. In presence of additional APC-derived 
co-stimulatory signals, TCR triggering results in the proliferation of the CD8 T cells and 
their differentiation into cytotoxic T cells (8). 
The majority of pathogenic bacteria replicate in the extracellular space of their 
host. Antigens derived from these bacteria are not accessible to the MHCI pathway, and 
the immune system requires alternative means of presenting this type of antigens to T 
cells. APCs sample their environment for extracellular antigens, process and present 
these antigens on MHCII molecules (13). Peptide-MHCII complexes (pMHCII) are 
recognised by specific TCRs on CD4 T cells. In presence of appropriate co-stimulation, 
recognition of antigen results in the activation of CD4 T cells, which then differentiate 
into functional TH cells (11). 
 
1.3 Activation of CD4 T Cells 
Each naïve T cell bears about 30,000 identical TCRs on its surface (11). The core 
of each one of these TCRs consists of two polypeptide chains with highly variable 
regions termed TCR-α and TCR-β (14). The TCR-αβ heterodimer is associated with 
invariant accessory molecules, such as the CD3 complex and the TCR-ζ chain. Both the 
TCR-α and the TCR-β chains have an N-terminal variable (V) region, which form a 
single antigen binding site upon dimerisation (15). In addition, both chains have an 
extracellular constant (C) region for association with CD3, a hinge region that is 
responsible for dimerisation, a hydrophobic transmembrane domain and a short 
cytoplasmic tail (14).  
TCRs on CD4 T cells respond to short contiguous peptides that are displayed on 
MHCII molecules on APCs in secondary lymphoid organs (11). For an efficient 
interaction with the APC to occur, the TCR is required to bind to both MHCII itself and 
the presented peptide. Upon recognition of a pMHCII complex, cytoplasmic domains of 
CD3 and the TCR-ζ chain become phosphorylated (16). This phosphorylation initiates 
signalling cascades that lead to the activation of transcription factors and altered gene 
expression, resulting in the overall activation of the T cell. CD4 is a co-receptor that is 
expressed on cells that recognise pMHCII complexes (CD4 T cells). Both the TCR and 
CD4 are required to interact with pMHCII for efficient activation of the T cell (11).  
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In addition, a co-stimulatory signal is required for optimal activation of naïve T 
cells (11). This co-stimulatory signal must come from the same APC that is presenting 
antigen, and is delivered by either B7.1 (CD80) or B7.2 (CD86) (11). These two 
structurally related glycoproteins are exclusively expressed on professional APCs, and 
interact with CD28 on the surface of T cells. Hence, signals through the TCR itself, 
through CD4 and through CD28 are required to act in concert for optimal activation of 
CD4 T cells (11). 
TCR signalling is not an all-or-nothing process, and can rather deliver signals of 
varying quality. Signalling through TCRs can trigger the production of different 
cytokines and the acquisition of distinct effector functions by the T cell, depending on the 
type, strength and frequency of the signal as well as the nature of co-stimulation (17). 
These variables also depend on the environment in which T cell stimulation occurs; for 
instance the presence of pro- or anti-inflammatory cytokines or the type of co-stimulatory 
molecules expressed by the APCs (17). 
Activation of T cells is followed by the process of clonal expansion, during which 
T cells proliferate and gradually acquire properties that distinguish them as effector T 
cells (TH cells in case of CD4 T cells). Once differentiated into functional TH cells, they 
can exert effector function through recognition of cognate pMHCII without further need 
for co-stimulation (11).  
 
1.4 CD4 T Cell Differentiation 
During clonal expansion, the pathway of differentiation of CD4 T cells is 
determined by the local cytokine environment, the type of co-stimulation and the nature 
of the pMHCII ligand (9). Hence, innate cells that present antigen, provide co-stimulation 
and produce cytokines play an important role in T cell differentiation into TH cell subsets.  
Initially two different effector phenotypes of CD4 T cells were proposed (18). 
These were distinguished on the basis of their cytokine production patterns, where TH1 
cells produce interferon-γ (IFN-γ) and promote inflammation and cell-mediated 
immunity; and TH2 cells produce interleukin-4 (IL-4), and are responsible for 
orchestrating the clearance of helminths and other extracellular pathogens by enhancing 
humoral immunity (17). Recently, a third subset of CD4 T cells has been discovered. 
This subset has been termed TH17 based on its prominent IL-17 production, and mediates 
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the clearance of certain classes of pathogens that cannot be effectively dealt with by TH1 
or TH2 cells. (19).  
Cytokines are the most important factors that drive the differentiation of naïve 
CD4 T cells into effector cells. Macrophages, monocytes and DCs secrete IL-12 in 
response to TLR stimulation, and IL-12 is the major cytokine that promotes TH1 cell 
differentiation (9, 20). TH1 cells can activate macrophages through the production of 
IFN-γ, which in turn destroy microbes through ROS production or phagocytosis (3). In 
addition, IFN-γ promotes the activation of CD8 T cells into active cytotoxic T cells that 
eliminate intracellular pathogens (8). TH1 responses are accompanied by severe 
inflammation, and often result in tissue damage, which stems from the toxic side effects 
of cytokines and other inflammatory mediators released during the immune attack on the 
pathogen (17).  
Development of TH2 cells is commonly considered to be regulated by IL-4 (20). 
TH2 cells are also characterised by a pronounced production of IL-4, and additional TH2 
cytokines are IL-5, IL-10 and IL-13 (20). These cytokines are critically involved in 
initiating and regulating immunity against extracellular pathogens, by stimulation of B 
cells to produce neutralising antibodies (9). TH2 cytokines also have anti-inflammatory 
functions, such as blocking IFN-γ induced macrophage activation (17). Hence, activation 
of TH2 cells results in the containment of acute and chronic inflammation and limits 
tissue damage. 
IL-6 and transforming growth factor-β (TGF-β) are the major cytokines that 
induce differentiation of TH17 cells (21). TH17 mediated immunity is considered to serve 
as a means to clear pathogens that cannot be effectively challenged by the other TH cell 
subsets (19). A pathogenic role of TH17 cells and associated cytokines is also implicated 
in autoimmune diseases in both experimental animals and humans (21).  
 
1.5 Tolerance 
An important feature of the immune system is its ability to distinguish between 
self and non-self, so that immune responses are mounted only against foreign antigens 
(10). The term tolerance refers to the multiplicity of mechanisms that the immune system 
uses to eliminate or contain cells that are potentially self-reactive (22). Central tolerance 
refers to the events that delete potential self-reactive lymphocytes during their 
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development in the bone marrow and the thymus. Peripheral tolerance involves the 
elimination or suppression of mature self-reactive lymphocytes in secondary lymphoid 
organs or peripheral tissue (22). 
1.5.1 Central Tolerance 
Central T cell tolerance involves the elimination of potentially self-reactive T 
cells and takes place in the thymus (22). Developing T cells (thymocytes) encounter 
endogenous pMHC complexes, and the affinity of their TCR to these complexes 
determines the fate of the thymocyte. Thymocytes that fail to recognise pMHC 
complexes do not mature and die within the thymus (10). By this way it is guaranteed 
that thymocytes that cannot recognise self-MHC molecules do not mature, as they would 
have no function in the periphery.  
Thymocytes that express TCRs with low affinity to self-peptide-MHC complexes 
undergo positive selection in the thymic cortex; they mature and egress to the periphery 
(22). Positive selection of cells that recognise self-MHC molecules also enriches the 
thymocyte pool for cells that are potentially self-reactive, i.e. in addition to self-MHC 
also recognise self-peptides. However, thymocytes with high affinity to self-pMHC 
complexes are deleted through induction of apoptosis in the thymic medulla (10). By this 
mechanism of negative selection, the immune system prevents these cells from reaching 
the periphery where they could become activated by APCs presenting self-peptides and 
cause damage to host tissue. 
Efficient negative selection is ensured by the promiscuous expression of 
peripheral antigens by epithelial cells in the thymic medulla (22). Many antigens that are 
otherwise restricted to certain tissues are also expressed in the thymus. This ensures that 
T cells specific for these tissue-specific antigens do not mature. However, not all tissue 
specific antigens are expressed in the thymus. Hence, although central tolerance 
mechanisms are highly effective, they cannot eliminate all potentially self-reactive 
lymphocytes (22).  
1.5.2 Peripheral Tolerance 
The fact that few people develop autoimmune disorders in spite of incomplete 
deletion of autoreactive cells by central tolerance mechanisms indicates that additional 
mechanisms of tolerance exist. Autoreactive cells that evade central tolerance are 
controlled by mechanisms collectively known as peripheral tolerance. Peripheral 
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tolerance mechanisms include anergy, ignorance and suppression of autoreactive cells 
(23). 
T cells that have low affinity to self-pMHCII complexes escape deletion in the 
thymus. However, these cells do not become activated when they encounter antigen. 
Instead, a state of antigen specific unresponsiveness, called anergy, is induced (23). This 
mechanism likely plays an important role in the development of tolerance to 
autoantigens, because many ubiquitous self-antigens are continuously presented to T cells 
(23). However, T cell anergy can be overcome when the T cells encounter antigen 
presented by APCs that express high levels of co-stimulatory factors as a result of 
infection, resulting in activation of the T cell and self-directed immune responses (23). 
An additional mechanism of peripheral tolerance is the presence of physical 
barriers between T cells and cognate antigen that can maintain a state of ignorance to 
self-antigens (24). For example, tissue-specific antigens that are only expressed in the 
central nervous system (CNS) are shielded from lymphocytes by the blood-brain barrier 
(BBB), which prevents entry of immune cells into the CNS (24). However, if the physical 
barrier is disrupted and becomes permeable to autoreactive cells, these self-antigens can 
become targets of autoimmune responses (25).  
Specialised T cells with the ability to suppress immune responses can regulate the 
activity of autoreactive cells. Principal among these suppressive cells are a population of 
CD4+ CD25+ regulatory T cells (T-regs) (26). T-regs can be identified in mice by the 
expression of the transcription factor Foxp3, a key regulator of T-reg development, 
maintenance and function (26). 
T-regs may suppress autoreactive cells through secretion of inhibitory cytokines 
such as IL-10 and TGF-β, secretion of pro-apoptotic factors such as granzymes, 
impairment of T cell stimulation by modulation of DCs; or consummation of IL-2, a 
survival factor of activated T cells, through high level expression of CD25 (IL-2 receptor 
α chain) (27). The importance of T-regs in maintaining tolerance is clearly demonstrated 
by the development of severe autoimmunity by both mice and humans that lack 
functional Foxp3 (26). 
Multiple central and peripheral tolerance mechanisms are required to act in 
concert to prevent immune responses to self-antigens without diminishing the ability of 
the immune system to mount efficient responses against pathogens. Failure of one or 
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several of these tolerance mechanisms can result in the initiation of self-directed immune 
responses and the development of autoimmune disorders. 
 
1.6 Autoimmunity 
Autoimmune responses resemble normal immune responses to non-self antigens, 
with the exception that they are specific for antigens expressed by the host, or 
autoantigens (25). Differences between some foreign antigens and autoantigens can be 
subtle; hence lymphocytes that recognise pathogen-derived antigens can also be reactive 
to autoantigens (10). 
The most common autoimmune diseases are thought to arise from specific 
activation of self-reactive lymphocytes by autoantigens, or by foreign antigens that 
closely resemble autoantigens. However, the antigens that incite autoimmunity are 
difficult to identify, due to the spontaneous nature of most autoimmune disorders. The 
study of autoantibodies and specificity of self-reactive T cells provides a means to 
identify target antigens of autoimmune responses (28).  
Immune responses to pathogens generally cease after the elimination of the 
pathogen. However, this pattern of resolution does not apply to autoimmune disorders, 
due to the vast excess and continuous synthesis of autoantigens (10). Hence, autoimmune 
diseases tend to develop into a chronic condition, accompanied by inflammation and 
tissue damage (25). As a result, more autoantigens are released, and additional 
autoantigens may become targets of immune responses, a phenomenon termed epitope 
spreading (28). Hence, autoimmune diseases cannot be cured or reversed once they are 
established. 
Two major patterns of autoimmune diseases can be distinguished. In systemic 
autoimmune disorders, immune responses are directed to ubiquitous autoantigens; for 
example in systemic lupus erythematosus, immune responses are directed against 
chromatin or the spliceosome complex (29). In contrast, in organ-specific autoimmune 
diseases, immune attack is directed against particular host organs or tissues. Examples of 
organ-specific autoimmunity are insulin-dependent diabetes mellitus or multiple 
sclerosis, in which immune responses target β cells in pancreatic islets or the myelin 
sheath that isolates nerve fibres in the CNS, respectively (25, 30). 
 
CHAPTER 1: GENERAL INTRODUCTION 
 11 
1.7 Multiple Sclerosis 
Multiple sclerosis (MS) is an inflammatory disease of the CNS white matter, 
characterised by infiltration of the CNS by T lymphocytes and macrophages, 
demyelination and axonal damage (31). Destruction of CNS tissue results in neurological 
deficits such as sensory loss, limb weakness, incontinence, cognitive defects and 
paralysis (32). MS has complex genetic determinants of susceptibility, and contribution 
of infectious agents to disease initiation or progression is also possible (33). 
1.7.1 Statistics and Epidemiology 
MS typically manifests between the ages of 20 and 40. It is more common in 
females than in males and estimated to affect 2.5 million people worldwide (25) and 
about one in 1000 people in New Zealand1. The prevalence of MS is significantly higher 
in populations in high latitudes such as in Europe and Australasia (33). However, MS is 
much less common among Maori people in New Zealand than among New Zealanders of 
European origin (34), indicating that the genetic background, rather than the geographic 
location, may be the determinant of susceptibility. 
The contribution of genetic determinants to disease susceptibility is illustrated by 
the fact that monozygotic twins have a concordance rate of 25-30% to develop MS, 
compared to only 3-5% in dizygotic twins and non-twin siblings (35). To date, HLA-DR2 
is the only locus that is linked to MS with certainty. However, the inheritance pattern of 
MS resembles those of polygenic diseases, and other loci may also contribute to 
susceptibility. Genetic factors account only in part for disease susceptibility, since 
monozygotic twins remain 70-75% discordant (35), suggesting that both genetic 
determinants and environmental factors play a role in the development of MS.  
The clinical course of MS is generally categorised as being either relapsing-
remitting (RRMS) or primary progressive (PPMS). RRMS is the disease type present in 
85-90% of total MS patients, and is characterised by a series of attacks that result in 
varying degrees of disability from which patients recover partly or completely, usually 
followed by a remission period of variable duration before another attack (32). The 
course of disease in about 40% of RRMS patients ultimately changes to a progressive 
form known as secondary-progressive MS (SPMS, ref. (31)). Progressive forms of the 
disease lack acute attacks, but rather involve a gradual clinical decline. An additional 
                                                
1 The Multiple Sclerosis Society of New Zealand (MSSNZ), http://www.msnz.org.nz/ 
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form, chronic relapsing MS, is characterised by a progressive disease course from onset 
with occasional relapses later in disease (35). 
The prognosis of MS is widely variable. On average, patients require unilateral 
assistance in ambulation fifteen years after diagnosis without treatment. At the same time, 
10-15% of patients even require a wheelchair, whereas 20-25% of the patients are 
unrestricted in their ambulance (35).  
It is known that both genetic and environmental factors contribute to MS 
susceptibility, but the disease-initiating event is unclear. Some infectious agents like 
Epstein-Barr virus, human herpes virus 6 or Chlamydia pneumoniae have been suggested 
to be involved in the onset of MS, but evidence for a causative link between infectious 
agents and MS is currently lacking (35). Investigating the cause of MS is particularly 
challenging, because disease is artificially induced in experimental models of MS (36). 
Therefore, even though these models are valuable for investigating immunological 
mechanisms, they cannot serve as a platform for studying possible causes of MS. 
1.7.2 Murine EAE as a Model of Human MS 
Experimental autoimmune encephalomyelitis (EAE, also known as experimental 
allergic encephalomyelitis) is a disease model of the immune system responding to 
priming with CNS-restricted self-antigens, that resembles human MS (36). Initial studies 
were carried out by Louis Pasteur and Thomas M. Rivers in the early 20th century on 
rabbits. Since then, EAE has been replicated in a range of species, including guinea pigs, 
mice, rats, pigs, dogs, sheep and primates (37).  
Susceptibility to EAE is variable among species, strains or even commercial 
sources of the animals. For instance, generally mice are more resistant to EAE than rats 
(37). In addition, some mouse strains are resistant to EAE induction (such as BALB/c), 
whereas some other strains (such as C57BL/6J) are susceptible (37). 
Two different types of EAE are distinguished: active EAE and passive EAE. 
Active EAE is induced by immunisation with homogenised CNS tissue or purified 
myelin components such as myelin basic protein (MBP), myelin oligodendrocyte 
glycoprotein (MOG) or proteolipid protein (PLP) emulsified in Complete Freund’s 
Adjuvant (CFA) (37). CFA is an emulsion that contains heat-killed Mycobacterium 
tuberculosis and paraffin oil, and ensures the gradual and constant release of the 
encephalitogenic peptides. The addition of mycobacteria amplifies the immune response 
by antigen non-specific immune stimulation through PRRs, and is required for 
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overcoming peripheral tolerance and the initiation of autoimmunity (37). In addition, 
injection of pertussis toxin is also required for the development of clinical EAE in mice 
(37).  
Passive EAE is induced by the adoptive transfer of myelin-reactive CD4 T cells 
from immunised animals into naïve recipients (37). Under these conditions, EAE 
develops more quickly, is less variable and injection of mycobacteria into the recipients is 
avoided. However, the generation of myelin-reactive T cell clones requires time-
consuming ex vivo restimulation with antigen (37).  
EAE models have several genetic, immunological and histopathological features 
common to MS. For instance, genetic susceptibility to MS is associated with the MHC, as 
is susceptibility to EAE in mice (38, 39). The major pathological features common in 
both mice and humans include the destruction of the myelin sheath that isolates nerve 
fibres with limited damage to the fibres themselves and the presence of multiple CNS 
lesions (36).  
Immunologically, both EAE and MS are considered to be TH1 mediated diseases 
(25). In addition, TH17 cells contribute substantially to disease pathogenesis, certainly in 
EAE and probably in MS (19, 40). TH1/TH17 cells infiltrate the CNS, and recruit and/or 
activate additional cell types like CD8 T cells, macrophages or neutrophils. These 
recruited cells are the main causes of CNS tissue damage in both EAE and MS (38).  
EAE models have proven very valuable because they are rapid in vivo models that 
exhibit many of the features of human MS (38). Therefore EAE models can be used to 
investigate whether the mechanism of action of a particular drug is likely to translate into 
a treatment for the human disease. The value of EAE is demonstrated by several drugs 
that were developed in EAE models and have either been approved or have shown 
promise in clinical trials for MS treatment, such as glatiramer acetate (GA) and 
mitoxantrone (41, 42).  
An obvious limitation of the murine EAE model is the lack of diversity in mouse 
strains as opposed to outbred human populations, which makes it difficult to estimate the 
proportion of responder patients in clinical trials based on data from mouse studies (38). 
MS is a disease with great heterogeneity in clinical manifestation and extent of disability, 
and this heterogeneity cannot be reproduced in EAE. In addition, MS treatment is often 
initiated at times of long-established disease, whereas EAE treatment is usually 
commenced concomitantly with disease induction or directly after the onset of disease. 
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Hence the immunological and pathological prerequisites at the time of EAE treatment 
cannot be readily extrapolated to the situation in MS patients (38).  
EAE is the first identified and best-characterised animal model of human 
autoimmune disease (36). It resembles human MS in several immunological and 
pathophysiological features. Despite its limitations, EAE offers great overall value for the 
study of demyelinating autoimmune disease, and has a strong track record in the 
development of drugs that are currently in clinical use for MS treatment (38). 
1.7.3 Pathogenesis of MS and EAE 
The immunopathogenesis of MS is characterised by an autoimmune attack against 
components of the oligodendrocyte myelin sheath that isolates axons in the CNS (25). 
Inflammation is initiated by the activation of myelin-specific T cells in the periphery, 
which subsequently infiltrate the CNS through the permeated BBB and recruit other types 
of inflammatory cells. These recruited cells are responsible for the destruction of the 
oligodendrocyte myelin sheath and damage to the axons (25). 
Under normal conditions, T cells specific for autoantigens are anergised or 
suppressed by peripheral tolerance mechanisms (10). In MS, tolerance is overcome and 
myelin-specific CD4 T cells become activated in the periphery by an as yet unknown 
mechanism (28). In EAE, self-reactive T cells are activated by APCs presenting 
artificially introduced myelin antigens. These APCs express high levels of co-stimulatory 
molecules that enable them to induce immunity to the myelin antigens, rather than 
tolerance (31). This mature APC phenotype is a consequence of TLR stimulation through 
bacterial components that are contained in CFA (36).  
Concurrently with their activation by APCs, CD4 T cells differentiate into pro-
inflammatory TH cells (38). IFN-γ producing TH1 cells were previously believed to be the 
main lymphocyte subset involved in the initiation of MS and EAE. However, recent 
studies have demonstrated that TH17 cells likely play a substantial role in the 
development of EAE as well (43). In addition, IL-17 expression is elevated in the CSF of 
MS patients (43), suggesting that TH17 cells may also be involved in the pathogenesis of 
the human disease.  
Mice that lack IL-17 are partially resistant to EAE, whereas IFN-γ deficient mice 
show exacerbated EAE (44, 45). However, pure populations of IL-17 producing TH17 
cells cannot induce passive EAE, whereas IFN-γ secreting TH1 populations can (46). In 
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EAE, TH1 and TH17 cells are differentially stimulated by different encephalitogenic 
peptides, and adoptively transferred CD4 T cells induce different forms of EAE, 
depending on the TH1:TH17 ratio in the transferred population (47). Hence, regulation of 
CNS autoimmunity by TH1 and TH17 cells is complex, and both subsets probably 
contribute to the initiation and progression of EAE. 
Activated myelin-specific CD4 T cells (probably both TH1 and TH17) are able to 
penetrate the BBB and enter the CNS. Increased expression of cell adhesion molecules on 
endothelial cells adjacent to CNS lesions is well documented in both MS and EAE (31). 
Activated CD4 T cells can bind to these adhesion molecules and extravasate through the 
endothelium. Activated CD4 T cells also produce matrix metalloproteases (MMPs) that 
promote the breakdown of the BBB by degrading type IV collagen, the main component 
of the basement lamina (31, 48). Blockage of selected endothelial adhesion molecules 
(such as activated leukocyte cell adhesion molecule (ALCAM) or very late antigen-4 
(VLA-4)), as well as MMPs (such as MMP9) can reduce severity and delay the onset of 
EAE (25, 49), suggesting that permeation of the BBB to allow entry of CD4 T cells into 
the CNS is a key event in the pathogenesis.  
Inflammatory CD4 T cells infiltrate the CNS and recognise myelin antigens that 
are presented by CNS resident APCs such as microglia (50). Recognition of antigen 
reactivates the CD4 T cells and stimulates them to produce inflammatory mediators such 
as cytokines, chemokines or MMPs (51). While increased levels of MMPs further 
promote BBB breakdown, chemokines and cytokines recruit and activate additional 
inflammatory cell types, such as CD8 T cells, B cells, neutrophils or macrophages (25, 
31). These recruited cells cause damage to CNS tissue through a number of different 
mechanisms (25). 
 CD4 T cells are crucial for the initiation of both MS and EAE (25), but their role 
in the effector phase of the diseases is probably limited to the recruitment of other 
inflammatory cell types. CD8 T cells are the main T cell population that are found in 
active MS lesions, and adoptive transfer of activated myelin-specific CD8 T cells can 
induce passive EAE (25). CD8 T cells contribute to destruction of the myelin sheath and 
axonal damage directly through their cytotoxic granules or by receptor-mediated 
induction of apoptosis, for instance through Fas-FasL interaction (25).  
 In addition to CD8 T cells, disease severity of both MS and EAE correlates with 
CNS-infiltrating macrophages (52). Macrophages can amplify the local inflammatory 
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response by presenting antigens to T cells (25). Moreover, activated macrophages 
directly cause tissue damage through production of MMPs, ROS or nitric oxide (NO). 
Free radicals like ROS and NO cause pronounced cytotoxicity during CNS inflammation 
in both MS and EAE (25).  
Macrophages and CD8 T cells are important contributors to tissue damage in both 
EAE and MS. In addition, autoantibodies that are produced by activated B cells and 
neutrophil-derived cytotoxic intermediates such as NO (25) also cause demyelination in 
EAE and may contribute to tissue damage in MS (50). Hence, a number of different cell 
types cause demyelination and axonal damage through different mechanisms, but disease 
initiation requires the activation of myelin specific CD4 T cells (25).  
In early stages of MS, autoreactive CD4 T cells are likely to be restricted in 
specificity to one or few self-antigens. In later stages, T cells specific for an increasing 
number of myelin antigens become activated, and this epitope spreading is also observed 
in EAE (28). Even though EAE is usually induced by immunisation with a single myelin 
protein epitope, T cells reactive to other epitopes of the same protein become activated, 
followed by T cell activation to other myelin proteins (28). 
Autoimmune responses can only be triggered when mechanisms of tolerance fail. 
Antigen specific anergy or regulatory T cells normally inhibit self-specific T cells in 
circulation. In mice, Foxp3+ T-regs are essential for the prevention of spontaneous 
autoimmune responses (53), and adoptive transfer of CD25+ cells can inhibit active EAE. 
In contrast, depletion of CD25+ cells results in exacerbation of disease (54). There is no 
numerical deficiency in T-regs in MS patients compared to healthy controls, but T-regs 
from MS patients show impaired ability to suppress proliferation of responder T cells 
(53). Therefore, impaired T-reg function probably contributes to the development of MS. 
 In summary, immunological events that promote pathogenesis of EAE and MS 
include the activation of myelin-specific TH1 and TH17 cells in the periphery, which is 
rendered possible by deficient peripheral tolerance mechanisms. The myelin-specific 
cells then transmigrate through the permeated BBB and become reactivated in the CNS. 
Upon reactivation, the TH1/TH17 cells produce inflammatory cytokines and chemotactic 
factors that potentiate local inflammation and recruit additional inflammatory cell types. 
Among these recruited cells, mainly CD8 T cells and macrophages are responsible for the 
damage to CNS tissue. 
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1.7.4 Current MS Treatment 
The cornerstone of current management of RRMS is the acute treatment of 
relapses with corticosteroids (CS) and long-term treatment with disease-modifying agents 
such as β-interferons (IFN-β) or glatiramer acetate (GA). Second-line treatment in non-
responders include more aggressive agents including natalizumab and mitoxantrone, and 
trials with combinations of disease-modifying drugs are ongoing (55).  
CS are a class of steroid hormones that have strong anti-inflammatory properties. 
High dose short-term oral or parenteral CS therapy is in common use for the treatment of 
acute exacerbations of inflammatory diseases (56). This therapy provides symptomatic 
relief, improves motor function and accelerates recovery from relapses in RRMS patients 
(56). CS are considered to act by suppressing lymphocyte proliferation and by inhibiting 
MMPs, thus reducing traffic of activated myelin-reactive lymphocytes into the CNS (56). 
However, CS treatment is associated with a number of adverse effects, including 
depression, insomnia, hypertension, diabetes, gastritis and oedema (56).   
Natalizumab (Tysabri®, Biogen Idec/Elan), a humanised monoclonal antibody 
directed against the cell adhesion molecule α4β1 integrin, is the most recent drug to be 
approved for treatment of RRMS (57). By blocking of α4β1 integrin, natalizumab 
prevents CNS infiltration by immune cells (57). Treatment with natalizumab reduces 
relapse frequency and impedes the overall disability progression more efficiently than 
any other RRMS treatment approved to date (55). However, blockage of α4β1 integrin 
also impairs the capability of the immune system to effectively combat infections (58). 
Natalizumab treatment can render patients susceptible to opportunistic infections, such as 
progressive multifocal leukoencephalopathy, a viral infection that almost exclusively 
occurs in severely immunocompromised patients (58). As a result, the use of natalizumab 
is largely restricted to patients that do not respond to other disease-modifying treatments 
and is only prescribed after vigorous risk-benefit assessment (58). 
Mitoxantrone (Novantrone®, EMD Serono) is approved for treatment of RRMS, 
SPMS and relapsing progressive MS (41). It exert cytotoxicity on proliferating cells by 
introducing double strand breaks in the DNA (59). Mitoxantrone has also non-cytotoxic 
immunosuppressive effects, and inhibits proliferation of T cells, B cells and macrophages 
(59). However, severe adverse effects such as cardiac dysfunction and therapy-related 
acute leukaemia have been associated with mitoxantrone treatment (41). Hence 
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mitoxantrone is considered to be a treatment option for patients who experience 
insufficient response to IFN-β or GA.  
 IFN-β are approved for RRMS treatment, and are used as a first-line therapeutic. 
At present, two types of recombinant human IFN-β are in use: IFN-β1a (Avonex®, 
Rebif®) and IFN-β1b (Betaferon®) (60). The therapeutic effect is considered to be 
predominantly due to the induction of a TH2 favouring cytokine shift through modulation 
of cytokine production by APCs. In addition, IFN-β treatment reduces transmigration of 
autoreactive lymphocytes through the BBB (60). The result of the treatment is a reduction 
of relapse frequency and disease progression of about 35% (61). IFN-β are generally well 
tolerated, but a major drawback of the use of β-IFN in MS treatment is the development 
of neutralising antibodies to IFN-β, which render one third of the patients unresponsive to 
treatment one year after its initiation (61).  
1.7.5 Glatiramer Acetate 
Glatiramer acetate (GA, Copaxone®, Teva Pharmaceuticals) is a random 
copolymer of L-alanine, L-glutamic acid, L-lysine and L-tyrosine in a molar ratio of 
4.2:3.4:1.4:1.0, respectively, with a degree of polymerisation of 45-100 (62). These 
amino acids are the main constituents of MBP, a major encephalitogen implicated in MS 
pathogenesis and used to induce EAE in mice (42).  
The initial purpose in synthesising GA was to develop a synthetic polypeptide that 
could mimic MBP to be used for the induction of EAE. Instead, GA was found to 
suppress EAE under certain conditions (42). EAE suppression by GA has been replicated 
in a number of species, including mice, rats and primates (42). Following these 
preclinical studies, GA successfully went through clinical trials, and was approved by the 
Food and Drug Administration for the treatment of RRMS in 1996 (42).  
In RRMS treatment, GA is subcutaneously administered daily at a dose of 20 mg. 
This treatment significantly reduces the frequency of relapses in RRMS patients and 
delays the overall progression of the disease (63). Sustained inhibition of disease progress 
and improvement of neurological function by long-term GA treatment has also been 
reported (64). 
GA is generally well tolerated and has an excellent risk-benefit profile in RRMS 
patients. Apart from single case reports on skin necrosis and hepatitis, only mild and 
transient adverse effects are known (65-67). These include mild injection site reactions 
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including inflammation and capillary congestion, as well as immediate post-injection 
reactions such as chest tightness, palpitations, shortness of breath or chest pain (65).  
Mechanism of Action 
The mechanism of action of GA is not fully understood. Most of the knowledge 
on its mechanism of action has been obtained in EAE studies using mice or rats. In spite 
of some differences between treatment of EAE and human MS, the mechanism of disease 
alleviation by GA has significant overlap in the rodent and human disease (62).  
 The induction of anti-inflammatory T cells is the best researched feature of GA 
treatment, and a shift from TH1 to TH2 is well established in both mice and humans (68-
70). GA-induced TH2 cells are able to cross the BBB and exert in situ immunomodulation 
and suppress ongoing inflammatory processes in the CNS by secreting anti-inflammatory 
cytokines (71). Consistent with this, disease inhibition correlates with increased 
production of anti-inflammatory TH2 cytokines such as IL-4, IL-10, IL-5 and TGF-β (72). 
The generation of an anti-inflammatory milieu in the CNS antigen non-
specifically inhibits the recruitment and function of inflammatory cells that mediate 
damage to CNS tissue, an effect termed bystander suppression (73). This feature of the 
drug not only allows suppression of EAE induced by a number of encephalitogens, but is 
also of particular benefit in MS treatment, where epitope spreading causes immune 
reactions directed against multiple antigens (33).  
CNS-infiltrating TH2 cells can also secrete soluble factors that directly prevent 
tissue damage. GA-reactive T cells in the brain of treated mice secrete brain-derived 
neurotrophic factor (BDNF), a neurotrophin family growth factor that can protect axons 
from pathological insult (74). GA-specific T cells isolated from treated MS patients also 
produce BDNF after restimulation in vitro (75). In addition, CNS-infiltrating TH2 cells 
may also have the potential to induce the production of BDNF and other neuroprotective 
factors by CNS resident cells (76). 
 In addition to the initiation of TH2 responses, GA treatment also results in the 
antigen-specific expansion of Foxp3+ T-regs in both mice (77) and humans (78). T-regs 
are able to inhibit myelin-directed T cell responses, and adoptive transfer of GA-induced 
T-regs efficiently suppresses EAE (77). Hence Foxp3+ T-regs appear to be significantly 
involved in suppression of EAE, and probably of human MS as well (78, 79).  
 GA treatment initiates both anti-inflammatory and regulatory T cell responses. 
Interestingly, GA-TH2 cells and T-regs are mutually exclusive populations in mice (80). 
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Hence GA may suppress EAE by two different non-overlapping T cell mediated 
mechanisms. However, T cell mediated mechanisms are not sufficient to explain the full 
extent of protection in EAE. Selective ablation of TH2 or regulatory T cell function does 
not completely abrogate protection from EAE in GA treated mice (81, 82). T cell 
independent mechanisms such increased lymphocyte apoptosis have been proposed (83), 
but in vivo data in support of these hypotheses are currently lacking. Therefore additional, 
as yet unidentified mechanisms are likely to contribute to GA therapy. 
GA does not affect T cells directly (84), therefore the induction of protective T 
cell responses likely occurs indirectly through effects of GA on cells that present antigen 
to T cells (80). Co-culture of CD4 T cells with monocytes or DCs that have been 
previously exposed to GA results in the preferential secretion of TH2 cytokines such as 
IL-4 and IL-5 (84, 85). In contrast, production of IFN-γ by the T cells is reduced. These 
findings are consistent with the idea that modulation of APCs by GA is responsible for 
the increased presence of TH2 cells in treated mice and MS patients (86). In further 
support of an important role for APCs in GA treatment, monocytes isolated from GA 
treated mice produce increased amounts of IL-10 and TGF-β, and reduced TNF-α and 
IL-12 in comparison to untreated mice (80). These monocytes are also able to present 
antigen and induce differentiation of TH2 cells and T-regs (80).  
The mechanism by which GA exerts immunomodulation on APCs is currently not 
known. GA can directly bind to MHCII molecules on the surface of APCs in vitro (87), 
regardless of the MCHII haplotype and without internalisation or processing (88). It is 
not known whether GA can induce T cells after direct binding to MHCII. However, GA 
can competitively inhibit binding of MBP, and PLP139-151 to a lesser extent, to MHCII 
molecules (89, 90), and inhibit MBP specific T cell responses by acting as a TCR 
antagonist in vitro (91). This mechanism of effector T cell inhibition may contribute to 
GA’s efficacy in suppressing EAE. However, the importance of TCR antagonism in the 
treatment of the human disease remains in dispute (62).  
In addition to modulating APCs to induce protective T cell responses, it has also 
been suggested that GA contributes actively to neural repair and neurogenesis (76). 
Elevated proliferation of oligodendrocyte progenitor cells has been observed in brains of 
GA-treated EAE mice. These progenitors migrated towards regions of tissue damage, and 
might differentiate into mature oligodendrocytes and replace damaged myelin (76). 
Consistent with this, mice treated with GA after the onset of clinical EAE often exhibit 
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full recovery of neurological function (76). However, it is not clear whether repair of 
damaged CNS tissue occurs in GA treated MS patients.  
 
Figure 1.1: Mechanism of Action of Glatiramer Acetate (GA) in EAE Suppression.  
1: GA primarily acts on APCs in the periphery, rendering them able to induce antigen-
specific TH2 cells. 2: In addition, GA-induced APCs also induce T-regs that are able to 
suppress pathogenic T cells in the periphery. 3,4: Constant activation by peripheral APCs 
renders the TH2 cells able to infiltrate the CNS. 5,6: After crossing the BBB, GA-specific 
T cells become reactivated and secrete anti-inflammatory cytokines that alleviate ongoing 
CNS inflammation. 7: In addition, TH2 cells also secrete neurotrophic factors or stimulate 
local cells to do so, which contributes to protection from axonal damage and supports 
remyelination. Adopted from ref. (63). 
 
 
In summary, the current data on the mechanism of action of GA suggests that GA 
primarily acts on APCs in peripheral tissue, rendering the APCs able to induce anti-
inflammatory and regulatory T cell responses (figure 1.1). These T-regs can then 
suppress pathogenic T cell responses in the periphery. In addition, GA-induced TH2 cells 
infiltrate the CNS after their activation and can exhibit bystander suppression in situ by 
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producing anti-inflammatory cytokines that dampen inflammation and neuroprotective 
factors that prevent damage to CNS tissue. 
 
1.8 Objectives 
GA is one of the most efficient therapies currently available for the treatment of 
MS. Currently available data suggests that the primary mode of action involves antigen 
specific expansion of anti-inflammatory and regulatory T cells (62), which likely results 
from a GA-induced phenotype shift in APCs (86).  
GA is only effective when administered daily at high doses, over long time 
periods (63). Hence strategies aimed at improving the efficacy of GA, thereby reducing 
the therapeutic dose, are desirable. The first objective of this study was to improve GA 
therapy in a murine EAE model, by conjugation to high affinity targeting molecules that 
specifically bind to cell surface components on APCs. This targeting strategy was 
hypothesised to substantially increase uptake of GA by the APCs and presentation of 
GA-derived peptides to CD4 T cells. Hence the targeting strategy exploits the antigen 
specific mechanisms of GA to achieve a significant reduction of the therapeutic dose in 
EAE. Drug targeting is currently a field of extensive research, and targeting GA to its 
target cells has the potential for clinical application in MS treatment. 
The primary target of GA are considered to be innate cells with the ability of 
antigen presentation, but experimental evidence of direct effects of GA on such cells in 
vivo is currently unavailable. Furthermore, the specific target of GA within the 
multiplicity of cell types that can present antigen is unknown. 
The second objective of this study was to identify the in vivo target cell 
population of GA. Additional aims were to characterise the target cells and assess their 
ability to exert direct T cell immunosuppression. Antigen non-specific suppression of 
autoreactive cells may contribute to the efficacy of GA in EAE and MS, and gaining a 
complete picture of the mechanism of action of GA may lead to the development of 
improved immunomodulatory therapies. 
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2.1 Mice 
2.1.1 Maintenance and Ethic Approvals 
All mice were bred and maintained at the Biomedical Research Unit of the 
Malaghan Institute of Medical Research, based at Victoria University of Wellington, 
New Zealand. Experiments were approved by the Victoria University Animal Ethics 
Committee and performed under the guidelines of the Victoria University, under the 
license numbers 2007R8M (Investigating the cause and inhibitory schemes of 
experimental autoimmune encephalomyelitis, a murine model for human multiple 
sclerosis) or 2006R19 (The use of mouse tissues for multiple research projects). 
2.1.2 Mouse Strains 
C57BL/6J (H-2b) mice were originally purchased from the Jackson Laboratory 
(Bar Harbour, ME, USA).  
2D2 mice have a transgenic TCR specific for the H-2b binding MOG35-55 peptide. 
The mouse strain was generated by microinjection of cDNA encoding a MOG35-55 
specific TCR, which expresses Vα3.2 and Vβ11 TCR segments, into fertilised oocytes of 
C57BL/6J mice (92). 2D2 mice were obtained from Prof. Vijay K. Kuchroo (Harvard 
Medical School, Boston, MA, USA). 
OT-II mice have a transgenic TCR specific for the H-2b binding OVA323-339 
peptide. The OT-II mice are on C57BL/6J background and were originally obtained from 
Dr. William Heath (Walter and Eliza Hall Institute for Medical Research, Melbourne, 
VIC, Australia).  
OT-I mice have a transgenic TCR specific for the Kb binding OVA257-264 peptide. 
The strain was generated by microinjection of cDNA encoding the specific TCR into 
C57BL/6J blastocysts. OT-I mice are on C57BL/6J background and were obtained from 
Prof. Frank Carbone (University of Melbourne, Melbourne, VIC, Australia).  
B6.SJL-ptprca mice were developed by intercrossing C57BL/6J mice with SJL/J 
mice. This mouse strain is genetically similar to C57BL/6J strain except that it carries the 
ptprca (protein tyrosine phosphatase receptor type c locus) allele (CD45.1) from the SJL/J 
strain. B6.SJL-ptprca mice were purchased from Animal Resource Centre (Canning Vale, 
WA, Australia). 
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B6Aa0/Aa0 mice lack the expression of MHC class II molecules. The strain was 
generated by the targeted mutation of the Aa gene, which encodes one of the polypeptide 
chains of the IA molecule. B6Aa0/Aa0 mice were obtained from Dr. H. Bluethmann 
(Hoffmann-La Roche, Basel, Switzerland). 
2.1.3 Genotyping of TCR Transgenic Mouse Strains 
TCR transgenic animals were genotyped by determining the expression of the 
transgenic TCR on peripheral blood lymphocytes by flow cytometry. Mice were tail bled 
and blood cells were prepared by water lysis as described in section 2.6.2. Cells were 
then stained with antibodies specific for Vα2 and Vβ5.1-5.2 for OT-II mice, or Vα3.2 
and Vβ11 for 2D2 mice. Stained cells were analysed by flow cytometry and transgenic 
mice were defined as those that contained both transgenic TCRα and TCRβ segments. 
 
2.2 Chemicals 
Chemicals were purchased from the following companies, as depicted in section 2.3: 
BDH Chemicals, distribution by VWR, West Chester, PA, USA 
Invitrogen, Carlsbad, CA, USA 
Merck KGaA, Darmstadt, Germany 
PAA, Pasching, Austria 
Roche, Basel, Switzerland 
Serva GmbH, Heidelberg, Germany 
Sigma-Aldrich, St. Louis, MO, USA. 
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2.3 Buffers and Solutions 
2.3.1 Buffers for Immunisations 
Pertussis toxin buffer 
Tris    15 mM  Invitrogen 
Sodium chloride  0.5 M   BDH 
Triton X-100   0.017% (v/v)  Serva 
in MilliQ water (Q-Gard® 1 Purification Pack, Millipore Corp., Billerica, MA, USA), pH 
adjusted to 7.4 with HCl. Filter sterilised using a 0.22 µm vacuum driven disposable 
bottle top filter (SteritopTM, Millipore). Stored at 4 °C, used sterile. 
 
2.3.2 Buffers and Media for Cell Preparation and Tissue Culture 
Alsever’s solution 
D-glucose   114 mM  Sigma-Aldrich 
Sodium citrate   27 mM  Sigma-Aldrich 
Sodium chloride  71 mM 
in MilliQ water, pH adjusted to 6.1 with 1 M citric acid (BDH). Filter sterilised, stored at 
4° C and used sterile. 
 
Complete Iscove’s Modified Dulbecco’s Medium (cIMDM) 
2-Mercaptoethanol  55 µM   Invitrogen 
Foetal calf serum (FCS) 5% (v/v)  PAA 
Non-essential amino acids 100 µM  Invitrogen 
Penicillin   1 U/ml   Invitrogen 
Sodium pyruvate  1 mM   Invitrogen 
Streptomycin   1 µg/ml  Invitrogen 
in sterile IMDM (Invitrogen). Stored at 4 °C for no longer than 14 days, used sterile.  
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DNase/Collagenase solution 
DNase I   0.2 mg/ml  Roche 
Collagenase Type II  1 mg/ml  Invitrogen 
in sterile cIMDM. Prepared fresh before each use, used sterile. 
 
Red blood cell lysis buffer 
Tris    20 mM 
Ammonium chloride  14 mM  DBH 
in MilliQ water, pH adjusted to 7.4 with HCl. Sterilised by autoclaving, stored at room 
temperature (RT) and used sterile. 
 
Würzburger buffer 
DNAse I   0.02 mg/ml 
FCS    1% (v/v) 
EDTA    5 mM   Invitrogen 
in sterile Dulbecco’s phosphate buffered saline (D-PBS, Invitrogen). Stored at 4 °C, used 
sterile. 
 
2.3.3 Buffers for Cell Purification 
FlowCompTM isolation buffer 
FCS    2 % (v/v) 
EDTA    1 mM 
in sterile D-PBS. Stored at 4° C, used sterile. 
 
autoMACSTM running buffer 
FCS    1% (v/v) 
EDTA    2 mM 
in D-PBS. Sterilised by autoclaving, FCS added after sterilisation. Stored at 4° C and 
used sterile. 
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autoMACSTM rinsing buffer 
EDTA    2 mM 
in D-PBS, sterilised by autoclaving. Stored at 4° C, used sterile. 
 
2.3.4 Buffers for Flow Cytometry 
FACS buffer 
Sodium azide   0.1% (w/v)  Sigma-Aldrich 
FCS    1% (v/v) 
EDTA    2 mM 
in D-PBS, stored at RT. 
 
2.3.5 Solutions for Preparation of Cl2MDP Liposomes 
 
Phosphatidylcholine stock solution 
L-α-phosphatidylcholine 100 mg/ml  Sigma-Aldrich 
in chloroform (Merck). Stored at -20 °C 
 
Cholesterol stock solution 
Cholesterol   20 mg/ml  Sigma-Aldrich 
in chloroform. Stored at -20 °C 
 
Dichloromethylene diphosphonate (Cl2MDP) solution 
Cl2MDP   0.7 M   Sigma-Aldrich 
in MilliQ water, pH adjusted to 7.1 with NaOH. Stored at -20 °C 
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2.3.6 Solutions for Immunohistochemistry 
Zinc fixative 
Tris    0.1 M 
Calcium acetate  3 mM   Sigma-Aldrich 
Zinc acetate   27 mM  Sigma-Aldrich 
Zinc chloride   37 mM  Sigma-Aldrich 
in MilliQ water, pH adjusted to 7.4 with HCl. Stored at RT. 
 
2.3.7 Solutions for SDS PAGE 
Staining solution 
Coomassie® brilliant blue G 250 0.1% (w/v)  Serva 
Glacial acetic acid   10% (v/v)  Merck 
Methanol    45% (v/v)  Merck 
in MilliQ water. Stored at room temperature (RT). 
 
Destaining solution 
Glacial acetic acid  7.5% (v/v) 
Methanol   5% (v/v) 
in MilliQ water. Stored at RT. 
 
2.3.8 Buffers for Chromatography 
FPLC running buffer 
Disodium hydrogen phosphate 8.1 mM BDH 
Sodium dihydrogen phosphate 11.9 mM BDH 
in MilliQ water, pH adjusted to 7.0. Filtered through 0.22 µm filter (SteritopTM, 
Millipore), stored at RT. 
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FPLC elution buffer 
Glycine   0.1 M   BDH 
in MilliQ water, pH adjusted to 2.7 with HCl. Filtered through 0.22 µm, stored at RT. 
 
FPLC neutralisation buffer 
Tris    1 M 
in MilliQ water, pH adjusted to 9.0 with HCl. Filtered through 0.22 µm, stored at RT. 
 
CNBr sepharose coupling buffer 
Disodium hydrogen phosphate 92.5 mM 
Sodium dihydrogen phosphate 7.5 mM 
Sodium chloride   0.5 M 
in MilliQ water, pH adjusted to 8.3. Filtered through 0.22 µm, stored at RT. 
 
CNBr sepharose blocking buffer 
Tris    0.1 M 
in MilliQ water, pH adjusted to 8.0 with HCl. Filtered through 0.22 µm, stored at RT. 
 
CNBr Sepharose low pH wash buffer 
Glacial acetic acid  0.5% (v/v)   
Sodium acetate  15 mM  BDH 
Sodium chloride  0.5 M 
in MilliQ water, pH adjusted to 4.0. Filtered through 0.22 µm, stored at RT. 
 
CNBr sepharose high pH wash buffer  
Tris    0.1 M 
Sodium chloride  0.5 M 
in MilliQ water, pH adjusted to 8.0 with HCl. Filtered through 0.22 µm, stored at RT. 
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2.4 Proteins, Peptides and Copolymers 
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was synthesised by 
Mimotopes (Clayton, Victoria, Australia). This H-2b binding peptide corresponds to 
amino acids 35-55 of the murine MOG protein. Purity of the peptide was >97%. 
OVA323-339 (ISQAVHAAHAEINEAGR) is an H-2b binding peptide derived from 
the chicken OVA sequence and corresponds to amino acids 323-339. OVA323-339 was 
synthesised by Mimotopes ( >95% pure). 
Recombinant MOG protein corresponds to the N-terminal extracellular domain 
(amino acids 1-117) of the murine MOG protein. MOG protein was provided by Prof. 
John D. Fraser, University of Auckland. 
Ovalbumin (OVA) protein was purchased from Sigma-Aldrich as a lyophilised 
powder. The protein is isolated from chicken egg, and has a purity of >98%. 
Trypsinogen (from bovine pancreas, Sigma-Aldrich) is the inactive precursor of 
the intestinal protease trypsin. The molecular weight is 24 kDa by calculation. It was 
purchased as an essentially salt-free, lyophilised powder and stored at -20° C, protected 
from moisture. After dissolving in PBS, it was stored at 4 °C. 
Glatiramer acetate (GA, Copaxone®) was purchased from Teva Pharmaceutical 
Industries Ltd. (Petach Tikva, Israel). 
SMEZ2 M1 is a modified form of the streptococcal superantigen SMEZ2 that 
contains the mutations W75L.K182Q.D42C. As a consequence, this modified 
superantigen cannot bind TCR. SMEZ2 M1 and the conjugates SMEZ2 M1-MOG and 
SMEZ2 M1-OVA were provided by Prof. John D. Fraser (Department of Molecular 
Medicine and Pathology, University of Auckland, Auckland). 
DM SMEZ2 is a modified form of the streptococcal superantigen SMEZ2 that 
contains the mutations Y18A.D42C.H202A.D204A. As a consequence, this modified 
superantigen cannot bind TCR or MHCII molecules. DM SMEZ2 was provided by Prof. 
John D. Fraser, University of Auckland. 
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2.5 Immunisations and Treatment 
2.5.1 EAE induction  
Eight to twelve week old female C57BL/6J or 2D2 mice were immunised with 
50 µg MOG35-55 emulsified in CFA (Difco Laboratories, Detroit, MI, USA) containing 
500 µg heat-killed Mycobacterium tuberculosis (Difco Laboratories). The components 
were emulsified by three homogenisation cycles of 90 seconds each in a Mini bead 
beater-8 (BioSpec Products, Bartlesville, OK, USA). The emulsion was transferred to 
1 ml syringes (BD Biosciences, Franklin Lakes, NJ, USA) by centrifugation. The mice 
were injected with 100 µl of the emulsion subcutaneously in each hind limb flank. One 
day after EAE induction, mice received intraperitoneal injections of 250 ng pertussis 
toxin (Sapphire Bioscience, Redfern, NSW, Australia) in 200 µl pertussis toxin buffer 
(section 2.3.1). 
The mice were monitored daily throughout 40 days after EAE induction. EAE 
scores were assigned as follows: 1, loss of tail tonicity; 2, limp tail; 3: hind limb 
weakness; 4: hind limb paralysis; 5: hind and fore limb paralysis, moribund state. Mice 
were scored and weighed daily. Mice that reached EAE score 5 or lost >20% of their total 
body weights within five days were euthanised. 
2.5.2 Treatment 
Co-immunisation. Eight to twelve week old female C57BL/6J or 2D2 mice were 
subcutaneously immunised in the hind limb flanks with 50 µg MOG35-55 and 500 µg GA 
emulsified in CFA containing 500 µg heat-killed M. tuberculosis. Mice received 
intraperitoneal injections of 250 ng pertussis toxin one day after co-immunisation.  
C57BL/6J mice were co-immunised with 50 µg MOG35-55 and either 5 µg 
SMEZ2 M1-GA, 20 µg M5/114-GA or 20 µg M1/70-GA subcutaneously in the hind limb 
flanks. Mice received intraperitoneal injections of 250 ng pertussis toxin one day after co-
immunisation.  
Treatment in the neck. Eight to twelve week old female C57BL/6J mice received 
subcutaneous injections of 500 µg GA in 100 µl PBS in the scruff of the neck on seven 
consecutive days before EAE induction. 
Eight to twelve week old female C57BL6/J mice were subcutaneously treated 
with 500 µg GA emulsified in 100 µl CFA containing 500 µg heat-killed M. tuberculosis 
in the scruff of the neck on the day of EAE induction. 
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Intravenous treatment. Eight to twelve week old female C57BL/6J mice received 
intravenous injections of 500 µg GA in 100 µl PBS on the day of EAE induction. 
2.5.3 Immunisations to Prime Cells for Proliferation Assays or to Study Lymphoid 
Tissue Infiltration 
Eight to twelve week old C57BL/6J or B6.SJL-ptprca mice were subcutaneously 
immunised in the hind limb flanks with 500 µg GA or 500 µg GA-FITC emulsified in 
CFA containing 500 µg heat-killed M. tuberculosis, or with CFA only. Eight hours to ten 
days after immunisation, cells were recovered from spleens, blood or draining (inguinal) 
lymph nodes.  
 
2.6 Tissue Harvest and Processing 
2.6.1 Preparation of Cells from Spleens and Lymph Nodes 
Mice were sacrificed by carbon dioxide asphyxiation followed by cervical 
dislocation. Mice were pinned on a dissection tray and the fur was soaked with 70% 
ethanol. Dissection tools were stored in 70% ethanol to maintain sterility. The peritoneal 
cavity was opened and inguinal, para-aortic or mesenteric lymph nodes or spleens were 
removed as required. The spleens and lymph nodes were placed in cIMDM (section 
2.3.2) on ice immediately after removal.  
For the study of total cells populating the lymphoid tissue, 1-2 ml of 
DNase/collagenase (section 2.3.2) solution was injected into the spleens, and the flow-
through was collected in 24 well plates (BD Biosciences). The spleens were then placed 
in the collected solution and incubated at 37 °C for 30 minutes. Lymph nodes were 
placed directly in 1 ml DNase/collagenase in 24-well plates and incubated as above. 
DNase/collagenase digestion was omitted for the isolation of lymphocytes from spleens 
and lymph nodes. 
For preparation of single cell suspensions, spleens and lymph nodes were 
disrupted with the back of the plunger of 1 ml syringes (BD Biosciences) and flushed 
with cIMDM (or with Würzburger buffer (section 2.3.2) after DNase/collagenase 
digestion) through 100 µm nylon cell strainers (BD Biosciences) into 50 ml tubes (BD 
Biosciences). The cells were centrifuged for three minutes at 2000 x g. Lymph node cells 
were washed once, resuspended in cIMDM and placed on ice until further use. Spleen 
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cells were resuspended in 1 ml cIMDM, and 5 ml of red blood cell lysis buffer (section 
2.3.2) per spleen was added. The tube was gently inverted several times, and centrifuged 
as above to pellet white blood cells. The cells were washed once and resuspended in 
cIMDM, filtered through a 100 µm cell strainer and placed on ice until further use. 
For counting lymphocytes, 10 µl of the cell suspension was diluted to 10 ml with 
ISOTON® II Diluent (Beckman Coulter, Fullerton, CA, USA) and cells in the size range 
of 4 µm – 8 µm were counted with a Z2TM Coulter Counter® (Beckman Coulter). 
2.6.2 Preparation of Cells from Blood 
Blood was collected from mice either by tail-bleeding or cardiac puncture. For 
tail-bleeding, mice were placed under a heat source for several minutes before tail 
bleeding. The mice were then placed in a restraining tube. The distal 0.5-1 mm of the tail 
was removed with a sharp pair of sterile scissors. The tail was gently rubbed from the 
base to the tip, and 4-5 drops of blood were collected in 1.7 ml tubes containing 200 µl of 
Alsever’s solution (section 2.3.2). The tubes were placed on ice until further use. 
For collecting blood by cardiac puncture, mice were sacrificed by carbon dioxide 
asphyxiation. Blood was collected with a 1 ml syringe and a 24 G needle. The mouse was 
laid on the back and needle was inserted horizontally from the left side of the thorax. 
About 1 cc of air was withdrawn after the insertion to create a vacuum by pulling the 
plunger. The needle was then directed to the ventricle until blood appeared in the needle. 
The vacuum was maintained by further gently pulling back on the plunger. The collected 
blood (500 – 800 µl) was immediately transferred to 1.7 ml tubes containing 700 µl 
Alsever’s solution. The tubes were placed on ice until further use. 
For preparation of total white blood cells for flow cytometry, red blood cells were 
lysed with MilliQ water (water lysis). Blood cells were resuspended in 500 µl MilliQ 
water. An equal volume of 1.8% NaCl was added after 20 seconds. The cells were then 
centrifuged for one minute at 10000 rpm (IEC Micromax, Thermo Scientific, Waltham, 
MA, USA), and the water lysis repeated as required. The cells were then resuspended in 
FACS buffer (section 2.3.4) and placed on ice until further use.  
For isolation of peripheral blood mononuclear cells (PBMCs) for tissue culture, 
blood cells were resuspended in 1 ml sterile D-PBS. Blood from individual mice was 
pooled in 15 ml tubes (BD Biosciences), and 2-4 ml of Lympholyte®-M cell separation 
media (Cedarlane Laboratories Ltd., Burlington, NC, USA) was added through sterile 
pasteur pipettes (Sigma-Aldrich). The cells were then centrifuged for 20 minutes at 
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2400 x g. Mononuclear cells were collected from the interface and transferred to a fresh 
tube. The cells were washed once, resuspended in cIMDM and placed on ice until further 
use. 
For counting white blood cells, 10 µl of cell suspension was mixed with 10 µl 
0.4% Trypan Blue Stain (Invitrogen). The mixture was placed on a Bright Line double-
ruling haemocytometer set (Boeco, Hamburg, Germany) and the living cells that 
excluded the dye were counted under 100x magnification with an Olympus CK40 
inverted microscope (Olympus, Central Valley, PA, USA). 
2.6.3 CFSE Labelling 
Cell suspensions were prepared from blood or lymphoid tissue (sections 2.6.1 and 
2.6.2). Red blood cells were not lysed during splenocyte isolation. The cells were 
resuspended in Hank’s Balanced Salt Solution (HBSS, Invitrogen) containing 2 mM 
EDTA at 20 x 107 cells/ml. Then, 20 µl of carboxyfluorescein succinimidyl ester (CFSE, 
200 µM stock in DMSO, Invitrogen) was added to the cells. The cells were incubated for 
seven minutes at RT, with occasional inversions. At the end of incubation, 30 ml of 
cIMDM was added and the cells centrifuged at 2000 x g for 5 minutes. The cells were 
then washed twice and resuspended in HBSS (without EDTA) or cIMDM for adoptive 
transfers or tissue culture, respectively. 
 
2.7 Cell Purification 
2.7.1 Magnetic Sorting of CD11bhi Cells 
CD11bhi cells were isolated with the autoMACSTM cell separation system 
(Miltenyi Biotec, Bergisch Gladbach, Germany). PBMCs were isolated from the blood as 
described in section 2.6.2. The cells were resuspended in 2 ml autoMACS running buffer 
(section 2.3.3) and filtered through 30 µm pre-separation filters (Miltenyi). To deplete 
dead cells, a positive selection was performed using an autoMACS separator (program 
“possel”, Miltenyi). The negative fraction was collected, washed once and resuspended in 
200 µl running buffer. A PE-conjugated antibody specific for CD11b (clone M1/70, 
Pharmingen) was added (1 µl), and the cells were incubated for 15 minutes on ice. The 
cells were then washed twice with 50 ml running buffer and resuspended in 200 µl. 
Subsequently, 20 µl of anti-PE beads (Miltenyi) were added, and the cells were incubated 
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for 30 minutes at 4° C under rotation. The cells were washed once, resuspended in 2 ml 
running buffer, and separated using the autoMACS separator as above. The positive 
fraction contained the CD11bhi enriched cells (>80% CD11bhi). The cells were then 
washed once and resuspended HBSS or cIMDM for adoptive transfer or tissue culture, 
respectively. 
2.7.2 Magnetic Sorting of CD4+ Cells 
CD4+ cells were isolated with the Dynabeads® FlowCompTM Mouse CD4 kit 
(Invitrogen). Briefly, splenocyte or lymph node cell suspensions were resuspended in 
2 ml isolation buffer (section 2.3.3) per 5 x 108 total cells in 5 ml polystyrene tubes (BD 
Biosciences). Then, 25 µl of FlowComp Mouse CD4 antibody (Invitrogen) was added. 
The cells were incubated for 10 minutes on ice, washed once (3 minutes at 2000 x g) and 
resuspended in 4 ml isolation buffer. Subsequently, 300 µl of FlowComp Dynabeads 
(Invitrogen) were added and the cells were incubated for 15 minutes at 4° C under 
rotation. The tube was placed in a DynaMagTM-15 magnet (Invitrogen) for two minutes. 
The supernatant was removed with a pipette. The tube was removed from the magnet, the 
cells resuspended in isolation buffer, and the magnetic separation step repeated. The cells 
were then resuspended in 4 ml FlowComp release buffer (Invitrogen) and incubated for 
10 min at RT under rotation. The tube was placed in the magnet for two minutes and the 
supernatant containing the CD4+ cells (>95% CD4+) transferred to a fresh tube. The cells 
were washed once and resuspended in HBSS for adoptive transfer, or in cIMDM for 
tissue culture. 
 
2.8 Adoptive Transfer 
 Cell pellets from blood, spleens or lymph nodes were labelled with CFSE as 
described in section 2.6.3. Then either CD4+ cells from lymphoid tissue or CD11bhi cells 
from blood were enriched as described in section 2.7. The cells were resuspended in 
HBSS. 
 For in vivo proliferation assays (section 2.9.3), 2 – 5 x 106 CFSE labelled CD4+ T 
cells from 2D2 mice were adoptively transferred into CD45 congenic B6.SJL-ptprca mice 
by intravenous injection into the tail vein. 
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 For the study of lymph node infiltration after immunisation (section 2.5.3), 
2 x 105 CD11bhi cells from C57BL/6J were adoptively transferred into CD45 congenic 
B6.SJL-ptprca mice by intravenous injection into the tail vein. 
 
2.9 Proliferation and Suppression Assays 
2.9.1 Antigen Specific in vitro Proliferation Assays 
Splenocytes or lymphocytes were isolated from immunised or TCR transgenic 
mice as described in section 2.6.1. Splenocytes from TCR transgenic mice (5 x 105 cells 
per well) or draining lymphocytes from immunised mice (1 x 106 cells per well) were 
incubated in 96-well flat bottom plates (BD Biosciences) with serial dilutions of antigen.  
The cultures were incubated with atmospheric air and 5% CO2 at 37° C in a 
HeraSafe tissue culture incubator (Thermo Scientific). After 48-72 hours of incubation, 
0.25 µCi [3H]-thymidine (GE Healthcare) was added, and the cultures were incubated for 
eight more hours. At the end of the incubation period, either [3H]-thymidine 
incorporation was analysed immediately, or the cultures were stored at -20° C until 
analysis. As a positive control of proliferation, splenocytes or lymph node cells were 
incubated with serial dilutions of a soluble anti-CD3 antibody (clone 2c11) for 48 hours, 
and additional eight hours after addition of [3H]-thymidine.  
For analysis, cells were harvested from the 96-well plates onto printed glass fibre 
filter mats (PerkinElmer Lifesciences Inc., Boston, MA, USA) using a Tomtec automatic 
96 well plate harvester (Tomtec, Hamden, CT, USA). Filter mats were dried in a 
microwave oven, placed into plastic sample bags (PerkinElmer) and scintillated with Beta 
Scint liquid scintillation cocktail (Wallac, Turku, Finland). The sample bags were sealed 
(Heat sealer, Wallac) and [3H]-thymidine incorporation was analysed using a 1450 
Microbeta Plus liquid scintillation counter (Wallac). 
2.9.2. In vitro Suppression Assays 
Suppression of polyclonal T cell proliferation. CD11bhi cells were enriched from 
the blood of C57BL/6J mice as described in section 2.7.1. Serial dilutions of enriched 
CD11bhi cells were co-cultured with 5 x 104 C57BL/6J splenocytes per well in presence 
of 2.5 x 104 Dynabeads® mouse CD3/CD28 T cell expander beads (Invitrogen) in a 
round-bottom 96-well plate (BD Biosciences). The co-cultures were incubated at 37° C 
CHAPTER 2: MATERIALS & METHODS 
 38 
for 24 hours. Then, 0.25 µCi [3H]-thymidine was added and the cultures were incubated 
for additional eight hours. The cultures were harvested and incorporation of 
[3H]-thymidine was analysed as described in section 2.9.1. 
Suppression of antigen specific T cell proliferation. Lymphocytes were isolated 
from 2D2 mice and labelled with CFSE and cultured with 10 µg/ml MOG35-55 in a round-
bottom 96-well plate (5 x 104 cells per well). Serial dilutions of enriched CD11bhi cells 
were added to the lymphocyte culture after 24 hours of incubation. The co-culture was 
incubated for additional 48-72 hours, and CFSE dilution in the responder cells was 
analysed by flow cytometry at the end of the incubation period. 
2.9.3 Antigen specific in vivo Proliferation Assays 
 CFSE labelled CD4+ cells from 2D2 mice were adoptively transferred into 
B6.SJL-ptprca mice (2 – 5 x 106 cells per mouse). The cells were mixed with either 
10 µg/ml MOG35-55 or with 10 µg/ml MOG35-55 and 250 µg/ml GA before injection, with 
control mice receiving cells only. CFSE dilution in the responder cells in the blood and 
the spleen of recipients was analysed by flow cytometry 48-96 hours after cell transfers. 
 In an alternative setting, CFSE labelled CD4+ 2D2 cells were adoptively 
transferred to B6.SJL-ptprca mice as above. One day after cell transfers, recipients were 
subcutaneously immunised with MOG35-55, or co-immunised with MOG35-55 and GA, as 
described in section 2.5, and control mice were immunised with CFA only. CFSE 
dilution in the responder cell population in the draining (inguinal) lymph nodes, spleens 
and blood of the recipients was analysed by flow cytometry 48-96 hours after 
immunisation. 
 
2.10 Flow Cytometry 
Single cell suspensions were prepared from various tissues at 1 x 106 – 
2.5 x 107 cells/ml. 200 µl of the cell suspensions per well were transferred to a round 
bottom greiner 96 well plate (BD Biosciences). The cells were centrifuged for 37 seconds 
at 3000 rpm (IEC Centra GP8R, Thermo Scientific), the supernatant was flicked off and 
the cells resuspended by vortexing. The cells were washed twice with 200 µl FACS 
buffer (section 2.3.4) and incubated with anti-CD16/CD32 antibody (clone 2.4G2) in 50 
µl FACS buffer for 10 minutes at RT. The cells were washed twice with FACS buffer as 
above, and then incubated with a mixture of fluorophor-labelled antibodies (table 2.1) 
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against cell surface molecules of interest in 50 µl FACS buffer for 10 minutes at RT. The 
cells were washed twice and incubated with fluorophor-conjugated streptavidin in 50 µl 
FACS buffer for 10 minutes at RT. The cells were then washed twice, resuspended in 
200 µl FACS buffer and transferred to Titertube® micro tubes (Bio-Rad Laboratories 
Inc., Hercules, CA, USA) through filter gauze. 
 
Table 2.1: Antibodies used for flow cytometry. 
Antigen Clone Source Isotype Fluorophor 
CD4 GK1.5 Pharmingen Rat IgG2b, κ Alexa647a, PE, PerCP 
CD8 2.43 homemade Rat IgG2b, κ Alexa647, PE 
CD11b M1/70 Pharmingen Rat IgG2b, κ PE, Alexa647a 
CD18 M18/2 eBioscience Rat IgG2a, κ Alexa647a 
IAb M5/114 Pharmingen Rat IgG2b, κ PE, Alexa647a 
CD11c N418 homemade Armenian 
hamster IgG 
Biotin 
F4/80 BM8 eBioscience Rat IgG2a, κ Biotin, Alexa488a 
Gr-1 RB6-8C5 Pharmingen Rat IgG2b, κ PE, Alexa647a 
CD19 eBio1D3 eBioscience Rat IgG2a, κ Biotin, Alexa647a 
PDCA-1 JF05-1C2. Miltenyi Rat IgG2b, κ APC 
Ly6C AL-21 BD Rat IgM, κ Biotin 
Ly6G 1A8 BD Rat IgG2a, κ Alexa647a, Biotin 
CD80 16-10A1 homemade Armenian 
hamster IgG 
Biotin 
CD86 PO3.1 eBioscience Rat IgG2b, κ Alexa647a 
CD45.2 104 eBioscience Mouse IgG2a, κ PE 
CD16/CD32 2.4G2 homemade Rat IgG2b, κ Alexa647 
CD45 30-F11 Pharmingen Rat IgG2b, κ PerCP 
Vα3.2 RR3-16 BD Rat IgG2b, κ FITC 
Vβ11 RR3-15 BD Rat IgG2b, κ Alexa647a 
a Purified unlabelled antibodies were purchased from the indicated companies and 
labelled with Alexa Fluor® 488 or Alexa Fluor® 647 (Invitrogen) as described in section 
2.13.5.  
CHAPTER 2: MATERIALS & METHODS 
 40 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Gating on total or mononuclear cells in flow cytometry.  
Contour plots acquired from unstained cell samples from blood, spleens or lymph nodes 
(LN) were used for gating on living cells or mononuclear cells, based on their FSC/SSC 
properties. 
 
 
Flow cytometric analysis was performed on a FACSort (BD Biosciences). 
Unstained samples were used to define the population of living cells or mononuclear cells 
by their forward scatter (FSC) and side scatter (SSC) properties (figure 2.1). Cell samples 
stained with antibodies corresponding to all four channels were used to adjust the voltage, 
and samples stained with single antibodies were used to compensate for overflow of 
fluorescence into other channels. When studying a specific cell population such as 
CD45.2+ or CD11bhi cells, gates were set on these populations (figure 2.2). Data 
acquisition was carried out with CellQuest Pro software (BD Biosciences) and the data 
were analysed using the FlowJo software (Tree Star Inc., Ashland, OR, USA). 
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Figure 2.2: Gating based on cell surface marker expression in flow cytometry.  
High-resolution contour plots with outliers were used for gating on CD4+, CD45.2+ or 
CD11bhi cells. Cell samples shown are prepared from spleens of immunised C57BL/6J 
mice (CD4 gate), spleens of immunised B6.SJL-ptprca recipients of CD45.2 congenic 
cells (CD45.2 gate), or blood of naïve C57BL/6J mice (CD11bhi gate). Plots are gated on 
mononuclear cells as shown in figure 2.1. 
 
 
2.11 In vivo Monocyte Depletion 
For preparation of Cl2MDP-liposomes, 1.1 ml of L-α-phosphatidylcholine stock 
solution (section 2.3.5) was added to 0.51 ml cholesterol stock solution (section 2.3.5) in 
a 500 ml round bottom flask. The solvent was removed by low vacuum rotation 
evaporation at 150 rpm (Rotavapor R-210, Büchi Labortechnik AG, Flawil, Switzerland) 
and 120 mbar (Vacuum controller V-850, Büchi) until a thin milky-white phospholipid 
film formed against the inside of the flask. The phospholipid film was dispersed in 10 ml 
of 0.7 M Cl2MDP solution (section 2.3.5) by gentle rotation (120 rpm) at RT for 10 
minutes. The resulting suspension was held under nitrogen gas at RT for two hours. The 
suspension was then gently shaken and sonicated in a waterbath at 40 kHz (Ultrasonic 
cleaner FXP8M, Unisonics, Manly Vale, NSW, Australia) for three minutes. The 
suspension was held under nitrogen gas overnight at 4° C.  
The liposome suspension was transferred to a 50 ml tube and centrifuged for 40 
minutes at 3500 g and 10° C. The aqueous phase containing the non-encapsulated 
Cl2MDP was removed with a 10 ml syringe. The Cl2MDP solution was stored at -20° C 
for further use. The liposomes were washed twice with 20 ml D-PBS (3500 g at 10° C for 
20 minutes) and resuspended to a final volume of 5.1 ml D-PBS. Liposomes were stored 
for up to one week at 4 °C before use.  
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For monocyte depletion, the Cl2MDP liposomes were transferred to 1 ml insulin 
syringes (BD Biosciences), and 200 µl liposomes were intravenously injected into the tail 
vein of mice. Immediately before transfer to syringes and before injecting, the 
suspensions were gently shaken to ensure even dispersion. 
 
2.12 Histology 
EAE was induced in mice as described in section 2.5.1. Mice were sacrificed 40 
days after EAE induction and spinal cords removed. For this, the dorsal fur was soaked 
with 70% ethanol and the skin was cut open from caudal to cranial. The head was 
removed and a cut was introduced to the spine about 5 cm from the cranial end with a 
sharp pair of sterile scissors. An 18 G needle was inserted into the neural tube from the 
caudal end of the dislocated spine, and the spinal cord was removed by flushing with cold 
D-PBS. 
Spinal cords were fixed in immunohistochemistry zinc fixative (section 2.3.6). 
Tissue was embedded in paraffin, sectioned at 6 µm and stained with hematoxylin and 
eosin by the Pathology Department at the Wellington School of Medicine. Histology 
slides were analysed with an Olympus BX551 microscope and Olympus DP70 digital 
camera (Olympus, Center Valley, PA, USA). 
 
2.13 Biochemical Methods 
2.13.1 Non-reducing SDS PAGE 
Non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS 
PAGE) was used to evaluate the efficiency of conjugations. For this, the sample was 
mixed with 4x LDS sample buffer (Invitrogen) and loaded on NuPAGE® Novex Bis-Tris 
gels (Invitrogen). Precision Plus Protein prestained standard (Bio-Rad) was added to one 
well of the gel. The gels were run using an XCell Sure LockTM Mini-Cell (Invitrogen) in 
MES SDS running buffer (Invitrogen) at constant voltage of 200 V from a PowerPac 
3000 power supply (Bio-Rad) for 40-45 minutes. The gels were then stained with 
Coomassie blue (section 2.3.7) for one hour with constant shaking. The gels were 
destained (section 2.3.7) for one hour, and boiled for one minute in a microwave oven 
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with soft tissue paper in distilled water (dH2O). Gel pictures were taken with a Molecular 
Imager Gel Doc XR (Bio-Rad).  
2.13.2 Conjugation of proteins to antibodies 
The conjugation system used for antibody conjugations consists of two 
complementary amine-reactive chemicals: C6-S-HyNic (Solulink, San Diego, CA, USA) 
incorporates aromatic hydrazines into proteins, whereas sulfo-S-4FB (Solulink) 
incorporates aromatic aldehydes. Once coupled to the respective proteins, these 
chemicals are only reactive to each other and form a bis-aryl-hydrazone bond upon co-
incubation. The chemicals were dissolved in dimethylformamide (DMF, Solulink) at a 
concentration of 10 mg/ml and stored as aliquots of 10 µl at -70°C until use.  
For conjugation, the antibodies were first modified with C6-S-HyNic, and the 
proteins were modified with sulfo-S-4FB. For this, proteins and antibodies were 
resuspended in modification buffer (Solulink) with ZEBA desalting columns (Pierce, 
Rockford, IL, USA) or Vivaspin 10K MWCO PES columns (Sartorius AG, Göttingen, 
Germany). C6-S-HyNic or sulfo-S-4FB were then added to the antibodies or proteins, 
respectively, and incubated for two hours at RT. Excess chemical was removed from the 
solutions with ZEBA desalting columns or by three consecutive concentration-dilution 
cycles in Vivaspin 10K MWCO PES columns.  
The modified antibodies were then mixed together with the modified proteins and 
incubated for one hour at RT. Conjugation efficiency was tested by non-reducing SDS 
PAGE. The conjugates were sterilised with 0.22 µm microcentrifuge filters (Corning Inc., 
Corning, NY, USA) before further use. 
2.13.3 Conjugation of GA to Superantigens 
For conjugation of GA to superantigens, the heterobifunctional amine/sulfhydryl-
reactive crosslinking chemical SMCCplusTM (ABD Bioquest, Sunnyvale, CA, USA) was 
used. SMCCplus was dissolved in 50% (v/v) of acetonitrile/dH2O at a concentration of 
50 mg/ml and aliquoted to 20 µl. The chemical was then dried in a Savant SpeediVac 
concentrator (Thermo Scientific) and the resulting dry aliquots were stored at -20° C 
protected from moisture. 
Prior to use for conjugation reactions the amount of remaining reactive chemical 
was determined. For this, a 1 mg aliquot of SMCCplus was dissolved in 100 µl of 
50% DMF/dH2O, and 10 µl of the dissolved SMCCplus was transferred to 500 µl of 
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dH2O, which was subsequently split in two tubes of 250 µl each. To one of the tubes, 
10 µl of 2 N NaOH was added to hydrolyse SMCCplus. The OD280 of both samples was 
measured immediately. The amount of reactive chemical that will conjugate to the 
proteins was calculated from the difference in absorbance of the hydrolysed (H) and the 
unhydrolysed (UH) sample using the following formula: α = 1 – (A280UH / A280H).  
GA was resuspended in D-PBS with ZEBA desalting columns and modified with 
((100 * n(GA/µmoles)) / α) µl SMCCplus (2-fold molar excess over GA) for two hours 
at RT. GA was diluted to 0.75 mg/ml during modification to avoid precipitation in the 
DMF-containing solution. Excess chemical was removed by three consecutive 
concentration-dilution cycles with D-PBS in Vivaspin 3K MWCO columns (Sartorius). 
Superantigens were reduced with 1 mM Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP-HCl, Pierce) for 30 minutes at RT. The reducing agent was then 
removed with ZEBA desalting columns, and reduced superantigen was used immediately 
for conjugation reactions. Reduced superantigen was co-incubated with a 10-fold molar 
excess of modified GA over night at 4 °C. Conjugation efficiency was tested by non-
reducing SDS PAGE.  
2.13.4 Fast protein liquid chromatography (FPLC) 
Preparation of Gel Filtration Columns. Pre-swollen Sephacryl® 300-HR 
suspension (Sigma-Aldrich) was resuspended by gentle shaking. For one 8 ml column, 
15 ml of the suspension was transferred to a 50 ml tube (BD Biosciences). The 
suspension was centrifuged for two minutes at 2000 g and resuspended in MilliQ water to 
a total volume of 10 ml. An empty glass Econo-column (Bio-Rad) was connected to a 
BioLogic LP low-pressure chromatography system (Bio-Rad). The column outlet was 
disconnected from the chromatography tubing and sealed, and the column bed was pre-
wet with 2-3 ml of FPLC running buffer (section 2.3.8). A 2 ml glass pipette was inserted 
into the column, with the tip of the pipette immersing into the buffer in the bottom of the 
column, but not touching the column bed. The Sephacryl suspension was then slowly 
poured into the column alongside the wall of the glass pipette. The pipette was slowly 
withdrawn from the column and the gel resin let settle for 10 minutes by gravity. Then, 
an Econo-column flow adaptor (Bio-Rad) was inserted into the column and sealed 0.5-1 
cm above the gel resin. The column was then packed at a flow rate of 6.5 ml/min with 
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FPLC running buffer (section 2.3.8) for one hour. If not proceeding directly to a 
separation run, the column was filled with 20% ethanol, sealed and stored at 4°C. 
Gel filtration chromatography. Gel filtration columns were connected to the 
tubing of the FPLC system, and the flow adaptor was inserted into the column and sealed 
0.5-1 cm above the gel resin. The gel filtration column was washed thoroughly with 
running buffer at 1 ml/min, until the conductivity became constant. The sample was 
resuspended in 200 µl FPLC running buffer using Vivaspin 10 kDa MWCO columns. 
The sample was then injected through the sample injection port, and the separation was 
performed at 1 ml/min. Fractions of 1.5 ml were collected in 1.7 ml Eppendorf tubes 
using a BioFrac fraction collector (Bio-Rad) and concentrated to 20-30 µl using Vivaspin 
10K MWCO columns. Efficiency of separation was tested by non-reducing SDS PAGE.  
Affinity chromatography. Affinity chromatography was performed using two 
different systems. First, a pre-packed HiTrap Protein G column (GE Healthcare, 
Piscataway, NJ, USA) was used, which binds specifically to the immunoglobulin (Ig) 
Fc region. The samples were resuspended in FPLC running buffer. The chromatography 
column was washed with running buffer, and the samples were applied through the 
sample injection port. The column was thoroughly washed with running buffer until no 
protein was detected in the effluent. The antibodies bound to the column were then eluted 
with elution buffer (section 2.3.8). Fractions of 1.3 ml were collected in 1.7 ml Eppendorf 
tubes containing 200 µl neutralisation buffer (section 2.3.8). The fractions were 
concentrated to 50-100 µl with Vivaspin 10 kDa MWCO columns and analysed by non-
reducing SDS PAGE.  
Second, affinity columns were used based on the monoclonal antibody MAR18.5, 
which is specific for rat Ig κ chains. CNBr-activated SepharoseTM beads (Amersham, 
Uppsala, Sweden) were used for the preparation a MAR18.5 affinity column. For this, 
MAR18.5 was coupled to the Sepharose beads following the manufacturer’s instructions. 
Briefly, the beads were swelled in 1 mM HCl, resuspended in coupling buffer (section 
2.3.8) and incubated with MAR18.5 for two hours. The beads were then blocked to avoid 
non-specific binding, washed several times in alternating pH (section 2.3.8) and 
resuspended in FPLC running buffer. The column was packed as described for the gel 
filtration columns. Affinity chromatography was performed with the MAR18/5 columns 
as described for the HiTrap Protein G columns. 
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2.13.5 Fluorophor Labelling of Antibodies and Proteins 
Labelling with fluorescein isothiocyanate (FITC). FITC (Sigma-Aldrich) was 
dissolved in DMSO (Sigma-Aldrich) at 20 mg/ml, and stored at -20°C in 10 µl aliquots. 
Proteins were resuspended in 50 mM borate buffer at 1 mg/ml using ZEBA desalting 
columns. While vortexing, 5 µg of FITC per 100 µg of protein was added, followed by 
incubation at RT for 45 minutes. Remaining reactive dye was sequestered by the addition 
of 0.1 Vol. 1 M Tris-Cl (pH 8.5). The labelled protein was subsequently resuspended in 
D-PBS using Vivaspin size exclusion columns with the appropriate molecular cut-off 
(Sartorius). The proteins were washed with D-PBS until no coloration of the filtrate was 
visually detectable. 
Labelling with Alexa Fluor succinimidyl esters or Sulfo-NHS biotin. Alexa 
Fluor 488, 555 or 647 (Invitrogen) or Sulfo-NHS biotin (Invitrogen) were dissolved in 
DMSO at 10mg/ml and stored at -20°C in 10 µl aliquots. Proteins or antibodies were 
resuspended in freshly made 0.1 M NaHCO3 using ZEBA desalting columns at 2 mg/ml 
(antibodies) or 0.5 mg/ml (proteins). 10 µg of fluorescent dye or biotin was added per 
100 µg of antibody, or 50 µg of protein, respectively. The samples were incubated at RT 
for 8 minutes and the labelling reaction stopped by the addition of 0.1 Vol of 1 M Tris-Cl 
(pH 8.5). The labelled proteins were then resuspended in D-PBS using Vivaspin columns 
with the appropriate cut-off and washed until the filtrate was transparent. Labelling of 
antibodies was validated by flow cytometry. 
 
2.14 Statistical Analysis 
Statistical analysis was performed on cell proliferation data or EAE scores using a 
two-tailed t-test when testing statistical significance between two data sets. When 
comparing multiple sets of EAE scores, repeated measures ANOVA was used followed 
by Tukey’s multiple comparison test. Statistical analysis was carried out with the 
software GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). 
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3.1 Introduction 
 Therapeutic efficacy of GA treatment in MS and EAE is commonly associated 
with the expansion of anti-inflammatory TH2 cells and T-regs (62, 77, 80). However, T 
cell mediated protection does not result from direct effects of GA on T cells (84). Rather, 
the observed T cell expansion is a consequence of the action of GA on innate cells that 
can present antigen to T cells (86). Although APCs are considered to be the primary in 
vivo target of GA, it is not known whether GA has the same effect on all APCs or 
preferentially acts through a specific subset. Nevertheless, a characteristic feature of the 
mode of action of GA appears to be the MHCII restricted presentation of GA peptides to 
CD4 T cells, which then become activated and can inhibit or counteract pathogenic 
events in EAE and MS (62, 63, 86). 
3.1.1 The MHCII Antigen Presentation Pathway 
Several classes of pathogens replicate inside membrane-surrounded compartments 
of the cell, and proteins derived from such pathogens are inaccessible to the cytosolic 
proteasome complex. Instead, these proteins are degraded within acidified endosomal 
compartments (93). The enzymes involved in degradation of these proteins are proteases 
that are activated at low pH, the best-characterised ones of which are the cathepsin family 
of proteases (93). Extracellular pathogens or pathogen components, as well as 
phagocytosed fragments of apoptotic or necrotic host cells are also degraded in 
endosomal compartments after their uptake by the APC. Short peptides emerge as 
degradation products and are subsequently loaded onto MHCII molecules for 
presentation to CD4 T cells (93). 
MHCII molecules consist of two transmembrane subunits, the α- and β-chains, 
both of which are co-translationally translocated into the ER (13). In the ER, the α- and 
β-chains assemble to functional MHCII molecules containing one peptide-binding groove 
(13). A short polypeptide called the invariant chain (Ii) prevents premature loading of 
MHCII molecules with ER-resident peptides by binding to and blocking the peptide-
binding groove (13). 
An additional function of the Ii is the direction of MHCII to late endosomes 
where peptide loading occurs (figure 3.1). MHCII molecules are first transported from 
the ER to the Golgi complex, and pass through its cisternae to the trans-Golgi network 
(TGN) (94). An endosomal sorting signal that is contained within the sequence of the Ii 
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mediates transport of the MHCII molecules from the TGN to late endosomes (94). Late 
endosomal compartments are the sites where the MHCII pathway intersects with the 
endocytic pathway. These compartments are therefore referred to as MIIC (MHCII 
containing compartment) (93). 
 
 
 
 
Figure 3.1: Overview on the MHCII antigen presentation pathway.  
Exogenous antigens are taken up by professional APCs and localise to endosomes, in 
which processing to peptides takes place. The peptides are delivered to the MIIC 
compartment. Newly synthesised MHCII molecules assemble in the ER and associate 
with the invariant chain (αβ-Ii), which prevents premature acquisition of ER-resident 
peptides and directs MHCII molecules to the MIIC compartment via the TGN. The Ii is 
sequentially cleaved by cathepsins and HLA-DM in the MIIC, so that MHCII molecules 
can acquire antigenic peptides. Peptide-loaded MHCII molecules are then transported to 
the cell surface. Cell-surface MHCII is constitutively internalised and locates to 
endosomes, from where it can be transported to MIIC for re-acquisition of new peptides 
Adopted from ref. (93). 
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In the MIIC, the Ii is sequentially cleaved by acidic proteases such as cathepsins, 
and peptides are loaded onto MHCII molecules. Peptide loading is catalysed by H-2m in 
the mouse (HLA-DM in humans), an MHCII-like molecule that predominantly localises 
to MIIC and is not expressed on the cell surface (93). Another function of H-2m is the 
release of weakly bound peptides from MHCII, which ensures that MHCII molecules are 
transported to the cell surface only with stably bound peptides (93).  
The final step in antigen processing and presentation is the transport of pMHCII 
complexes from the MIIC to the cell surface. The complexes are transported within 
vesicles, and the directed transport to the cell surface is mediated by microtubules and 
associated motor proteins (6). At the cell surface, pMHCII can be recognised by specific 
TCRs on CD4 T cells (6).  
Peptide binding to MHCII is usually irreversible, but pMHCII are constitutively 
internalised from the cell surface (94). Internalised pMHCII localise to endocytic 
vesicles, where peptides are removed. MHCII molecules can subsequently be transported 
to MIIC compartments, for re-loading with new antigenic peptides (figure 3.1). This 
results in presentation of newly acquired peptides by recycled MHCII on the surface of 
the APC, rather than solely depending on a supply of de novo synthesised MHCII (94). 
3.1.2 Cross-presentation 
Professional APCs, and DCs in particular, have the capacity to take up and 
degrade extracellular pathogen-derived compounds or cell fragments, deliver peptides to 
the MHCI antigen presentation pathway and present them to CD8 T cells, a process 
known as cross-presentation (95). This feature of the immune system allows priming of 
CD8 T cells to combat pathogens that do not infect APCs.  
The mechanism of cross-presentation and the route antigens take can vary, 
depending on the nature of the antigen and the type of cross-presenting cell (96). Most 
studies have found that endocytosed antigens are required to escape the endocytic 
pathway and be degraded by the proteasome in the cytosol (95, 96). The antigens are 
subsequently transported into the ER by the transporter associated with antigen 
processing (TAP) complex. In the ER, loading of antigenic peptides onto newly 
synthesised MHCI molecules occurs, similar to the loading of intracellular pathogen-
derived antigens. However, it is not clear how material contained in endocytic vesicles 
gains access to the cytosol across membranes (96). 
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Recent reports have shown that internalised virions can be processed and the 
resulting peptides loaded on MHCI molecules in early endocytic vesicles of plasmacytoid 
DCs in a proteasome-independent manner (97). These vesicles may represent a 
specialised compartment for processing and cross-presentation of antigens derived from 
the cell exterior. Soluble antigens can also be diverted to the cross-presentation pathway 
in early endosomes. This requires their processing by proteasomes and re-import into 
endosomes by the TAP complex, which is recruited to endosomal membranes through 
TLR4 signalling (98). 
Research on the mechanisms of cross-presentation has been of great impact, 
because manipulation of this pathway may prove useful in the development of improved 
vaccines against viral infections and tumours, the challenge of which require a robust 
CD8 T cell response (99). 
3.1.3 Superantigens 
Superantigens (SAgs) are toxins that are predominantly produced by the gram-
positive bacteria Staphylococcus aureus and Streptococcus pyogenes, as well as by 
several other bacteria and viruses (100). Bacterial SAgs are secreted monomeric proteins 
with a molecular mass of 24-28 kDa (101). The benefit of SAgs to the bacteria that 
produce them is not fully understood. However, SAgs can have substantial effects on the 
immune system and cause severe pathologies like toxic shock or food poisoning (100). 
SAgs have the ability to simultaneously bind to MHCII molecules and to TCRs. 
In this way, SAgs are able to induce polyclonal T cell expansion and systemic release of 
inflammatory cytokines (102). Unlike conventional peptide antigens, SAgs can bind 
directly to MHCII and the TCR Vβ domain without being processed (103). In contrast to 
the highly specific interaction between TCRs and pMHCII complexes, SAgs are able to 
antigen non-specifically activate any T cell that expresses the correct TCR Vβ segment 
on its surface (103). As a result, a specific pMHCII complex activates an estimated one in 
105 to 106 T cells, where up to 20% of total T cells can be reactive to a given SAg (100). 
Streptococcal mitogenic exotoxin Z (SMEZ) is one of the most potent SAgs 
discovered to date (104). It has been found to be highly polymorphic, and more than 20 
allelic variants have been discovered from clinical isolates in New Zealand (105). A 
strain-specific variant, SMEZ2, has been recovered from S. pyogenes strain 2035, based 
on sequence homology to the original SMEZ (101). 
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 SMEZ2 M1 is a modified form of SMEZ2 that carries mutations in three amino 
acid residues (W75L, K182Q, D42C) that are responsible for TCR binding (106). As a 
result of these mutations, SMEZ2 M1 maintains the ability to bind MHCII without the 
toxic effects associated with the wild-type SAg.  
3.1.4 Objectives 
The first objective of the experiments presented in this chapter was to establish a 
GA treatment model of EAE suppression. Different GA formulations, sites of 
administration and doses were tested in order to set up a consistent EAE therapy. The use 
of a reliable model of GA treatment was of crucial importance for the subsequent 
assessment of drug targeting strategies.  
The main objective was to use the GA treatment model to develop a targeting 
strategy, aiming at the direct delivery of GA to MHCII molecules on the surface of 
APCs. For this, two different targeting molecules were used: a monoclonal antibody 
recognising MHCII or a modified SAg (SMEZ2 M1) that can also bind to MHCII with 
high affinity. This targeting strategy was hypothesised to significantly enhance uptake of 
GA by APCs and its presentation to CD4 T cells, resulting in an enhancement of GA-
specific T cell responses and an increase in the drug’s efficiency.  
Prior to use in EAE treatment, the targeting strategy was validated by in vitro 
proof-of-concept experiments, in which expansion of TCR transgenic T cells was 
measured after incubation with MHCII-targeted cognate antigen. 
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3.2 Results 
3.2.1 Establishment of a GA Treatment Model of EAE Suppression 
3.2.1.1 Pre-treatment with GA in PBS does not suppress EAE 
In the EAE model that was used throughout this study, disease was induced in 
C57BL/6J mice by subcutaneous immunisation with 50 µg MOG35-55 emulsified in CFA 
in the hind limb flanks. The average disease onset was apparent 10-12 days after EAE 
induction (figure 3.2). Untreated mice developed severe disease (EAE score 3-4) within 
four to five days after onset, and maintained clinical symptoms until the end of the 
40-day observation period. In some experiments a slight decrease of the clinical score 
was observed following the initial phase of severe disease, but total remittance or 
recovery did not occur (figure 3.3). 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Pre-treatment with GA in PBS does not suppress EAE. 
C57BL/6J mice received subcutaneous injections of 150 µg GA in PBS in the neck on 
seven consecutive days before EAE induction. Control mice (EAE) were injected with 
PBS only. (p > 0.05 for EAE vs. GA; mean ± SEM of n = 5 mice per group). Data 
represents one out of two independent experiments. 
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In order to establish a GA treatment model of EAE suppression, first a GA 
formulation was tested that did not contain adjuvants. Mice received subcutaneous 
injections of 150 µg GA in PBS into the scruff of the neck on seven consecutive days 
preceding EAE induction. As shown in figure 3.2, this mode of GA treatment did not 
have any effect on EAE onset or progression. Hence, subcutaneous injection of GA in 
PBS in the neck before disease induction was not an effective treatment for EAE. 
3.2.1.2 Co-Immunisation with MOG35-55 and GA Suppresses EAE 
In further effort to establish a GA treatment model, another GA formulation was 
tested that contained CFA as an adjuvant. EAE was induced in control mice as described 
above. For treatment, GA and MOG35-55 were mixed with CFA and subcutaneously 
injected into the hind limb flanks as a single emulsion that contained both the disease-
causing peptide and the disease-suppressing drug (107). As shown in figure 3.3, this GA 
formulation effectively suppressed EAE. This “co-immunisation” treatment was used as a 
positive control for EAE suppression for the rest of this study. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Co-immunisation with MOG35-55 and GA in CFA suppresses EAE. 
C57BL/6J mice received a single subcutaneous immunisation with 50 µg MOG35-55 with 
or without 500 µg GA in CFA. (p < 0.001 for EAE vs. GA; mean ± SEM of n = 5 mice 
per group). Data represents one out of twelve independent experiments. 
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At the end of the 40-day observation period spinal cords were removed from co-
immunised and untreated mice and sections of the spinal cords were stained with 
hematoxylin and eosin (figure 3.4). Local cellular infiltration of the spinal cords was 
evident in the sections from untreated mice, but no such infiltrations could be detected in 
the sections from the GA treated mice. 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: GA treatment prevents cellular infiltration of the spinal cord.  
EAE was induced in C57BL/6J mice, and the mice were either left untreated or co-
immunised with 500 µg GA. Spinal cords were removed 40 days after immunisation and 
paraffin-embedded 6 µm sections were stained with hematoxylin and eosin. Original 
magnification is 100x in upper panels. Lower panels show boxed area at 400x 
magnification. Scale bars: 200 µm (upper panels) or 50 µm (lower panels). Arrows: 
Clusters of infiltrating cells. Images shown are representative for three individual mice 
per group from one EAE experiment. 
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Co-immunisation with 500 µg GA almost completely suppressed EAE in most of 
the experiments. To determine whether EAE could be efficiently suppressed by lower 
doses of GA, mice were treated by co-immunisation with decreasing doses. As shown 
earlier, 500 µg GA was very efficient in suppressing EAE (figure 3.5). Reduction of the 
dose to 250 µg resulted in a statistically significant loss of protection. Mice treated with 
100 µg GA developed slightly more severe EAE than mice treated with 250 µg GA. 
Finally, 50 µg GA lacked significant protective effects (figure 3.5). These findings 
showed that 500 µg GA were necessary to achieve efficient EAE suppression by co-
immunisation treatment. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Determination of the optimal dose of GA for efficient EAE suppression.  
C57BL/6J were treated by co-immunisation with the indicated doses of GA. Control mice 
(EAE) were left untreated. (p < 0.05 for GA (500 µg) vs. GA (250 µg), p > 0.05 for EAE 
vs. GA (50 µg); mean ± SEM of n = 5 mice per group). Data represents one out of two 
independent experiments. 
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EAE than the untreated mice, but this difference did not reach statistical significance 
(figure 3.6). Disease onset was similar in treated and untreated mice. Mice treated by co-
immunisation were better protected from EAE than mice that had been treated in the 
neck, suggesting that the treatment site may be important for protection from EAE. 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Co-immunisation treatment is superior to GA treatment in the neck.  
C57BL/6J were either treated by subcutaneous co-immunisation or subcutaneous 
injections of 500 µg GA in CFA in the neck. Control mice (EAE) were left untreated. 
(p < 0.001 for GA vs. GA (neck), p > 0.05 for EAE vs. GA (neck); mean ± SEM of n = 5 
mice per group). 
 
 
3.2.1.3 Mannitol is not Required for Effective Co-Immunisation Treatment 
The formulation of GA that is approved for MS therapy and that was used in 
previous experiments contains 40 mg/ml mannitol as a stabilising agent. Strategies of GA 
targeting involve the chemical conjugation of GA to targeting molecules. The 
conjugation process includes several steps of desalting; hence the GA conjugates do not 
contain mannitol. Therefore, it was tested whether the absence of mannitol from the 
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amount of GA in the concentrate was determined by OD280 measurement. Mice were then 
treated by co-immunisation with 500 µg GA without mannitol. As shown in figure 3.7, 
mice treated with GA with or without mannitol showed a similar extent of protection 
from EAE. Some of the mice treated with the mannitol-containing GA formulation 
developed mild EAE from day 25 after EAE induction, while the mice treated with 
mannitol-free GA were completely protected. However, the difference between the two 
treatment groups was not statistically significant. This finding showed that therapeutic 
effect of GA in EAE treatment did not depend on the presence of mannitol. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Therapeutic effect of GA does not depend on the presence of mannitol.  
C57BL/6J received EAE induction and were co-immunised with two different GA 
formulations, either with or without mannitol (p < 0.001 for EAE vs. GA (-mannitol), 
p > 0.05 for GA vs. GA (-mannitol); mean ± SEM of n = 5 mice per group). Data 
represents one out of two independent experiments. 
 
3.2.1.4 GA does not Suppress EAE in MOG35-55 TCR Transgenic Mice 
 To determine whether suppression of EAE by GA was dependent on T cell 
recognition of GA peptides presented on MHCII molecules, the co-immunisation 
treatment was tested in mice that express a transgenic TCR that is not reactive to GA. 
2D2 mice express a transgenic TCR on their CD4 T cells that is specific for 
MOG35-55 (92). 2D2 mice developed more severe EAE compared to their wild-type 
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counterparts, and all of the mice were euthanised between days 20-30 after disease 
induction due to severe EAE (figure 3.8). Reduction of the dose of MOG35-55 from 50 µg 
to 25 µg for EAE induction did not improve EAE severity or survival of 2D2 mice (see 
A1.1). In this 2D2 model of EAE, co-immunisation with 500 µg of GA failed to 
ameliorate disease or increase survival (figure 3.8), suggesting that T cell recognition of 
GA peptides presented on MHCII molecules is key for EAE suppression. 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: GA does not suppress EAE in MOG35-55 TCR transgenic mice.  
EAE was induced in 2D2 mice with 50 µg MOG35-55. Mice were either left untreated 
(EAE) or co-immunised with 500 µg GA. (p > 0.05 for EAE vs. GA; mean ± SEM of 
n = 5 mice per group). Data represents one out of three independent experiments. † 
indicates that all mice in the corresponding group were euthanised due to severe EAE. 
 
 In summary, a GA treatment model of EAE suppression was established in 
C57BL/6J mice. In this model mice were subcutaneously co-immunised with the disease 
causing MOG peptide and GA in a single CFA emulsion in the hind limb flanks. The 
treatment was most effective at a dose of 500 µg GA and did not depend on the presence 
of mannitol. Although effective in wild-type mice, co-immunisation treatment failed to 
suppress EAE in transgenic mice that express a MOG35-55 specific TCR and cannot mount 
GA-specific T cell responses. The co-immunisation treatment was used in the treatment 
of wild-type mice throughout the rest of this study in the investigation of drug targeting 
strategies. 
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3.2.2 Antigen Targeting to MHCII with a Specific Antibody in vitro  
The aim of targeting GA into the MHCII antigen presentation pathway was to 
increase the efficacy of the drug by enhancing its uptake and presentation. Being a 
random copolymer, GA lacks a defined primary sequence, and can give rise to a range of 
different MHCII binding peptides (42). As a consequence, TCR transgenic systems 
specific for GA are not available. For this reason, a series of in vitro proof-of-concept 
experiments was performed using MOG and OVA proteins and splenocytes from the 
respective TCR transgenic 2D2 and OT-II mice. 
3.2.2.1 Conjugation of MOG and OVA Proteins to an anti-MHCII Antibody  
Due to the apparent importance of MHCII-restricted presentation of GA peptides 
to CD4 T cells during GA therapy, a monoclonal antibody specific for MHCII of the H-2b 
haplotype (clone M5/114) was chosen as targeting molecule. For conjugation of proteins 
to M5/114, a two-component chemical conjugation system was used. The conjugation 
process involved the modification of the antibody and the protein with the two chemicals 
separately, followed by the co-incubation of the modified antibody and protein. The two 
chemicals (C6-S-HyNic and sulfo-S-4FB) react with primary amines, i.e. with lysine 
residues and the N-terminal amine group of peptide backbones, and are complementary 
to each other, so that homotypic conjugation does not occur (108). The use of a single 
heterobifunctional amine/cysteine-reactive chemical was not feasible, because it would 
require the reduction of antibodies, which would in turn result in the loss of its quaternary 
structure and consequently in the loss of its function. 
Different experimental conditions were tested in order to optimise the conjugation 
protocol. Variables were the molar ratio of M5/114 to C6-S-HyNic (HyNic hereafter), the 
ratio of MOG or OVA to the complementary sulfo-S-4FB (4FB hereafter), and the ratio 
of the modified antibody to protein during co-incubation. Efficiency of conjugation was 
evaluated by non-reducing SDS-PAGE. A summary of the optimisation of the 
M5/114-MOG conjugation is given in table 3.1, and a representative SDS gel picture of 
the conjugates is shown in figure 3.9. The optimal reaction conditions were found to be 
the following for M5/114-MOG: Ratio (M5/114:HyNic) 1:100; ratio (MOG:4FB) 1:5; 
ratio (M5/114:MOG) 1:30. The conditions for the optimal conjugation of M5/114 to 
OVA were similar, except that the ratio (OVA:4FB) was 1:20 in this case. 
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Table 3.1: Optimisation of the conjugation of M5/114 to MOG.  
Correlation of molar ratios of antibody or protein to the respective chemical used for 
modification, as well as the molar ratios of antibody to protein with the efficacy of 
conjugation. Representative SDS gel images of “poor”, “fair” and “good” conjugation 
reactions are shown in figure 3.9.  
M5/114:HyNic MOG:4FB M5/114:MOG Outcome 
1:20 1:20 3:1 Poor conjugation 
1:20 1:20 1:1 Poor conjugation 
1:20 1:20 1:3 Poor conjugation 
1:20 1:20 1:10 Poor conjugation 
1:20 1:20 1:20 Poor conjugation 
1:20 1:20 1:50 Poor conjugation 
1:20 1:20 1:100 Poor conjugation 
1:10 1:5 1:3 Poor conjugation 
1:10 1:5 1:30 Fair conjugation 
1:10 1:20 1:3 Poor conjugation 
1:10 1:20 1:30 Poor conjugation 
1:100 1:5 1:3 Poor conjugation 
1:100 1:5 1:30 Good conjugation 
1:100 1:20 1:3 Poor conjugation 
1:100 1:20 1:30 Fair conjugation 
1:100 1:5 1:15 Fair conjugation 
 
Conjugates of a molecular weight of > 205 kDa were frequently observed 
(figure 3.9). The binding of a large number of proteins to one antibody molecule is not a 
satisfactory explanation for this observation, because high molecular weight (MW) 
complexes were observed in clusters over a relatively narrow range of molecular weight. 
Rather, the high-MW complexes probably consisted of two or more antibodies 
interconnected by protein molecules.  
In almost every permutation of reaction conditions tested, there was excess MOG 
or OVA protein left over in the reaction mixture that did not conjugate to M5/114 (see 
figure 3.9). Overall, reaction conditions with low amounts of unconjugated antibody were 
favoured over those with low amounts of unconjugated protein. The reason for this was 
that the removal of excess protein from the conjugates by size exclusion or gel filtration 
was anticipated to be less challenging than the removal of excess antibody. 
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Figure 3.9: Optimisation of the conjugation of MOG and OVA proteins to M5/114.  
The effect of varying reaction conditions on the efficacy of conjugation of MOG or OVA 
to M5/114 was evaluated. MOG or OVA were conjugated to M5/114 under varying 
conditions (see table 3.1), and efficiency of conjugation was assessed by non-reducing 
SDS-PAGE and Coomassie blue staining. M5/114 and MOG and OVA proteins were 
loaded alone as controls. The location of conjugates on the gel is exemplified in two lanes 
by arrows. MWM: molecular weight marker. 
 
 
Several different chromatographic approaches were tested for the removal of 
excess protein from the conjugates (table 3.2). The use of self-packed gel filtration 
columns did not result in satisfactory separation of the conjugates from any of the free 
proteins tested. For removal of excess MOG, both mini-centrifuge size-exclusion 
columns (50 kDa MW cut-off) and Ig-based affinity chromatography (HiTrap Protein G 
columns) were effective. However, for removal of OVA, neither of these methods was 
suitable. The use of self-packed affinity columns that contained an antibody specific for 
rat IgG κ chains (clone MAR18.5) also failed to bind to M5/114-OVA and therefore 
could not be used to separate the conjugate from free OVA (table 3.2). A control mixture 
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of unconjugated M5/114 and OVA could be effectively separated with both affinity 
columns. 
 
Table 3.2: Purification of M5/114-antigen conjugates by chromatography.  
MOG, OVA and GA were conjugated to M5/114. The indicated chromatography 
columns were used to separate the conjugates from excess free protein (see Materials and 
Methods). The outcome of the different means of purification is stated. 
Conjugate Purification method Column Outcome 
M5/114-MOG Gel filtration Sephacryl 300 HR Poor purification 
M5/114-MOG Size exclusion Vivaspin 50K MWCO Good purification 
M5/114-MOG Affinity HiTrap Protein G Good purification 
M5/114-OVA Gel filtration Sephacryl 300 HR Poor purification 
M5/114-OVA Size exclusion Vivaspin 50K MWCO No purification 
M5/114-OVA Affinity  HiTrap Protein G No purification 
M5/114-OVA Affinity  CNBr Sepharose-MAR18.5 No purification 
M5/114-GA Size exclusion Vivaspin 50K MWCO Poor purification 
M5/114-GA Affinity HiTrap Protein G Good purification 
 
 
In summary, the experimental procedure for conjugation of MOG and OVA 
proteins to M5/114 was optimised. Excess unconjugated MOG protein was effectively 
separated from the conjugates, and the M5/114-MOG conjugate was then tested for its 
potential to induce in vitro T cell proliferation (section 3.2.2.2). Excess OVA could not 
be removed, and the conjugate was therefore used as a mixture of M5/114-OVA and 
OVA in the in vitro proliferation assays. 
3.2.2.2 Targeting MOG and OVA to MHCII Enhances CD4 T Cell Proliferation in 
vitro 
T cell proliferation assays were performed in vitro using M5/114-MOG and 
splenocytes from TCR transgenic 2D2 mice. MOG protein was conjugated to M5/114 
and M5/114-MOG was separated from excess MOG as described in the previous section 
(figure 3.10A). Concentration of M5/114-MOG was determined by OD280 measurement. 
The molecular weight (MW) of M5/114-MOG was considered to be 175 kDa on average, 
as estimated from gel pictures (figure 3.10A). 
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Figure 3.10: Targeting MOG to MHCII enhances CD4 T cell proliferation in vitro.  
(A) MOG protein was conjugated to M5/114 and the conjugates purified with Protein G 
columns as described in Materials and Methods. The purified (+) and unpurified (-) 
conjugates as well as loading controls were analysed by non-reducing SDS-PAGE and 
stained with Coomassie blue. MWM: Molecular weight marker. (B) Proliferation assay 
with splenocytes from 2D2 mice. Splenocytes were incubated with the indicated 
concentration of antigens at 5 x 105 cells per well. The cells were incubated for 72 hours, 
and eight more hours in presence of [3H]-thymidine. Proliferation was measured by the 
incorporation of [3H]-thymidine. Data represents one out of five independent experiments 
(mean ± SEM of triplicate wells).  
 
 
Purified M5/114-MOG was incubated with 2D2 splenocytes to compare the 
proliferative response to free MOG. As shown in figure 3.10B, M5/114-MOG stimulated 
CD4 T cell proliferation at more than 100-fold lower concentrations than free MOG. A 
mixture of unconjugated M5/114 and MOG failed to induce proliferation at the same 
concentration as M5/114-MOG. As expected, M5/114-OVA failed to stimulate MOG-
specific T cells (figure 3.10B).  
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M5/114-OVA (estimated average MW 190 kDa, figure 3.11A) stimulated CD4 T 
cells at an almost 1000-fold lower concentration than free OVA (figure 3.11B). Although 
the conjugates could not be separated from excess OVA (figure 3.11A), a mixture of 
unconjugated M5/114 and free OVA failed to induce T cell proliferation at comparable 
doses to M5/114-OVA (figure 3.11B), indicating that the free OVA in the conjugation 
mixture was unlikely to contribute to the observed T cell proliferation in response to 
M5/114-OVA. The enhanced T cell expansion induced by M5/114-MOG and 
M5/114-OVA showed that uptake of selected antigens can be enhanced by conjugating 
them to an anti-MHCII antibody, resulting in markedly enhanced capacity of APCs to 
induce proliferation of CD4 T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Targeting OVA to MHCII enhances CD4 T cell proliferation in vitro.  
(A) OVA protein was conjugated to M5/114. M5/114-OVA could not be separated from 
OVA. The purified (+) and unpurified (-) conjugates as well as loading controls were 
analysed by non-reducing SDS-PAGE and stained with Coomassie blue. MWM: 
Molecular weight marker. (B) Proliferation assay with splenocytes from OT-II mice. 
Splenocytes were incubated with the indicated concentration of antigens at 5 x 105 cells 
per well. The cells were incubated for 72 hours, and eight more hours in presence of 
[3H]-thymidine. Proliferation was measured by the incorporation of [3H]-thymidine. Data 
represents one out of three independent experiments (mean ± SEM of triplicate wells). 
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3.2.2.3 Enhanced CD4 T Cell Proliferation is Independent of FcγR Mediated Uptake 
of M5/114-Antigen Conjugates 
Fcγ receptors (FcγR) are expressed by a variety of different cell types, including 
DCs, monocytes, macrophages and B cells (109). These receptors can bind to the 
constant Fc region of antibodies of the IgG isotype, and mediate uptake of the antibody 
and eventually bound or opsonised antigen into the cell interior (109). M5/114 is of the 
IgG2b isotype, and it was therefore possible that uptake of the M5/114 conjugates was 
mediated by FcγRs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Increased CD4 T cell proliferation to M5/114-MOG is not diminished 
by FcγRII/III blocking.  
Splenocytes from 2D2 mice were incubated with M5/114-MOG at the indicated 
concentrations either with or without 1 µg/ml anti-CD16/CD32 antibody (clone 2.4G2) at 
5 x 105 cells per well. MOG was used as a control antigen at the indicated concentrations. 
Anti-MOG-MOG (8.18C5-MOG) was used as a further control. The cells were incubated 
for 72 hours, and eight more hours in presence of [3H]-thymidine. Proliferation was 
measured by the incorporation of [3H]-thymidine. Data represents one out of two 
independent experiments (mean ± SEM of triplicate wells).   
 
 
To test whether FcγRs play a role in the uptake of M5/114-antigen conjugates, a 
proliferation assay was performed with M5/114-MOG in the presence of a blocking 
antibody specific for FcγRIII/II (CD16/CD32, clone 2.4G2). The presence of 2.4G2 did 
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not diminish M5/114-MOG induced CD4 T cell proliferation (figure 3.12). In addition, 
the use of an anti-MOG antibody (anti-MOG-MOG, clone 8-18C5) instead of M5/114 
failed to induce T cell proliferation (figure 3.12). These results indicated that increased T 
cell proliferation in response to M5/114-MOG was most likely not due to increased 
uptake of antigens via FcγR mediated pathways. 
3.2.2.4 Targeting OVA to MHCII enhances CD8 T cell Proliferation in vitro 
The enhanced CD4 T cell proliferation in response to MHCII targeted antigen was 
probably a result of increased antigen uptake and processing in endosomal compartments. 
As antigens can gain access to the MHCI pathway from early endosomes (98), the ability 
of the M5/114-antigen conjugates to increase antigen presentation on MHCI molecules 
was also investigated. For this, proliferation assays were performed using splenocytes 
from OT-I mice, which express a transgenic TCR on CD8 T cells that is specific for the 
OVA257-264 peptide. M5/114-OVA was 100-fold more potent in stimulating CD8 T cells 
than free OVA, whereas a mixture of unconjugated M5/114 and OVA failed to induce 
proliferation (figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Targeting OVA to MHCII enhances CD8 T cell proliferation in vitro.  
Splenocytes from OT-I mice were incubated with the indicated concentrations of antigens 
at 5 x 105 cells per well. The cells were incubated for 48 hours, and eight more hours in 
presence of [3H]-thymidine. Proliferation was measured by the incorporation of 
[3H]-thymidine. Data represents one out of two independent experiments (mean ± SEM 
of triplicate wells). 
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Taken together, these findings suggested that conjugation of antigens to an 
antibody specific for MHCII was a suitable approach to deliver these antigens selectively 
to MHCII-expressing professional APCs. The improved antigen delivery to APCs 
resulted in a substantially enhanced induction of T cell proliferation by the APCs. Uptake 
of the conjugates was not mediated by FcγR, and the conjugates were much more 
efficient in inducing proliferation of both CD4 and CD8 T cells than the respective free 
antigens. 
 
3.2.3 Antigen Targeting to MHCII with a Modified Superantigen in vitro. 
In order to further consolidate the effectiveness of targeting MHCII, MOG and 
OVA proteins were conjugated to an alternative targeting molecule, a modified SAg. The 
modified SAg SMEZ2 M1 has three point mutations that prevent its binding to TCRs, but 
MHCII binding is still intact (106). SMEZ2 M1 can therefore be used as a non-toxic 
vector for antigen-delivery to MHCII.  
When MOG was conjugated to SMEZ2 M1 (SMEZ2 M1-MOG), it was a 
100-fold stronger inducer of CD4 T cell proliferation than free MOG upon incubation 
with 2D2 splenocytes (figure 3.14A). Likewise, SMEZ2 M1-OVA induced proliferation 
at about 100-fold lower concentration than free OVA (figure 3.14B). 
Contribution of free proteins that were present in the conjugation mixture could 
be excluded in these experiments, since free MOG or OVA proteins were essentially 
absent from the conjugates. As for the M5/114-antigen conjugates, T cell proliferation 
was antigen-specific, whereby SMEZ2 M1-MOG failed to induce proliferation of OT-II 
cells, and SMEZ2 M1-MOG-OVA did not induce proliferation of 2D2 cells. 
These findings were consistent with the enhanced T cell proliferation induced by 
the M5/114 conjugates and emphasised the role of MHCII as a target for efficient 
delivery of antigen to APCs.  
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Figure 3.14: Targeting MOG and OVA proteins to MHCII with a modified SAg 
results in enhanced CD4 T cell proliferation in vitro.  
The proliferative response to the SMEZ2 M1-MOG (A) or SMEZ2 M1-OVA (B) 
conjugates was measured using splenocytes from 2D2 (A) or OT-II (B) mice. Free MOG 
or OVA proteins and conjugates containing irrelevant antigen were used as experimental 
controls. Splenocytes were incubated with the indicated concentrations of antigens at 
5 x 105 cells per well. The cells were incubated for 72 hours, and eight more hours in 
presence of [3H]-thymidine. Proliferation was measured by the incorporation of 
[3H]-thymidine. Data represents one out of three (A) or two (B) independent experiments 
(mean ± SEM of triplicate wells). 
 
 
3.2.4 Targeting GA to MHCII Increases T Cell Proliferation in vitro 
The enhancement of T cell proliferation in the TCR transgenic models illustrated 
the potential for targeting GA to the MHCII pathway to enhance proliferation of GA-
specific T cells to improve EAE suppression. To test the proliferative response to 
MHCII-targeted GA, proliferation assays were performed using draining lymph node 
(dLN) cells from mice previously immunised with GA.  
GA was conjugated to M5/114 with the conjugation system that had been used for 
the conjugation of MOG and OVA to the same antibody (figure 3.15A). The most 
efficient conjugation was achieved at a ratio (GA:4FB) of 1:2, whereas the other 
conditions were the same as for the M5/114-MOG conjugation (see table 3.1). Free GA 
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was removed by affinity chromatography (see table 3.2), and the final concentration of 
M5/114-GA was determined by OD280 measurement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Targeting GA to MHCII results in enhanced T cell proliferation.  
(A) GA was conjugated to M5/114 and purified by affinity chromatography. Purified (+) 
and unpurified (-) conjugates were analysed by non-reducing SDS-PAGE. M5/114 
antibody (Ab) and GA were loading controls. MWM: Molecular weight marker. (B) 
C57BL/6J mice were immunised with GA. Seven days after immunisation, draining 
lymph node cells were incubated with M5/114-GA, GA or M5/114-MOG for 80 hours, 
and 16 more hours in presence of [3H]-thymidine. Proliferation was measured by the 
incorporation of [3H]-thymidine. (C) GA was conjugated to SMEZ2 M1 as described in 
Materials and Methods. The conjugate was analysed by non-reducing SDS-PAGE and 
stained with Coomassie blue. Unconjugated oxidised and reduced SMEZ2 M1 (M1 and  
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SMEZ2 M1 was conjugated to GA using SMCCplus, a heterobifunctional 
chemical, which has two functional groups that react with sulfhydryls and primary 
amines, respectively. First, GA was activated with SMCCplus, and then activated GA 
was co-incubated with reduced SMEZ2 M1 for conjugation. The reaction conditions were 
optimised (see A1.2 and A1.3), and the optimal conditions were a ratio (GA:SMCCplus) 
of 1:5; a ratio (SMEZ2 M1:GA) of 1:10, and an overnight incubation of activated GA 
with SMEZ2 M1 at 4° C (figure 3.15C). The conjugate contained only insignificant 
amounts of free GA, and was used in proliferation assays without need for further 
purification. 
To test the potency of the GA conjugates to induce T cell proliferation, C57BL/6J 
mice were immunised with 500 µg GA in CFA. Seven days later, cells were isolated from 
draining (inguinal) lymph nodes of the mice. The cells were incubated with GA or 
M5/114-GA and proliferation was measured. As shown in figure 3.15B, M5/114-GA was 
100-fold more potent inducer of T cell proliferation than free GA. Proliferation was also 
observed to M5/114-MOG, albeit at a much lower level. SMEZ2 M1-GA also induced 
proliferation of draining lymph node cells of GA-primed C57BL/6J mice at a 100-fold 
lower concentration than free GA (figure 3.15D). 
Taken together, these results showed that antigens could be targeted to MHCII by 
conjugation to two different targeting molecules. This targeting resulted in markedly 
enhanced proliferation of TCR transgenic cells in vitro, and also of antigen-primed non-
transgenic T cells. This increased proliferation was therefore predicted to increase the 
efficacy of GA in EAE treatment, by promoting the expansion of protective T cells. 
 
 
 
 
 
 
 
 
 
 
M1(red), respectively) and GA were controls. (D) C57BL/6J mice were immunised with 
500 µg GA. Seven days after immunisation, draining lymph node cells were incubated 
with SMEZ2 M1-GA, GA or SMEZ2 M1-MOG for 96 hours, and 16 more hours in 
presence of [3H]-thymidine. Proliferation was measured by the incorporation of 
[3H]-thymidine. Data (B and D) represents one out of two independent experiments each 
(mean ± SEM of triplicate wells). 
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3.2.5 Targeting GA to MHCII does not suppress EAE  
Induction of GA-specific T cell responses is considered important for efficient 
protection from EAE (see figure 3.8 and ref. (62)). As a result, targeting GA to the 
MHCII antigen presentation pathway had the potential to significantly enhance T cell 
proliferation.  
To test the potential of targeting GA to MHCII to improve EAE suppression, 
C57BL/6J mice were treated by co-immunisation with M5/114-GA. As shown in figure 
3.16, 20 µg M5/114-GA failed to ameliorate EAE. GA effectively suppressed EAE at a 
dose of 500 µg, but failed to suppress EAE at an equimolar amount to M5/114-GA 
(GA(e.m), figure 3.16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Targeting GA to MHCII with a monoclonal antibody does not suppress 
EAE.  
C57BL/6J mice were left untreated (EAE), treated with 20 µg M5/114-GA, or with 
1.2 µg GA (GA(e.m)) following the co-immunisation protocol. Mice were co-immunised 
with 500 µg GA as a positive control. (p > 0.05 for EAE vs. M5/114-GA and for EAE vs. 
GA (e.m), p < 0.001 for GA vs. GA (e.m) and for GA vs. M5/114-GA; mean ± SEM of 
n = 5 mice per group). Data represents one out of two independent experiments. 
 
Similar results were obtained using the other MHCII targeting conjugate, 
SMEZ2 M1-GA (figure 3.17). This conjugate did not ameliorate EAE after co-
immunisation with 5 µg per mouse. M5/114-GA (estimated average MW 170 kDa, see 
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figure 3.15A) and SMEZ2 M1-GA (average MW 40 kDa, see figure 3.15C) were used at 
comparable molar amounts in the EAE experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Targeting GA to MHCII with a modified SAg does not suppress EAE.  
C57BL/6J mice were left untreated (EAE), or co-immunised with 5 µg SMEZ2 M1-GA, 
or with 500 µg GA. (p > 0.05 for EAE vs. SMEZ2 M1-GA, p < 0.001 for 
SMEZ2 M1-GA vs. GA; mean ± SEM of n = 5 mice per group). Data represents one out 
of two independent experiments. 
 
 
3.2.6 Summary 
A GA treatment model of EAE suppression was established to be used in 
investigating drug targeting strategies. In this model, co-immunisation of mice with 
500 µg GA resulted in efficient EAE suppression. This treatment mode was used as a 
control to evaluate the efficacy of MHCII targeted GA as a therapeutic agent. 
Targeting antigens to the MHCII antigen presentation pathway enhanced CD4 and 
CD8 T cell responses by 100- to 100-fold in vitro. This could be achieved by the 
conjugation of antigens to two different targeting molecules, which have in common the 
high affinity binding to MHCII. Conjugation of GA to both targeting molecules also 
resulted in increased in vitro proliferation of GA-primed lymphocytes. However, 
treatment of EAE with GA conjugated to either of the targeting vectors was not effective.
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3.3 Discussion 
Presentation of GA on MHCII molecules may be a key process for GA therapy of 
EAE and MS (figure 3.8 and ref. (62)). For this reason, targeting GA directly into the 
MHCII antigen presentation pathway was anticipated to result in an increase in 
therapeutic effect in EAE and hence in a marked decrease of the therapeutic dose. The 
results presented in this chapter involved the establishment of a GA treatment model of 
EAE that was subsequently used to investigate the drug targeting approach. The targeting 
strategy was validated by in vitro antigen targeting experiments before proceeding to the 
in vivo EAE model. 
3.3.1 Establishment of a GA Treatment Model in C57BL/6J Mice 
For MS treatment, GA is injected subcutaneously at a dose of 20 mg per day (86). 
In mice, GA can suppress EAE induced with MBP (68), MOG (39), PLP (110) and 
MSCH (111). EAE suppression can be achieved with different GA formulations, 
including subcutaneous treatments in CFA, IFA and PBS (73, 80, 107). EAE suppression 
can be achieved by a single GA injection in CFA or IFA before or concomitantly with 
disease induction (73, 107, 111). In absence of adjuvants, continuous GA treatment 
before disease induction or after disease onset is required (80, 82). In addition to these 
subcutaneous treatment models, GA also ameliorates MBP-induced EAE upon oral 
treatment. However, the oral route of administration has not proven beneficial for MS 
treatment in clinical trials (112). 
The EAE model used in the current study involves the subcutaneous injection of 
MOG35-55 peptide emulsified in CFA. Immunisation of mice with the peptide in CFA 
induces an immune attack that is primarily directed against MOG epitopes and results in 
demyelination and axonal damage (39, 107). MOG35-55 induced EAE in H-2b mice 
displays a chronic disease course, and is often accompanied by optic neuritis, which 
results from demyelination and damage to the optic nerve (39, 92). 
The objective of the experiments presented in this chapter was the establishment 
of a treatment model of EAE using GA as the therapeutic agent. GA has previously not 
been used in our laboratory for EAE therapy. Moreover, subtle differences in 
experimental settings can have substantial influence on therapeutic outcome, as discussed 
below. It was therefore necessary to establish a treatment model, on which subsequent 
drug targeting approaches could be based.  
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First, the efficacy of subcutaneous GA injections in PBS was tested, because 
treatment without adjuvants is more readily applicable to MS treatment. The lack of EAE 
suppression after pre-treatment with GA in PBS over a seven-day period preceding 
disease induction (see figure 3.2) contradicts findings from other groups (80). The 
different results may be due to different treatment sites. In this study, mice received GA 
injections in PBS at the scruff of the neck, whereas in the other study, mice were treated 
in the hind limb flanks (M. S. Weber, personal communication). The contradicting results 
indicate that the treatment site is an important factor in GA treatment of EAE. Consistent 
with this, treatment with GA in CFA did not significantly improve EAE when given 
subcutaneously in the scruff of the neck, as opposed to the co-immunisation treatment in 
the flanks (see figure 3.6). 
The observation that GA treatment needs to take place at the same site as EAE 
induction suggests that the drug modulates cells in the immediate surroundings of the 
injection site, which can then prevent or suppress the initiation of pathogenic T cell 
responses in the draining lymph node. It should be noted that, even in studies where the 
therapeutic formulations do not contain adjuvants per se, the injections take place at the 
same site as EAE induction; hence CFA is present at the site of treatment (80, 82). 
Therefore, CFA components may influence cells that GA eventually acts on, even when 
the GA formulation does not contain CFA. 
Co-immunisation of mice with a single emulsion of CFA that contained both the 
encephalitogenic MOG peptide and GA proved highly efficient in suppressing EAE. This 
GA treatment efficiently prevented immune cell trafficking into the spinal cord 
parenchyma, and the majority of the treated mice lacked clinical signs of EAE over the 
complete observation period. The lack of effect of mannitol on EAE treatment was also 
confirmed, making co-immunisation an effective positive control for this study.  
3.3.2 GA does not Protect TCR Transgenic Mice from EAE 
2D2 mice express a transgenic TCR on their CD4 T cells that is specific for the 
MOG35-55 peptide (92). These mice develop spontaneous optic neuritis and more severe 
EAE than their wild-type counterparts upon immunisation with MOG35-55 (92).  
In contrast to EAE suppression in wild-type mice, GA failed to alter the disease 
course in 2D2 mice (figure 3.8). Begum-Haque et al. recently reported a slight but 
statistically significant reduction of EAE severity in GA-treated 2D2 mice (82). EAE of 
2D2 mice was milder than that of 2D2 mice used in this study (mean maximum EAE 
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score 3 vs. 5). It is possible that disease severity plays a role in GA treatment, where GA 
is more effective in suppressing moderate disease pathology in 2D2 mice. However, both 
the results of this study and the study of Begum-Haque et al. show that GA is less 
effective in treatment of EAE in 2D2 mice than in their wild-type counterparts (see figure 
3.8 and ref. (82)). 
Two potential scenarios can explain the lack of protection in 2D2 mice. First, an 
overwhelming pathogenic T cell response that overcomes GA-induced protection may be 
induced in the TCR transgenic mice by immunisation with MOG35-55 (82). Second, the 
absence of GA-specific T cell responses in the transgenic mice may be the reason for the 
lack of suppression. GA does not cross-react with MOG epitopes on TCR level (80), 
hence a GA-specific T cell response (including TH2 cells or T-regs) is absent in 2D2 
mice. Presentation of disease-unrelated peptides by GA-conditioned monocytes induces 
expansion of Foxp3+ T-regs in vitro (80), but it is unknown whether this can happen with 
the disease-promoting MOG35-55 peptide in vivo. Hence a GA-specific T cell response is 
likely required for efficient EAE suppression. 
Either individual scenario or a combination of both is plausible. Consistent with 
the second, GA is known to act through multiple mechanisms. Although not mentioned 
by the authors, T cell independent mechanisms such as apoptosis of TH1 or TH17 cells 
(113) or neuroprotective effects (114) may be responsible for the minor beneficial effects 
of GA on moderate EAE observed by Begum-Haque et al. (82). A further possible 
explanation for the discrepancy is that continuous daily GA treatment (82) may be able to 
ameliorate disease where co-immunisation (present study) fails. 
3.3.3 Targeting Antigens to MHCII Enhances T Cell Proliferation in vitro 
TCR transgenic 2D2 or OT-II mice were used to evaluate in vitro antigen 
presentation and CD4 T cell proliferation in response to MOG and OVA conjugates, 
respectively. Both M5/114-MOG and M5/114-OVA caused a pronounced increase of 
proliferation relative to the respective free proteins (see figures 3.10 and 3.11). These 
results are consistent with the findings of Lunde et al. (115), who showed a similar 
increase in T cell proliferation using genetically engineered anti-MHCII antibodies. 
These “Troy-bodies” contained T cell epitopes within the constant region of their heavy 
chains. Increased antigen presentation required internalisation and processing of the 
Troy-bodies (115). 
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Despite the different means of antigen incorporation into the anti-MHCII 
antibody, it is highly likely that the M5/114-antigen conjugates used in this study 
function by the same mechanism as Troy-bodies in antigen targeting. Internalisation and 
processing of the M5/114 conjugates are likely to be key processes for efficient antigen 
presentation, because the proteins are covalently bound to the antibody. Hence the 
mechanism probably involves the uptake of the M5/114-antigen conjugates by APCs, 
their processing in acidic compartments within the endocytic pathway, and the 
subsequent loading of the released peptides onto recycling MCHII molecules within the 
MIIC compartment (see figure 3.1). 
The increased CD4 T cell proliferation in response to M5/114-MOG was not 
affected by blocking FcRγIII/II with a specific antibody (116). In addition, a complex of 
MOG and MOG-specific IgG (clone 8-18C5) did not induce T cell proliferation (see 
figure 3.12). To note, the isotypes of M5/114 and 8-18C5 are IgG2b and IgG1, 
respectively. MOG-specific antibodies of the IgG2b isotype were not available. Although 
these findings do not formally exclude contribution of FcγRs that are not blocked by 
2.4G2, they strongly suggest that uptake of M5/114 conjugates occurs through an MHCII 
dependent mechanism. A similar increase of antigen presentation was observed when the 
targeting molecule M5/114 was replaced by SMEZ2 M1 (see figure 3.14). Increased CD4 
T cell proliferation in response to SMEZ2 M1-antigen conjugates is in consistence with 
previous findings (117), and further supports an MHCII-dependent uptake of the 
M5/114-antigen conjugates. 
Various attempts to separate M5/114-OVA from free OVA failed, because 
M5/114-OVA did not bind to Ig specific affinity chromatography columns, and gel 
filtration yielded insufficient separation due to poor resolution of the column. (see table 
3.2). Hence, M5/114-OVA could not be purified (see figure 3.11A) and was used as a 
mixture of M5/114-OVA and free OVA in the in vitro proliferation assays. However, it is 
unlikely that contaminating free OVA contributed substantially to increased proliferation. 
OVA concentration was much lower in wells supplemented with M5/114-OVA than in 
control wells containing free OVA protein (see figure 3.11). In addition, a mixture of 
unconjugated M5/114 and OVA failed to improve antigen presentation over free OVA.  
In addition to increased antigen presentation on MHC II molecules, M5/114-OVA 
was also efficient in directing OVA peptides into the cross-presentation pathway (see 
figure 3.13). This observation is consistent with previous findings reporting that, upon 
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incubation with SMEZ2 M1-OVA, DCs can efficiently present OVA peptides on MHCI 
molecules (117). Efficient stimulation of CD8 T cells with low doses of M5/114-OVA 
has great potential for the development of improved vaccines, considering that cross-
presentation of free antigens is biased towards presentation of high-abundance antigens 
(95).  
M5/114-GA and SMEZ2 M1-GA induced increased in vitro proliferation of GA-
primed non-transgenic lymphocytes (see figure 3.15). Unlike cultures from TCR 
transgenic mice, lymph node cell suspensions from wild-type mice contain both CD4 and 
CD8 T cells that can be potentially reactive to GA. Hence, increased proliferation of 
lymph node cells may in part be attributable to CD8 T cells. However, expansion of TH 
cells in response to GA is well-established (68, 69, 73, 80), and enhanced proliferation of 
CD4 T cells was evident in the TCR transgenic systems. Targeting GA to MHCII is 
therefore likely to primarily induce CD4 T cell proliferation. 
In summary, targeting antigens to the MHCII antigen presentation pathway 
resulted in significantly enhanced antigen uptake and presentation and gave rise to 
increased antigen-specific proliferation of CD4 and CD8 T cells in vitro. Next, it was 
tested whether the increased T cell proliferation in response to MHCII targeted GA was 
beneficial in EAE treatment. 
3.3.4 Targeting GA to MHCII in EAE Treatment 
Targeting antigens to professional APCs has been explored for a long time as a 
strategy for the development of improved vaccines (99). The major advantage of targeted 
vaccines is the potential of priming immune responses at low doses of antigen. Targeting 
antigens to cell surface molecules of DCs has also been shown to induce antigen specific 
tolerance in EAE (99), illustrating potential therapeutic applications in the treatment of 
diseases such as MS. 
It has been reported more than two decades ago that subcutaneous immunisation 
with an anti-MHCII conjugated antigen can induce secondary serological responses to a 
later challenge with the free antigen in mice, even when the conjugates are administered 
without adjuvant (118). These responses are depend on MHCII haplotype compatibility 
to the antibody used for targeting (119). In addition, oral or intraduodenal immunisation 
with anti-MHCII conjugated antigens efficiently targets intestinal epithelial cells, and the 
targeted antigens are superior to free antigens in inducing specific serum IgG and IgA 
(120). 
CHAPTER 3: TARGETING GA TO ANTIGEN PRESENTING CELLS 
 79 
In addition to the magnitude of the response, targeting antigens by conjugating 
them to anti-MHCII antibodies can also induce isotype switching (121). Hence targeting 
antigens to MHCII is a promising strategy for the generation of efficient antibody 
responses. However, MHCII has not been used as a target molecule for the induction of 
suppressive of regulatory T cell responses. 
Although targeting GA to MHCII by conjugating it to M5/114 or SMEZ2 M1 
significantly enhanced T cell proliferation in vitro, both M5/114-GA and SMEZ2 M1-GA 
failed to suppress EAE. The conjugates were used at a molar dose approximately 
500-fold lower than the therapeutic dose of free GA. The dose of conjugates used for 
EAE treatment were based on the finding that MHCII targeted antigens can induce CD4 
T cell proliferation at concentrations 100- to 1000-fold lower than free antigen (see 
figures 3.10 and 3.15). However, it is possible that a higher dose of M5/114-GA is 
required for therapeutic effect in vivo than is necessary to induce proliferation in vitro. 
SMEZ2 M1-MOG35-55 has been shown to ameliorate EAE at a 105-fold lower 
molar dose than the free peptide as a result of antigen specific tolerance (122). However, 
antigen-specific suppression of MOG35-55 specific T cells is unlikely to contribute to the 
effect of GA, since GA does not cross-react with MOG35-55 on TCR level (80). It 
therefore remains possible that the dose of GA conjugates used for treatment in this study 
was too low for therapeutic benefit.  
Another possible explanation for the failure of the GA conjugates to suppress 
EAE is that internalisation and processing leads to the destruction of TCR epitopes that 
are contained within GA. The drug may be required to bind to MHCII directly without 
internalisation in order to stimulate protective T cells or to block pathogenic T cell 
responses (88). However, this is unlikely to be the case as the proliferative response to 
M5/114-GA showed that GA was also effective in inducing T cell responses after being 
internalised and processed to peptides (see figure 3.15).  
Despite increased uptake and presentation of the drug by APCs, the conjugates 
may have failed to induce differentiation of the target cells into anti-inflammatory or 
tolerogenic APCs. Used as a conjugate, GA may have acted as a mere antigen, devoid of 
its immunomodulatory properties that promote the induction of anti-inflammatory or 
regulatory T cell responses (73, 80, 84, 85). Therefore, although the conjugates are 
capable of increasing T cell expansion, the T cells may not express the phenotype that is 
required for EAE suppression. 
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3.3.5 Conclusions 
Targeting proteins to MHCII expressing cells enhanced antigen-specific 
proliferation of T cells in vitro, as hypothesised. However, increased in vitro T cell 
proliferation did not translate into protection from EAE. The lack of EAE suppression 
may have been due to insufficient amounts of the GA conjugates used for treatment. 
However, other explanations for the failure of the conjugates are also possible. 
Free GA induces a phenotype shift of APCs through an unknown mechanism, 
rendering them able to induce anti-inflammatory/regulatory T cell responses (80). 
Inability of the conjugates to induce this phenotype shift is a possible explanation for the 
lack of therapeutic effect of MHCII-targeted GA. Proliferation of GA specific T cells was 
observed in response to MHCII-targeted GA in vitro, but may by itself not be sufficient 
for disease suppression in vivo in absence of APC derived qualitative signals that 
promote differentiation of TH2 cells or T-regs. 
It is not known whether GA can act through all MHCII expressing cells, or 
preferentially targets a particular APC subset. Hence sequestration of the conjugates by 
MHCII expressing cells that are irrelevant to GA’s mechanism may have been 
responsible for the lack of protection. Thus targeting GA to a specific APC subset, rather 
than to total MHCII-expressing cells, may be a promising approach for treatment of EAE. 
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4.1 Introduction 
MS and EAE are considered to be primarily CD4 T cell mediated diseases (51). 
However, there is evidence that monocytes and macrophages also substantially contribute 
to disease progression. Macrophages play important roles in the destruction of CNS 
tissue, the production of pro-inflammatory cytokines, and as APCs in the CNS (25). 
Depletion of macrophages in the CNS (123) or blockade of monocyte trafficking into the 
CNS (124) reduces severity of EAE, indicating that these cells are key players in the 
effector phase of the disease and are required for the development of clinical EAE. 
In addition to disease-promoting functions, monocytes and macrophages can also 
play protective roles during treatment. GA is effective in treatment of MS and EAE 
suppression, and can alter monocyte or macrophage phenotype leading to their 
production of anti-inflammatory cytokines such as IL-10 or TGF-β (80, 125). In addition, 
GA treated monocytes are able to induce regulatory T cell responses that suppress EAE 
(80). Hence modulation of monocytes by GA may be a central part of its mechanism in 
MS treatment.  
4.1.1 Monocytes in Innate and Adaptive Immunity 
Monocytes are mononuclear leukocytes of myeloid lineage. They develop in the 
bone marrow from myeloid progenitors and are released into the bloodstream (126). They 
either reside in the blood as circulating monocytes, or enter peripheral tissue both under 
steady-state conditions and in response to inflammation, where they differentiate into 
macrophages or DCs (3). Monocytes fulfil important functions in innate immunity, 
including phagocytosis and clearance of pathogens or debris (127). In addition, 
monocytes can also induce adaptive immune responses by presenting antigen to T cells 
(128). 
4.1.1.1 Monocyte Subpopulations 
Monocytes are primarily identified by the expression of CD11b (αM integrin 
subunit) and low levels of F4/80 in mice (3). Recent findings have shown that murine 
monocytes can be further divided into at least two subpopulations that differ in their 
ability to respond to environmental signals and their potential to differentiate (129). One 
population expresses intermediate levels of the CX3C-chemokine receptor-1 (CX3CR1) 
and high levels of Ly6C (CX3CR1int Ly6Chi monocytes), a marker of unknown function 
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that is part of granulocyte antigen-1 (Gr-1). The other subset expresses high levels of 
CX3CR1 but only low levels of Ly6C (CX3CR1hi Ly6Clo, ref.(129)).  
CX3CR1int Ly6Chi monocytes express the chemokine receptor CCR2 and can be 
recruited to sites of inflammation by MCP-1, the ligand for CCR2. Consequently, 
CX3CR1int Ly6Chi monocytes are commonly referred to as inflammatory monocytes 
(129). Inflammatory monocytes can home to sites of infection and differentiate into 
F4/80hi macrophages or CD11chi DCs (3). Macrophages are highly phagocytic and play 
an important role in the clearance of pathogens and the resolution of inflammation (3). In 
addition, both macrophages and DCs can contribute to pathogen clearance by producing 
cytotoxic molecules such as nitric oxide (NO) and inflammatory cytokines such as 
tumour necrosis factor-α (TNF-α, refs. (3, 130)). Following their activation in inflamed 
tissue, inflammatory monocytes and monocyte-derived DCs also acquire the ability to 
present antigen and prime CD4 T cell responses (126). 
CX3CR1hi Ly6Clo monocytes persist longer in the blood than inflammatory 
monocytes during homeostasis, and are therefore referred to as resident monocytes (129). 
The main function of resident monocytes is thought to be the replenishment of resident 
tissue macrophages, although they also have the potential to differentiate into DCs and to 
present antigen (126). Current data suggests that monocytes show the phenotype of 
inflammatory monocytes when they egress from the bone marrow and that differentiation 
into resident monocytes occurs subsequently to their release into the circulation (126, 
131).  
Monocytes gradually upregulate CD11c or F4/80 during their differentiation into 
DCs or macrophages, respectively (3). In most cases, CD11bhi F4/80lo CD11c-/lo 
monocytes can be distinguished from mature DCs (CD11chi) or macrophages (F4/80hi, 
refs. (3, 131)). However, phenotypical and functional traits of monocytes overlap with 
those of macrophages/DCs during differentiation, and classification of differentiating 
cells can be ambiguous (3). A more stringent definition refers to monocytes as 
mononuclear phagocytic cells in the circulation with the propensity to differentiate into 
macrophages, in addition to their CD11bhi F4/80lo cell surface phenotype (128). This 
definition is based on the assumption that differentiation programs are initiated in 
monocytes concurrently with their extravasation, and hence excludes cells that have left 
the bloodstream (128). 
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4.1.1.2 Differential Activation of Monocytes and Macrophages 
Inflammatory and resident monocytes play different roles in immunity. In 
addition, different types of stimuli can induce differential activation of monocytes and 
macrophages (3). Based on in vitro experiments of macrophage activation in response to 
defined stimuli, three common activation types have been identified to date: classical 
activation, alternative activation and type II activation (132).  
Classical activation by inflammatory stimuli such as TLR ligands can trigger pro-
inflammatory responses. Classically activated macrophages produce high levels of 
TNF-α and IL-12, have increased capacity to present antigen and produce high amounts 
of ROS (3, 132). In contrast, alternative activation by anti-inflammatory cytokines (e.g. 
IL-4, IL-5) results in poor antigen presentation and the production of low levels of anti-
inflammatory cytokines (132). Type II activation can be achieved by immune complexes 
(e.g. Ig-opsonised antigen), and type II activated macrophages produce high levels of 
IL-10, but also show increased production of NO and efficient antigen presentation (132).  
It is possible that monocytes respond to environmental stimuli in a similar 
fashion, and their differentiation into macrophages may happen concomitantly with 
differential activation in vivo. For instance, GA treatment induces type II monocytes that 
produce high levels of IL-10 and efficiently present antigen to CD4 T cells in vivo (80). 
However, classification of activation states is not as clear-cut in the more complex in vivo 
environment, and intermediate phenotypes of activation also exist (3, 131).  
Production of NO is one feature of type II activated monocytes/macrophages, and 
high-level production of NO in peripheral lymphoid tissue is associated with T cell 
suppression in autoimmunity (45). Inflammatory monocytes with suppressive ability 
accumulate in spleens of mice immunised with CFA (133). These monocytes suppress T 
cell proliferation through production of NO in vitro (133). However, the in vivo role of 
these suppressive monocytes remains unclear, since mice develop clinical EAE despite 
their accumulation. 
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4.1.2 Myeloid-Derived Suppressor Cells 
Accumulation of cells expressing myeloid markers has been described in tumour-
bearing mice and in cancer patients (134). These cells have immunosuppressive ability, 
and are commonly referred to as myeloid-derived suppressor cells (MDSCs, ref. (135)). 
Myeloid cells with suppressive ability have also been found to accumulate in numerous 
other conditions such as bacterial and parasitic infections, acute and chronic 
inflammation, graft-versus host disease and autoimmune diseases (133, 134, 136-138). 
Although most of the studies have focused on the suppression of CD8 T cells that 
predominate in anti-tumour immunity, subsets of MDSCs have also been shown to 
suppress CD4 T cell responses (138). 
Subsets of myeloid cells with suppressive ability include monocytes, 
macrophages, DCs, granulocytes and early myeloid progenitors (133, 139, 140). MDSCs 
can employ several mechanisms to suppress T cell proliferation in an antigen non-
specific manner, including IFN-γ induced NO production (133), IL-4/IL-13 dependent 
arginase 1 (ARG1) upregulation (134) and inhibition of signalling through the TCR-ζ 
chain (136).  
Subsets of MDSCs show augmented expression of the inducible NO synthase 
(iNOS) and suppress T cell responses through production of NO (139). NO-mediated 
suppression is associated with an inhibition of key intracellular signalling components 
such as Janus-activated kinases, STAT-3 or STAT-5, which results in T cell 
unresponsiveness, cell cycle arrest or apoptosis (139). NO may directly mediate these 
effects by oxidation or S-nitrosylation of the target proteins (134). 
Some MDSC subsets upregulate ARG1 in response to TH2 cytokines like IL-4, 
IL-13, TGF-β and IL-10, an enzyme that reduces L-arginine to urea and ornithine (139). 
ARG1 mediated suppression is associated with reduced expression of TCR-ζ chain on T 
cells, which renders T cells unresponsive to stimulation (139). 
Subsets of MDSCs have different suppressive potential and employ different 
mechanisms to suppress immune responses (139, 140). In addition, individual MDSC 
subsets can exhibit suppressive function through more than one mechanism, as blockade 
of iNOS or ARG1 reduces, but does not completely abrogate suppression by MDSCs 
(140). Recent studies also suggest that, throughout a number of tumour and other disease 
models, mononuclear CD11b+ Gr-1lo F4/80lo cells possess consistent and comprehensive 
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suppressive ability, whereas suppressive potential of other MDSC subsets is more 
variable (133, 140, 141). 
4.1.3 Objectives 
GA can induce the production of anti-inflammatory mediators by DCs, 
macrophages, monocytes and microglia in vitro (84, 85, 125), and induce type II 
activation of monocytes in vivo (80). However, it is unclear whether GA preferentially 
targets a specific cell type or can act through multiple cell subsets in vivo. The primary 
aim of the experimental work presented in this chapter was to identify the in vivo target 
cell population of GA. The further objective was to characterise the target cells and to 
assess their potential to antigen non-specifically suppress T cell proliferation. Direct 
suppression of self-reactive cells is a potential mechanism that contributes to protection 
from EAE (45), and understanding the mechanisms of suppression could pave the way 
for the development of improved therapeutics.  
Finally, targeting GA to its target cell population in vivo by conjugating it to a 
specific monoclonal antibody was hypothesised to enhance the therapeutic efficacy of 
GA in EAE and to substantially reduce the therapeutic dose. Drug targeting by the use of 
monoclonal antibodies is a promising approach for the treatment of many diseases (99), 
and GA targeting has the potential of clinical application in MS therapy.  
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4.2 Results 
4.2.1 GA Binds to CD11bhi Cells in vivo, but not in vitro 
GA can modulate CD11b+ CD11c- monocytes in vivo (80), but it is not clear 
whether this is a result of direct action on monocytes. The primary in vivo target cell 
population of GA is currently not known. GA has been shown to bind to MHCII 
expressing cells in vitro (87). However, it is currently unclear whether or not in vitro GA 
binding is specific to a particular type of MHCII expressing cell. In addition, targeting 
GA to MCHII is ineffective in suppressing EAE at low dose (see figures 3.16 and 3.17). 
It is therefore possible that MHCII molecules are not the main in vivo targets of GA. 
To identify its in vivo target cell population, GA was labelled with Alexa 
Fluor® 488 (Alexa488), and injected intravenously to C57BL/6J mice. Cell suspensions 
were prepared from the blood, spleen and lymph nodes (inguinal, para-aortic or 
mesenteric) one hour after the injections, and analysed by flow cytometry (figure 4.1). 
GA bound to a population of cells in the blood and spleen that expressed high levels of 
CD11b (CD11bhi) and located to the mononuclear fraction on the side scatter (SSClo). 
Alexa488 labelled OVA was used as control, and did not bind to the same cells. Bovine 
trypsinogen, an inactive precursor of the intestinal protease trypsin, and DM SMEZ2, a 
modified bacterial superantigen, also bound to CD11bhi cells in both blood and spleen 
(figure 4.1). MOG protein was included as a further control protein and, like OVA, did 
not bind to any cells. 
The percentage of GA+ cells showed considerable variation between individual 
mice and this variation correlated with the percentage of total CD11bhi SSClo cells 
(compare figures 4.1 and 4.2). Hence the variation was not due to differences in GA 
binding, but due to variance in the presence of target cells. In addition, GA, but not 
DM SMEZ2 or trypsinogen, also bound to a significant percentage of CD11b- cells in 
blood and spleen, but the fluorescence intensity was much lower than the staining of 
CD11bhi cells (figure 4.1).  
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Figure 4.1: GA binds to a CD11bhi cell population after intravenous injection.  
C57BL6/J mice received intravenous injections of 50 µg Alexa488 labelled proteins in 
PBS. Cells from indicated tissues were recovered one hour after the injections, stained for 
cell surface antigens and cells of individual mice were analysed by flow cytometry. Plots 
are gated on mononuclear cells. Data represents one out of at least three independent 
experiments for each protein. 
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Binding to CD11bhi cells was also observed when the mice were injected with 
fluorescein isothiocyanate (FITC) labelled GA (figure 4.2); hence GA staining was not 
limited to one particular fluorophor. However, GA staining could not be detected upon 
intravenous injection of biotinylated GA and subsequent incubation of blood cells with 
PerCP-conjugated streptavidin in vitro (figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: GA staining of CD11bhi cells with different fluorophors.  
C57BL6/J mice received intravenous injections of 50 µg of GA or OVA, which had been 
labelled with Alexa488, FITC or biotinylated. Cells from the blood were recovered one 
hour after the injections and stained for cell surface antigens. Cells from mice that had 
received biotinylated proteins were stained with streptavidin (SA)-PerCP. Cells from 
individual mice were analysed by flow cytometry. Plots are gated on mononuclear cells. 
Data represents one out of two independent experiments (n = 2 mice per group). 
 
 
To test whether binding to CD11bhi cells would occur in vitro, Alexa488 labelled 
GA (GA-Alexa488) was incubated with single cell suspensions from blood, spleens or 
lymph nodes of C57BL/6J mice at 37 °C in PBS containing 1% FCS for one hour. The 
cells were then analysed by flow cytometry for GA staining. Even though some CD11bhi 
cells showed weak GA staining compared to OVA (figure 4.3), the staining was much 
less pronounced than the in vivo staining of CD11bhi cells by GA. Some CD11b- cells 
showed distinct GA staining in vitro (figure 4.3), and these cells were heterogeneous in 
MHCII expression (see A1.4). The pattern of staining was essentially the same upon 
incubation in buffer supplemented with 0.1% sodium azide (data not shown). Hence, the 
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weak GA staining in vitro was likely due to binding to cell surface molecules, rather than 
fluid-phase pinocytosis, since OVA-Alexa488 stained less cells than GA and GA staining 
was also observed in azide-containing buffer (142). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: GA does not bind to CD11bhi cells in vitro.  
Single cell suspensions were prepared from spleens, inguinal lymph nodes and blood of 
C57BL/6J mice. The cells were incubated in absence (PBS) or presence of 10 µg/ml 
Alexa488 labelled GA or OVA for one hour at 37 °C in a 96-well plate at 5 x 104 cells per 
well. The cells were then stained for cell surface markers and analysed by flow cytometry. 
Data represents one out of two independent experiments with duplicate wells. 
 
 
In summary, GA binding to CD11bhi cells was observed in vivo in blood and 
spleen using two different fluorophors, but significant staining of CD11b+ or MHCII+ 
cells was not observed in vitro upon incubation with cell suspensions from the same 
tissues.  
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4.2.1.1 GA+ Cells in the Blood Show Monocyte Cell Surface Phenotype 
Next, the cells that showed GA staining in vivo were further characterised based 
on their expression of cell surface markers. GA-Alexa488 was injected intravenously as 
above, and cell surface marker expression of GA-binding cells in the blood was 
examined. GA binding cells were heterogeneous in expression of Ly6C, Gr-1, CD11c 
and MHCII (figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: GA+ cells in the blood show monocyte cell surface phenotype.  
GA-Alexa488 was injected intravenously to C57BL/6J mice at a dose of 50 µg per 
mouse. CD11bhi cells were enriched from pooled blood of five mice by magnetic sorting 
one hour after the injections. The cells were then stained for cell surface markers and 
analysed by flow cytometry. Bottom right panel row shows the FSC/SSC profile of GA+ 
cells in comparison to total blood cells. Data represents one out of two experiments. 
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Virtually all cells that bound GA lacked cell surface expression of Ly6G and were 
SSClo, indicating that the cells were not neutrophils or other granulocytes (140). GA-
binding cells expressed low levels of F4/80 and high levels of CD11b (figure 4.4), 
indicating that they were monocytes (3). The heterogeneity in Ly6C and Gr-1 indicates 
that both inflammatory and resident monocytes were contained within the GA binding 
population (131). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Binding of GA to CD11bhi cells is independent of MHCII.  
MHCII deficient B6Aa0/Aa0 mice received intravenous injections of 50 µg of Alexa488-
labelled proteins in PBS. Cells were recovered from the indicated tissues of individual 
mice one hour after the injections. The cells were stained for cell surface markers and 
analysed by flow cytometry. Plots are gated on mononuclear cells. Data represents one of 
two independent experiments. 
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Both GA and trypsinogen bound to monocytes in MHCII deficient B6Aa0/Aa0 
mice (figure 4.5). The percentage of cells that bound GA and trypsinogen were higher 
than in wild-type mice, due to an elevated overall percentage of monocytes in the blood 
of MHCII deficient mice. In addition, GA-binding cells in MHCII deficient mice were 
also F4/80lo and Ly6G-, similar to GA+ cells in wild-type mice (see A1.5). 
In summary, GA bound to a heterogeneous population of monocytes in the blood 
after intravenous injection. The binding was independent of MHCII, because virtually all 
CD11bhi cells of the mononuclear fraction bound GA in both wild-type and MHCII 
deficient mice (see figures 4.1 and 4.5).  
4.2.1.2 Time-course of Monocyte Staining by GA 
In the above experiments, blood cells were recovered for analysis one hour after 
injection of fluorophor-labelled GA. To investigate the time profile of GA staining, 
GA-Alexa488 was intravenously injected, and blood cells of individual mice were 
analysed over time. Consistent with previous experiments, more than 90% of monocytes 
were GA+ one hour after injection (figure 4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: GA staining of blood monocytes is stable over 18 hours.  
C57BL/6J mice were intravenously injected with 50 µg of GA-Alexa488. Mice were tail-
bled at the indicated time points after the injections and blood cells were analysed by 
flow cytometry. Data originates from separate experiments for time ranges of 20 minutes 
to six hours and from six hours to 96 hours. Both experiments were performed twice with 
five mice each. 
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Essentially the same percentage of monocytes was GA+ 20 minutes after 
injection. The percentage of GA+ monocytes remained stable for six hours, and decreased 
only slightly between six and 18 hours after injection, but the mean fluorescence index 
(MFI) of GA+ cells declined gradually after one hour. After 48 hours, only a low 
percentage of monocytes could be identified as GA+, and the MFI had declined further. 
Two separate experiments were performed to cover the time periods from 20 minutes to 
six hours, and from six hours to 96 hours, respectively. Due to ethical regulations, tail 
bleeding was limited to four times for every individual mouse.  
In summary, GA was found to rapidly bind to blood monocytes in an MHCII 
independent manner after intravenous injection. To determine the specificity of this 
binding, other proteins were tested for their ability to bind to monocytes in vivo. 
Trypsinogen and DM SMEZ2, but not MOG or OVA bound to blood monocytes, 
indicating that GA binding to monocytes was not an artefact of non-specific binding. 
Although these results suggested that GA may specifically target monocytes in vivo, 
whether GA binding alters monocyte function remained unclear.  
4.2.2 Intravenous GA Treatment Enhances the Suppressive Ability of Monocytes 
Immunosuppressive MDSCs with monocyte-like phenotype have been described 
in murine tumour models (140, 143) as well as in EAE (133). In addition, independent 
studies in our laboratory have shown that blood monocytes from naïve mice can suppress 
T cell proliferation in an antigen non-specific manner (C. Slaney, unpublished data). To 
determine if T cell suppression by monocytes could play a role in GA treatment, the 
effect of GA treatment on the suppressive ability of blood monocytes was investigated.   
To test the suppressive ability of GA-treated blood monocytes, C57BL/6J mice 
were injected intravenously with GA, and PBMCs were recovered through density 
gradient separation of blood isolated three hours after GA treatment. Monocytes were 
enriched by magnetic sorting and co-cultured with C57BL/6J splenocytes in presence of 
beads coated with anti-CD3/anti-CD28 antibodies that promote polyclonal T cell 
expansion. Monocytes from naïve mice suppressed T cell proliferation in a dose-
dependent manner, and monocytes from GA treated mice were even more potent 
suppressors of T cell proliferation (figure 4.7). Suppression was not simply due to 
phagocytosis of the beads by monocytes, because the same effect was also observed in 
anti-CD3/anti-CD28 coated wells (C. Slaney, unpublished data). CFSE dilution assays 
also showed that proliferation of both CD4 and CD8 T cells in the mixed splenocyte 
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culture was suppressed by monocytes (C. Slaney, unpublished data).  These results 
suggested that the binding of GA to monocytes in blood could have functional relevance, 
by enhancing the potential of monocytes to suppress T cell dependent immune responses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: GA enhances the ability of monocytes to suppress polyclonal T cell 
proliferation.  
C57BL/6J mice received intravenous injections of 50 µg GA or were left untreated 
(control). PBMCs were recovered three hours after the injections, and CD11bhi 
monocytes enriched by magnetic sorting (>80% CD11bhi). The monocytes were co-
cultured with 5 x 104 C57BL/6J splenocytes at the indicated ratios in presence of beads 
coated with anti-CD3/anti-CD28 in round-bottom wells. The cells were incubated for 24 
hours, and additional eight hours in the presence of [3H]-thymidine. Proliferation was 
measured by [3H]-thymidine incorporation. Results represent one out of two independent 
experiments (Mean ± SEM of triplicate wells; * p < 0.01, two-tailed t-test). 
 
 
To test whether GA treatment could also enhance the suppression of antigen 
specific T cell proliferation, monocytes were enriched from PBMCs of GA treated mice 
or of naïve controls. The monocytes were co-cultured with CFSE labelled TCR 
transgenic 2D2 lymphocytes in the presence of MOG35-55 peptide. CD4 T cell 
proliferation in the co-culture was assessed by flow cytometric analysis of CFSE dilution. 
Monocytes of GA treated mice were equally potent suppressors of MOG35-55 specific 
CD4 T cell proliferation as naïve monocytes (figure 4.8). The failure to detect superior 
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suppression by GA treated monocytes could have been due to limitations of the 
experimental setting, as discussed in section 4.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: GA treated and naïve monocytes equally suppress MOG35-55 specific T 
cell proliferation in vitro.  
C57BL/6J mice received intravenous injections of 50 µg GA or were left untreated. 
PBMCs were recovered three hours after the injections, and CD11bhi monocytes enriched 
by magnetic sorting (>80% CD11bhi). Monocytes from GA treated (blue histogram) or 
untreated (red histogram) mice were co-cultured with 5 x 104 C57BL/6J lymphocytes in 
presence of 10 µg/ml MOG35-55 in round-bottom wells. The ratio of monocytes to 
lymphocytes was 1:2. 2D2 lymphocytes were cultured in presence (open black 
histogram) or absence (shaded histogram) of MOG35-55 as controls. The cells were 
cultured for 72 hours, and CFSE dilution was analysed by flow cytometry. Results 
represent one out of two independent experiments with duplicate wells. 
 
To further investigate the possible role of T cell suppression in GA treatment, an 
in vivo proliferation assay was performed. CD4+ cells were purified from 2D2 mice, 
labelled with CFSE, and adoptively transferred to congenic mice, which express the 
CD45.1 marker on their leukocytes rather than CD45.2, which is expressed by C57BL/6J 
mice (and 2D2 mice, which are on C57BL/6J background). Together with the cell 
transfer, mice received intravenous injections of either MOG35-55 alone or MOG35-55 and 
GA. Analysis of CFSE dilution in spleens and blood of the recipients showed that 
Lymphocytes + MOG35-55 +  
naïve CD11bhi 
 
 
Lymphocytes + MOG35-55 +  
GA CD11bhi 
 
 
Lymphocytes + MOG35-55 
 
  
Lymphocytes only 
 
CFSE 
 
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
%
 o
f 
M
a
x
CHAPTER 4: TARGETING GA TO MONOCYTES 
 97 
MOG35-55 specific proliferation of TCR transgenic donor cells was reduced in GA treated 
mice, in comparison to mice injected with the MOG peptide only (figure 4.9).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Intravenous GA treatment suppresses CD4 T cell proliferation in vivo.  
Splenocytes from 2D2 mice were labelled with CFSE and CD4+ cells were purified by 
magnetic sorting. Purified CD4+ cells were adoptively transferred to CD45-congenic 
mice (4 x 106 cells per mouse, > 95% CD4+). Mice were either injected with cells only 
(shaded histograms), with cells and 2 µg MOG35-55 (red histograms) or with cells and 2 
µg MOG35-55 and 50 µg GA (blue histograms). Two to four days after cell transfer, CFSE 
dilution in the spleens and blood of the recipients was analysed by flow cytometry. 
Histograms are gated on CD45.2+ CD4+ cells. Data represents one out of two independent 
experiments (n = 2 mice per group). 
 
These results showed that intravenous GA treatment could modulate monocytes to 
exhibit an increased capacity to suppress polyclonal, but not MOG35-55 specific, T cell 
proliferation in vitro. However, MOG35-55 specific T cell proliferation was impaired in 
vivo upon intravenous GA treatment. It is therefore possible that suppression of myelin-
specific T cells by GA modulated monocytes contributes to GA therapy in EAE. 
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4.2.3 Effects of GA on Monocytes cannot be Detected in Draining Lymph Nodes  
Enhanced suppressive ability of GA treated monocytes was observed after 
intravenous injection of GA (section 4.2.2), but it remained unclear whether increased T 
cell suppression contributed to suppression of EAE in the subcutaneous co-immunisation 
GA treatment model.  
The first question addressed was whether binding of GA to monocytes could be 
detected after subcutaneous injection. For this, C57BL/6J mice were subcutaneously 
immunised with 500 µg FITC-labelled GA emulsified in CFA. Draining (inguinal) lymph 
node cells were analysed by flow cytometry two to four days after immunisation (figure 
4.10). A small population of CD11bhi cells (0.9-1.9%) was present in the lymph nodes of 
immunised as well as naïve mice, but these cells did not show GA staining. GA staining 
could not be detected after subcutaneous injection in PBS either (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: GA-FITC cannot be detected in lymph nodes after immunisation.  
C57BL/6J mice were subcutaneously immunised with 500 µg GA-FITC in CFA. 
Draining lymph nodes were digested with DNase/collagenase (see Materials & Methods) 
at indicated time points after immunisation cells of individual mice were analysed by 
flow cytometry. Data represents one out of three experiments (n = 2 mice per time point).  
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The constant percentage of CD11bhi cells in draining lymph nodes suggested that 
monocyte infiltration of draining lymph nodes did not occur within the first four days 
after immunisation. A more extensive time course experiment was performed to study the 
CD11bhi population in the draining lymph nodes of immunised mice. The percentage of 
CD11bhi cells did not change in draining lymph nodes during eight days following 
immunisation with CFA containing unlabelled GA (figure 4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: The percentage of CD11bhi cells in the draining lymph node does not 
change after immunisation.  
C57BL6/J mice were immunised with 500 µg GA emulsified in CFA. Draining lymph 
nodes were digested with DNase/collagenase at indicated time points after immunisation 
and single cell suspensions of individual mice were analysed by flow cytometry. Data 
represents one out of four independent experiments (n = 2 mice per time point). 
 
  
In CFA-immunised mice, accumulation of CD11bhi cells was observed in the 
blood and spleen. The accumulating cells were CD11bhi Ly6Cint Ly6G+ (figure 4.12), 
suggesting that they were neutrophils or other granulocytes (140). An increase in the 
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SSClo CD11bhi monocyte population was not observed in spleens or blood of immunised 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: CD11bhi Ly6G+ granulocytes accumulate in spleen and blood after 
immunisation with CFA.  
C57BL/6J mice were subcutaneously immunised with CFA. Single cell suspensions from 
spleens and blood were prepared eight or 48 hours after immunisation and analysed by 
flow cytometry. Plots are gated on CD11bhi cells. Data represents one out of four 
independent experiments (n = 2 mice per time point). 
 
 
The lack of monocyte accumulation in draining lymph nodes after immunisation 
raised the question whether blood monocytes escaped detection because they had 
undergone phenotypic changes following immunisation, for instance matured into DCs. 
To address this question, enriched CD11bhi monocytes from naïve C57BL/6J mice were 
adoptively transferred to naïve CD45-congenic mice. One day after cell transfer, 
recipients were immunised with CFA. Cells expressing CD45.2 were not detected in 
draining lymph nodes of recipients five days after cell transfer (figure 4.13). However, 
CD45.2+ cells could not be detected in the blood of the recipients, either. The small 
percentage of seemingly CD45.2+ CD11b+ cells observed in both tissues were likely to be 
auto-fluorescent cells, because they were also present in tissues from mice that had not 
received cell transfer (figure 4.13). 
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Figure 4.13: Adoptively transferred monocytes cannot be detected in draining 
lymph nodes of immunised recipients.  
PBMCs from C57BL/6J mice were enriched for CD11bhi monocytes by magnetic sorting 
(>80% CD11bhi). The monocytes were adoptively transferred to CD45-congenic mice 
(2 x 105 cells per mouse). One day after cell transfer, recipients were immunised with 
500 µg GA emulsified in CFA, or CFA only, or were not immunised (cells only). Four 
days after immunisations, cells were isolated from draining lymph nodes (dLN) and the 
blood and analysed by flow cytometry. Data represents one out of two independent 
experiments (n = 1 mouse per group). 
 
 
In summary, monocyte infiltration could not be detected in draining lymph nodes 
of immunised mice. The lack of monocyte infiltration was evident over eight days 
following immunisation, and adoptively transferred CD11bhi cells could not be recovered 
from draining lymph nodes or blood of immunised congenic recipients.  
4.2.4 GA Treatment does not Impair T Cell Proliferation in EAE  
The lack of monocyte infiltration of the draining lymph nodes after immunisation 
raised the question whether increased T cell suppression by monocytes after intravenous 
GA treatment would translate to the subcutaneous treatment model. To clarify whether 
suppression of myelin specific T cells contributes to GA therapy in EAE, an ex vivo and 
an in vivo approach was undertaken. 
First, the ex vivo proliferative capability of lymphocytes from GA treated mice 
was compared to untreated mice. For this, EAE was induced in C57BL/6J mice, and the 
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mice were either left untreated or co-immunised with GA. Seven days later, lymphocytes 
were isolated from draining lymph nodes of immunised mice and cultured in presence of 
MOG35-55. In this ex vivo setting, lymphocytes from GA treated mice did not show 
reduced proliferation in comparison to untreated mice (figure 4.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Co-immunisation with GA does not impair ex vivo MOG35-55 specific T 
cell proliferation.  
C57BL/6J mice were immunised with MOG35-55 or GA treated by co-immunisation 
(MOG35-55 + GA). Cells were isolated from draining lymph nodes seven days after 
immunisations and incubated in presence of MOG35-55 (5 x 105 cells per well). The cells 
were incubated for 80 hours, and additional 16 hours in presence of [3H]-thymidine. 
Proliferation was measured by [3H]-thymidine incorporation (p > 0.1 for MOG35-55 vs. 
MOG35-55 + GA). Data represents one out of two independent experiments (Mean ± SEM 
of triplicate wells).  
 
 
Secondly, MOG35-55 specific T cell proliferation was investigated in vivo in GA-
treated mice. CFSE labelled CD4+ cells from 2D2 mice were adoptively transferred to 
CD45-congenic mice. One day after cell transfer, recipients were immunised with CFA 
only, with MOG35-55, or GA treated by co-immunisation. Two to four days after 
immunisation, CFSE dilution in donor cells was assayed in spleens, draining lymph 
nodes and blood of the recipients (figure 4.15). No significant differences in proliferation 
were detected in any of the analysed tissues between GA treated and untreated mice. 
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Figure 4.15: Co-immunisation treatment with GA does not suppress MOG35-55 
specific T cell proliferation in EAE.  
Splenocytes from 2D2 mice were labelled with CFSE and CD4+ cells were purified by 
magnetic sorting. Purified CD4+ cells were adoptively transferred to CD45-congenic 
mice (4 x 106 cells per mouse, >96% CD4+). One day after cell transfer, recipients were 
immunised with CFA only (shaded histograms), with MOG35-55 (red histograms) or GA-
treated by co-immunisation (blue histograms). Two to four days after the immunisations, 
CFSE dilution in the spleens, draining lymph nodes (dLN) and blood of the recipients 
was analysed by flow cytometry. Histograms are gated on CD45.2+ CD4+ cells. Data 
represents one out of at least two independent experiments (n = 2 mice per group). 
 
In summary, suppression of MOG35-55 specific T cell proliferation was not 
observed in mice co-immunised with GA. These results are in contrast to the 
enhancement of in vitro suppressive ability of monocytes and reduced in vivo MOG35-55 
specific CD4 T cell proliferation following intravenous GA treatment (see figures 4.7 and 
4.9), and suggest that suppression of myelin specific T cells does not occur after 
subcutaneous co-immunisation with GA.  
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4.2.5 Temporary Monocyte Depletion does not Impair GA Treatment of EAE 
Enhanced T cell suppressive ability of monocytes after intravenous GA treatment 
did not translate into increased suppression of myelin reactive T cells in the subcutaneous 
treatment model. However, monocytes have been shown to contribute to GA treatment in 
EAE by inducing regulatory and anti-inflammatory T cell responses (80). Furthermore, 
the in vivo binding assays presented in section 4.2.1 suggested that GA may preferentially 
target monocytes in EAE treatment. Therefore the next question to be addressed was 
whether therapeutic efficacy of GA in EAE is dependent on monocytes. 
Monocytes can be depleted in vitro and in vivo with dichloromethylene 
diphosphonate (Cl2MDP) loaded liposomes, which are taken up by phagocytic cells and 
induce their apoptosis (144). To investigate whether the presence of monocytes is 
essential for efficacy of GA treatment, monocytes of C57BL/6J mice were depleted by 
intravenous injection of Cl2MDP-liposomes prior to EAE induction and GA treatment. 
Monocytes comprised less than 1% of PBMCs 24 hours after liposome injection, as 
opposed to 5-10% in mice that had not received liposomes (data not shown). GA treated 
mice were protected from EAE to the same extent, regardless of whether they had 
received monocyte depleting treatment or not (figure 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Temporary monocyte depletion does not impair GA treatment of EAE.  
C57BL/6J mice received intravenous injections of Cl2MDP-liposomes 16 hours before 
EAE induction and GA treatment by co-immunisation. (p < 0.001 for Cl2MDP + EAE vs. 
Cl2MDP + GA; p > 0.05 for GA vs. Cl2MDP + GA; mean ± SEM of n = 5 mice per 
group). Data represents one out of two independent experiments. 
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GA-treated mice that received Cl2MDP developed slightly more severe EAE than 
GA-treated mice without monocyte depletion. This difference occurred 25-30 days after 
monocyte depletion and was not statistically significant. This slight difference is 
therefore unlikely to be attributable to the temporary depletion of monocytes.  
Monocyte depletion did not interfere with the onset or the progression of EAE in 
untreated control mice. Depletion of monocytes by Cl2MDP is only transient, and 
monocyte numbers recover three to four days after their depletion (131). Hence, this 
finding showed that GA therapy did not depend on the presence of monocytes in the early 
phase of treatment. 
4.2.6 Targeting GA to CD11b does not Suppress EAE at Low Dose 
The association of GA with monocytes as well as its effects on suppressive 
function of monocytes after intravenous treatment did not translate to the subcutaneous 
co-immunisation model. In a reciprocal approach, intravenous injection of C57BL/6J 
mice with a single dose of 500 µg of GA immediately after EAE induction failed to 
suppress disease (figure 4.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Intravenous GA treatment does not suppress EAE.  
C57BL/6J mice received intravenous injections of 500 µg GA in PBS immediately before 
EAE induction (GA (i.v)). Mice were left untreated (EAE) or co-immunised with GA as 
controls. (p > 0.05 for EAE vs. GA (i.v); mean ± SEM of n = 5 mice per group). Data 
represents one out of two independent experiments. 
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The failure of intravenous GA treatment to suppress EAE may have been due to a 
lack of a sustained effect on monocytes after a single injection. Persistent effects of GA 
on the immune system is ensured by CFA in the subcutaneous treatment model, which 
gradually releases the drug into the system over time (37). Hence, a subcutaneous 
treatment strategy of targeting GA to monocytes was tested to assess whether sustained 
release of monocyte-targeted GA could suppress EAE. 
For monocyte targeting, GA was conjugated to an antibody specific for CD11b 
(clone M1/70), a cell surface molecule that all GA-binding monocytes invariably 
expressed at high levels (see figure 4.4). The concentration of the conjugate was 
determined by OD280 measurement. For treatment of EAE, mice were co-immunised with 
20 µg of the conjugate (M1/70-GA). As shown in figure 4.18, mice that had been treated 
with M1/70-GA were not protected from EAE. Consistent with earlier findings (see 
figure 3.16), an equal molar amount of GA that corresponded to the molarity of the 
conjugate (1.2 µg) also failed to ameliorate EAE. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Targeting GA to CD11b does not suppress EAE.  
C57BL/6J mice were left untreated (EAE), or treated with 20 µg M1/70-GA, or with 
1.2 µg GA (GA(e.m)) following the co-immunisation protocol. Mice were co-immunised 
with 500 µg GA as a positive control. (p > 0.05 for EAE vs. M1/70-GA, p > 0.05 for 
EAE vs. GA (e.m), p < 0.001 for GA vs. GA (e.m) and for GA vs. M1/70-GA; 
mean ± SEM of n = 5 mice per group). Data represents one out of two independent 
experiments. 
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4.2.7 Summary 
Fluorophor-labelled GA bound to a heterogeneous population of monocytes in the 
blood of mice after intravenous injection. The binding was independent of MHCII 
expression by the monocytes, and suggested that GA treatment may primarily target 
monocytes in vivo. GA binding to monocytes also altered monocyte function, since 
intravenous GA treatment enhanced the intrinsic ability of the monocytes to suppress 
polyclonal T cell proliferation in vitro in an antigen non-specific manner.  
MOG35-55 specific T cell proliferation was also reduced in vivo after intravenous 
GA treatment. However, MOG35-55 specific CD4 T cell proliferation was not impaired in 
subcutaneous GA treatment of EAE, suggesting that direct suppression of MOG35-55 
specific T cells by monocytes did not contribute to GA therapy in the co-immunisation 
treatment model.  
Monocytes are known to play an important protective role in GA therapy of EAE 
in mice (80). It was shown in this chapter that temporary depletion of monocytes did not 
impair efficiency of GA treatment, which may have been due to the temporary nature of 
depletion. Alternatively, other cell types such as DCs may be able to initiate protective 
responses in a similar way to monocytes and to compensate for the loss of monocytes. 
Targeting GA to monocytes using a monoclonal antibody specific for CD11b was 
ineffective in suppressing EAE. This may have been due to the use of an inadequate dose 
of the conjugate or its sequestration by other CD11bhi cells such as neutrophils. 
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4.3 Discussion 
 Modulation of innate immune cell function is considered to be an important 
feature of GA treatment in EAE and MS (86). GA-modulated innate cells can act as 
APCs and induce anti-inflammatory or regulatory T cell responses (80). However, the 
mechanism by which GA alters APCs phenotype remains unknown. GA has been shown 
to directly bind to MHCII in vitro (87), but there is currently no experimental evidence 
supporting that this binding to MHCII is responsible for changes in APC function. In 
addition, it is unclear whether GA preferentially acts on a particular subset of APCs or 
can modulate multiple APC subsets in a redundant manner. Finally, T cell independent 
mechanisms of immunosuppression by GA-modulated innate cells may also contribute to 
the inhibition of autoimmunity. 
4.3.1 GA Binding to Blood Monocytes in vivo 
Fluorophor labelled GA bound to a CD11bhi cell population in blood and spleen 
after intravenous injection. The cell surface phenotype of these cells suggests that they 
are a heterogeneous population of monocytes and monocyte-derived cells (126). Some of 
the GA binding cells expressed CD11c or MHCII, suggesting that they may be 
monocytes in an intermediate state of differentiation into DCs (126). Alternatively, the 
CD11c+ cells may be resident monocytes, which have also been shown to express CD11c 
(131). In support of a resident monocyte phenotype, CD11c and MHCII mostly did not 
co-localise on the same GA+ cells, and CD11c+ resident monocytes have been shown to 
lack MHCII expression (131). 
Binding of fluorophor-labelled GA to CD11b expressing cells in vitro could not 
be detected (see figure 4.3). GA-Alexa488 was used at a concentration of 10 µM 
(100 µg/ml) in the in vitro binding assays. With the assumption that mice have a total of 
at least one millilitre blood, the concentration of GA-Alexa488 in the bloodstream was 
50 µg/ml after intravenous injection of 50 µg GA-Alexa488. Hence, the lack of in vitro 
binding to monocytes was not due to a lower concentration of GA compared to the in 
vivo binding assays.  
GA did not bind to MHCII expressing cells in vitro, either (see A1.4), in contrast 
to earlier findings (87, 88). The conflicting results may be attributable to the difference in 
antigen concentrations used in the two studies. Fridkis-Hareli et al. used GA at a 
concentration of 750 µM (87), which is much higher than the 10 µM that was used in this 
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study. Sequestration of labelled GA by other cells was not responsible for the failure to 
detect GA staining of MHCII+ cells in this study, because the percentage of total cells 
that showed GA staining was very low (see figure 4.3 and A1.4). However, in vitro 
binding to MHCII itself may require high abundance of GA.  
Incubation of cells with low dose GA better represents in vivo exposure of 
immune cells to the drug, because GA is quickly degraded by extracellular proteases after 
injection (62). Moreover, GA is administered in an adjuvant-containing emulsion in most 
murine models (107), so that it is slowly released in small amounts at a time. Hence it is 
not clear whether the in vitro binding to MHCII observed by Fridkis-Hareli et al. at high 
abundance (87) has functional relevance towards GA treatment in vivo. 
The majority of GA+ monocytes in the blood did not express MHCII, and GA also 
bound to monocytes in MHCII deficient mice (see figure 4.5), thus formally excluding 
participation of MHCII molecules in the binding of GA to monocytes. This finding is in 
further support of a recent study that reported an MHCII independent modification of 
monocyte function during GA treatment (80).  
The lack of in vitro binding of GA to monocytes indicates that in vivo staining of 
blood monocytes may be dependent on the presence of an as yet unidentified soluble 
factor in the blood. This soluble factor may be a component of the complement system. 
For example, GA can bind to mononuclear cells via αMβ2 integrin (Mac-1, 
CD11b/CD18), and αMβ2 integrin can act as a complement receptor (145). αMβ2 integrin 
is expressed by blood monocytes and may be the target of GA on the surface of the 
monocytes. However, other soluble factors may also be responsible for GA binding to 
monocytes.  
In addition to GA, DM SMEZ2 and trypsinogen also bound to blood monocytes 
after intravenous injection. DM SMEZ2 is taken up into intracellular compartments by 
blood monocytes (C. Slaney, unpublished data). Biotinylated GA could not be detected 
on the surface of the monocytes (see figure 4.2), suggesting that GA, too, may be 
internalised after binding to monocytes.  
The mechanism by which GA associates with blood monocytes requires further 
study. Investigation of the precise mechanism was beyond the scope of this study and 
was not addressed further. 
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4.3.2 Does GA Treatment Affect Monocytes in the Draining Lymph Node? 
In the co-immunisation treatment model, GA may act on blood-derived 
monocytes that infiltrate the site of immunisation. However, the site of immunisation 
(subcutaneous at the hind limb flanks) was not accessible to cell recovery techniques 
used in this study. Hence, analysis was limited to cells that infiltrate the local draining 
(inguinal) lymph nodes. 
In the draining lymph nodes, GA-FITC staining could not be detected on any cells 
after immunisation with the labelled drug. Staining may have been below detection level, 
due to dispersion, degradation or slow leakage of GA-FITC from the emulsion. 
Alternatively, the soluble factor that presumably mediates binding to monocytes in the 
blood may be absent from the lymph nodes. Finally, cells in the lymph node may be 
unable to bind GA and cells that may bind GA at the site of immunisation may not 
subsequently home to the draining lymph node, or loose staining during migration (see 
figure 4.6). In support of the latter possibility, the percentage of overall CD11bhi 
monocytes remained unchanged in the draining lymph nodes following immunisation 
(see figure 4.11).  
Monocyte populations in spleens and the blood also remained constant after 
immunisation. In contrast, accumulation of CD11bhi Ly6G+ granulocytes was observed in 
the spleens and the blood of immunised mice (see figure 4.12). This observation in part 
contradicts previous findings of Zhu et al. (133), who observed accumulation of both 
CD11bhi Ly6G+ granulocytes and CD11bhi Ly6G- Ly6Chi inflammatory monocytes in 
spleens of CFA immunised BALB/c mice. In the study by Zhu et al., the percentage of 
monocytes was low (< 0.5%) in naïve spleens (133), and considerably more monocytes 
were present in naïve spleens of C57BL/6J mice used in this study (> 2%). Significant 
monocyte accumulation may not have been observed in the present study because of the 
more pronounced presence of monocytes in the naïve tissues. Alternatively, enrichment 
of monocytes may have been masked by the concomitant strong granulocyte 
accumulation.  
The lack of monocyte infiltration into the draining lymph nodes after 
immunisation with CFA is consistent with findings of Zhu et al. (133). Escape of 
monocyte infiltration from detection due to phenotypic transformation is an unlikely 
possibility, because monocytes usually retain expression of CD11b during heir 
differentiation into macrophages or DCs (126, 146). In addition, adoptively transferred 
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monocytes could not be detected in the draining lymph nodes of immunised congenic 
recipients (see figure 4.13). However, the failure to detect transferred cells may have 
been due to a general loss of these cells, as CD45.2+ cells could not be recovered from 
the blood of the recipients, either.  
The importance of draining lymph nodes as sites of monocyte-mediated 
protection in GA treatment remains unclear. Although GA-reactive T cells are present in 
the draining lymph nodes after immunisation with GA (see figure 3.15), these T cells 
may become activated by APCs other than monocytes, such as conventional DCs, which 
do not express CD11b (126). Alternatively, monocytes may act at other sites such as in 
peripheral tissue or the spleen to contribute to suppression of autoreactivity (80). 
4.3.3 T Cell Suppression by GA-Modulated Monocytes 
Naïve blood monocytes have an intrinsic ability to suppress polyclonal as well as 
antigen specific T cell proliferation in vitro (see figures 4.7 and 4.8). These monocytes 
can be classified as MDSCs, because they are of myeloid origin, have an immature 
phenotype and the ability to suppress T cell proliferation (135). However, it is a common 
perception that MDSCs are induced by non-host derived factors, such as tumours, 
allografts or infectious agents (138-140). As T cell suppressive ability is an intrinsic 
feature of the monocytes investigated in this study, they are referred to as suppressive 
monocytes to differentiate them from elicited MDSCs. 
GA+ suppressive monocytes are a heterogeneous population of mononuclear 
CD11bhi F4/80lo cells (see figure 4.4). Various phenotypes of mononuclear MDSCs have 
been described do date, including phenotypes of inflammatory monocytes, DCs and 
macrophages (133, 140). Hence it is not clear which subpopulation of GA+ monocytes 
exhibits T cell suppressive activity. It is also possible that two or more subpopulations act 
in concert to achieve T cell suppression.  
GA treated monocytes were superior to naïve monocytes in suppressing 
polyclonal T cell proliferation, but no differences were observed in the suppression of 
antigen specific proliferation in vitro (see figures 4.7 and 4.8). The lack of difference in 
the ability of naïve and GA-treated monocytes may have been due to limitations of the 
available assays for the detection of suppression.  
Measurement of [3H]-thymidine incorporation and measurement of CFSE dilution 
are both established methods for the assessment of T cell proliferation (147). However, 
both methods have their limitations, and one method may be preferable over the other 
CHAPTER 4: TARGETING GA TO MONOCYTES 
 112 
depending on the experimental settings (148). Polyclonal stimulation of splenocytes 
results in a robust proliferative response that can be measured by [3H]-thymidine 
incorporation even at low cell numbers (see figure 4.7). In contrast, in vitro antigen 
specific proliferation is less pronounced, and suppression of antigen specific proliferation 
by [3H]-thymidine uptake at low cell numbers can be problematic (148). The procedure 
of monocyte enrichment was accompanied by low yield in cell numbers (2 x 105 – 
5 x 105 cells from total blood of five mice), although it consistently produced good purity 
of mononuclear CD11bhi cells (> 80% pure). Due to the low cell numbers, suppression of 
antigen specific proliferation could not be comprehensively measured by [3H]-thymidine 
incorporation.  
Measurement of CFSE dilution in responder populations is a more adequate 
method for studying proliferation at low cell numbers, due to the higher sensitivity of 
flow cytometric analysis (148). However, detecting subtle differences between two 
suppressive cell populations by measuring CFSE dilution in responder cells can be 
difficult. This is particularly the case when the duration of suppression is of interest, 
because of the prolonged time span of the assay. In contrast, [3H]-thymidine uptake that 
is restricted to a defined time span that can be freely chosen (147). Hence, the failure to 
detect increased suppression by GA treated monocytes as compared to naïve monocytes 
may have been due to limitations of the assays. Hence, it cannot be conclusively resolved 
whether GA treatment affects the ability of monocytes to suppress antigen specific T cell 
proliferation in vitro.  
 Reduced in vivo proliferation of MOG35-55 specific T cells after intravenous GA 
treatment (see figure 4.9) indicates that differences between GA treated and naïve 
monocytes may indeed have escaped detection in the antigen specific in vitro assay. 
However, there is no direct evidence that reduced in vivo proliferation in GA treated mice 
is attributable to suppressive monocytes. Demonstrating recovery of T cell proliferation 
upon depletion of monocytes would provide direct evidence for in vivo suppressive 
function of monocytes. However, depletion of monocytes using Cl2MDP loaded 
liposomes (144) interferes with T cell proliferation and therefore cannot be used for the in 
vivo suppression assay (C. Slaney, unpublished data). Hence, currently there is only an 
indirect correlation between the binding of GA to monocytes after intravenous injection 
and reduced MOG35-55 specific T cell proliferation after intravenous GA treatment. 
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 Reduced proliferation of T cells was associated with GA treatment both in vitro 
and in vivo, but impaired proliferation of MOG35-55 specific CD4 T cells was not 
observed in GA treatment of EAE (see figure 4.15). These findings suggest that direct 
suppression of CD4 T cells may not be a central mechanism that contributes to EAE 
suppression in the co-immunisation GA treatment model. However, suppression of 
MOG35-55 specific T cells may have escaped detection in this setting, due to immune 
manipulations in the EAE model (38). 
 EAE induction requires injection of CFA, which delivers a strong pro-
inflammatory stimulus to the immune system (38). CFA promotes the induction of robust 
inflammatory T cell responses that may have overcome antigen non-specific suppression 
that can potentially be exerted by GA modulated monocytes. Since CFA is not present in 
MS patients during GA treatment, it remains possible that the antigen non-specific 
suppression of T cells observed in this study contributes to GA therapy in MS. 
4.3.4 Targeting GA to Monocytes in EAE Treatment 
Regardless of whether or not they can directly suppress T cells, monocytes are 
key players in GA treatment of EAE. Monocytes initiate both anti-inflammatory and 
regulatory T cell responses upon GA treatment of the murine disease (80). As such 
monocytes represent a useful target for GA treatment of EAE and therefore of MS.  
The cell surface molecule chosen for targeting GA to monocytes was CD11b. 
Expression of this marker is not limited to GA+ cells in the blood, but all GA+ cells 
express CD11b at high levels (see figure 4.4). Moreover, drugs can be targeted efficiently 
to Cd11bhi macrophages by conjugating them to a monoclonal antibody to CD11b (149), 
and antigen targeting to CD11b results in the efficient delivery of the antigens into the 
MHCII antigen presentation pathway (150). Hence targeting GA to CD11b was 
hypothesised to promote GA-specific T cell responses by enhancing its uptake and 
MHCII-restricted presentation.  
M1/70-GA failed to ameliorate EAE in the co-immunisation treatment model. As 
the conjugate was administered at an approximately 500-fold less molar amount than the 
therapeutic dose of free GA, the dose may have been too low to suppress EAE. In 
addition, expression of CD11b by other cell types like neutrophils (133) may have 
resulted in the sequestration of M1/70-GA, further reducing the amount of GA that is 
effectively delivered to monocytes. Alternatively, GA may have been efficiently 
delivered to monocytes, but failed to induce their differentiation towards an 
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immunosuppressive or anti-inflammatory phenotype, which is required for protective 
immunity (80, 132). The latter scenario is supported by previous findings, which showed 
that immune responses to antigens targeted to CD11b expressing cells are biased towards 
TH1, producing high amounts of IFN-γ, but no IL-4 or IL-10 (150). Hence, targeting GA 
to CD11b may skew the resulting immune response in a way that is not favourable for 
treatment.  
To test the dependency of GA therapy on monocytes in EAE, monocyte-depleted 
mice were treated with GA. The treatment was as efficacious as in mice that had not 
received monocyte-depleting treatment. Monocyte depletion by Cl2MDP-liposomes is 
only temporary, and the cells are replenished by myeloid progenitors in the bone marrow 
within three to four days following liposome administration (131). Although monocytes 
were only depleted in the early phase after co-immunisation, this phase is considered to 
be of great importance for the initiation of pathogenic as well as protective T cell 
responses in EAE (see figure 4.14 and ref. (80)). Hence, GA therapy does not depend on 
the presence of monocytes in this early phase of the disease.  
It is possible that a delayed response to GA by monocytes after their 
replenishment from bone marrow progenitors following Cl2MDP depletion is sufficient 
for protection from EAE. Monocytes are involved in pathogenic events such as 
destruction of CNS tissue during later stages of EAE (124); hence longer-term depletion 
of monocytes by multiple injections of Cl2MDP liposomes results in partial resistance to 
EAE (52). In addition, Cl2MDP liposomes have been shown to partially deplete other cell 
types in the blood (131), as well as phagocytic cells in other tissues (151, 152). As a 
consequence, long-term depletion of monocytes is not a suitable approach to investigate 
the dependence of GA treatment on monocytes.  
4.3.5 The Role of Trypsinogen and DM SMEZ2 
 Trypsinogen and DM SMEZ2 stained a similar cell type in the blood as GA, 
albeit with different intensity (see figure 4.1). The different intensity may in part be due 
to the different efficacy of their labelling with the fluorophor. Alexa488 is reactive to 
primary amines, and can therefore label GA more brightly, due to the high abundance of 
lysine residues in the copolymer (62). Furthermore, higher molar amounts of GA 
(7-10 kDa in average) than trypsinogen (25 kDa) and DM SMEZ2 (24 kDa) were injected 
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into the mice, which could also contribute to the brighter staining of monocytes from 
mice injected with GA. 
Trypsinogen was found to suppress EAE at a dose of 500 µg by co-immunisation 
treatment (see A1.6). In spite of being an inactive precursor of trypsin in theory, 
trypsinogen2 can have up to 10% of the enzymatic activity of trypsin3 supplied by the 
same manufacturer. Furthermore, trypsinogen solutions are only stable in a range of 
pH 2-4, and autocatalytic activation to trypsin occurs in neutral buffers4. As a 
consequence, protection from EAE upon co-immunisation with trypsinogen may be due 
to degradation of the disease causing peptide, rather than having an effect on monocytes. 
A conjugate of DM SMEZ2 and MOG35-55 is able to ameliorate EAE at a dose as 
low as 2 µg when administered in Incomplete Freund’s Adjuvant (C. Slaney, unpublished 
data). Treatment with this DM SMEZ2-MOG35-55 conjugate may target the peptide to 
monocytes, rendering them able to induce antigen-specific anergy or activation and/or 
expansion of T-regs. Unconjugated DM SMEZ2 was not available in sufficient quantities 
to evaluate its capacity to suppress EAE at a comparable dose to GA. The functional 
relevance of the binding of these three compounds to blood monocytes for the 
suppression of EAE therefore remains unclear.  
4.3.6 Conclusions 
The findings presented in this chapter showed that GA could bind to murine 
monocytes in vivo, indicating that monocytes may be its primary targets in therapy. 
Intravenous GA treatment enhanced the intrinsic ability of monocytes to suppress T cell 
proliferation, suggesting that suppression of myelin-specific T cells by GA modulated 
monocytes may contribute to the efficiency of GA therapy. As discussed in section 4.3.3, 
the current EAE model has inherent inadequacies of an experimental model in mimicking 
immunopathogenesis of the human disease; hence direct suppression of T cells may 
contribute to GA therapy in MS, although impaired T cell proliferation was not detected 
in EAE in this study. 
Monocytes are key players in EAE suppression by GA, and possible in vivo 
targets of the drug during treatment. However, targeting GA to monocytes did not 
                                                
2 http://www.sigmaaldrich.com/catalog/search/SpecificationSheetPage/SIGMA/T1143 
3 http://www.sigmaaldrich.com/catalog/search/SpecificationSheetPage/SIAL/T1426 
4 http://www.sigmaaldrich.com/sigma/product%20information%20sheet/T1143pis.pdf 
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suppress EAE at low dose. Disease amelioration at higher doses of conjugate remains 
possible, but the likely scenario is that targeted GA failed to induce the phenotype shift in 
monocytes that renders them able to prime anti-inflammatory or regulatory T cell 
responses. Conjugating GA to antibodies may result in a loss of its immunomodulatory 
properties. 
A crucial dependence of GA treatment on monocytes could not be conclusively 
demonstrated in this study. Depletion of monocytes with Cl2MDP liposomes may not be 
a suitable approach to investigate the possible dependence of GA on monocytes, as 
discussed in section 4.3.4. Alternatively, GA may also be able to induce anti-
inflammatory/tolerogenic DCs or type II activated macrophages that can compensate for 
the absence of monocytes. GA, trypsinogen and DM SMEZ2 all bound to blood 
monocytes after intravenous injections. A correlation between binding to blood 
monocytes of these three compounds and their ability to suppress EAE in different 
settings is possible, but remains speculative based on the current findings. 
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5.1 Summary 
GA is currently in use for the treatment of RRMS and can suppress EAE. The 
primary in vivo target of GA are considered to be innate cells, which act as APCs and 
expand Foxp3+ T-regs or induce immune deviation by stimulating TH2 responses (80). 
GA-modulated innate cells may also suppress auto-reactive T cells directly in an antigen 
non-specific manner (83). However, it is not known which type of innate cell GA 
preferentially acts on. The objectives of this work were to identify the in vivo target cells 
of GA, and to investigate direct effects of GA on its target cells. In addition, the potential 
of high-affinity targeting GA directly to cell surface molecules on its target cells to 
improve EAE treatment was assessed.  
Upon intravenous injection, fluorophor-labelled GA was found to bind to blood 
monocytes independently of their MHCII expression. Intravenous GA treatment 
enhanced the intrinsic ability of the monocytes to suppress T cell proliferation in vitro. 
Proliferation of myelin specific CD4 T cells was also reduced in vivo following 
intravenous GA treatment. However, GA treatment did not reduce T cell proliferation in 
EAE. 
Direct binding of GA to a distinct cell population in vivo is reported for the first 
time in this study. The identification of monocytes as the probable in vivo target of GA is 
of great value, because it suggests that focusing on monocytes may pave the way for 
improved GA therapy or the development of alternative immunotherapies for MS. In 
addition, it is shown for the first time within this study that direct suppression of myelin-
specific T cells by GA modulated monocytes may be part of the mechanism by which 
GA inhibits autoimmune responses in EAE and MS. 
Targeting GA to monocytes with an anti-CD11b antibody or to the sum of APCs 
with an anti-MHCII antibody did not ameliorate EAE. MCHII targeted GA failed to 
suppress EAE in spite of substantially enhanced in vitro T cell proliferation in response to 
MCHII targeted antigens, suggesting that enhanced proliferation of GA specific T cells 
alone is not sufficient for protection from EAE. As a conjugate GA may fail to alter 
monocyte function, and conjugate-treated monocytes/APCs may thus not be able to 
exhibit immunosuppression or to prime regulatory/suppressive T cell responses.  
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5.2 Antigen Targeting Strategies in Disease Treatment 
Professional APCs can present antigen on MHCII or MHCI molecules to induce 
CD4 or CD8 T cell responses, respectively (6). Among the APCs, DCs are the most 
potent inducers of CD4 and CD8 T cell responses, owing to the high expression of cell 
surface receptors and co-stimulatory molecules involved in these processes. DCs also 
have the greatest capacity for cross-presentation, but other subsets of APCs are also 
capable of directing extracellular antigens into the cross-presentation pathway (6). 
Antigen and drug targeting by the use of monoclonal antibodies has become a 
critical part of the treatment of cancer and infectious diseases as well as vaccine 
development (99). These strategies are based on the ability of the antibodies to 
specifically bind to the biological target of choice in the patient or the experimental host. 
Targets are usually pathogens, malignant cells in tumours or APCs for vaccinations (99). 
Even though APCs possess mechanisms of internalising and processing antigens for their 
subsequent presentation, this process can be made by far more efficient by targeting 
antigens directly to cell surface molecules of these cells (99). 
5.2.1 MHCII as an Antigen Target 
Cell surface molecules on APCs that have been used for targeting antigens 
include MHCII (120), the C-type lectin receptors DEC205 (153) and the mannose 
receptor CD206 (99); Fcγ receptors (154) and complement receptors (155). Antigen 
targeting studies usually aim at the initiation or enhancement of immunity towards the 
targeted antigen. MHCII is a particularly attractive candidate for this purpose, since it is 
regularly internalised and recycled within endocytic compartments (94). In this way, 
MHCII-targeted antigens are directly delivered into the antigen presentation pathway. 
In this study, significantly enhanced CD4 and CD8 T cell responses were 
observed in vitro when antigens were targeted to MHCII (see figures 3.10 and 3.13). The 
use of engineered MHCII specific antibodies that contain CD4 T cell epitopes has been 
reported to result in a similar increase of CD4 T cell proliferation (115). Furthermore, 
enhanced cross-presentation upon antigen targeting to MHCII has also been reported 
(117).  
Cross-presentation of free antigens is strongly biased towards the presentation of 
high-abundance antigens (95). The knowledge that antigens can be efficiently targeted to 
promote cross-presentation should therefore be particularly useful in the design of 
CHAPTER 5: GENERAL DISCUSSION 
 120 
vaccines against intracellular pathogens and tumors where robust CD8 T cell responses to 
low antigen doses are desirable (156). In addition, simultaneous stimulation of CD4 T 
cells has the potential to boost the CTL response and further enhance the potency of the 
targeted vaccines (157). Further investigation of CD8 T cell responses to MHCII targeted 
antigens was beyond the scope of this study, but M5/114-OVA is currently being tested 
as an anti-tumour vaccine in a murine melanoma model (E. Spittle, unpublished data). 
5.2.2 Does Targeting GA to Cell Surface Molecules Have Therapeutic Potential? 
GA specific anti-inflammatory CD4 T cells are present in treated mice and MS 
patients (80, 158), and GA has been shown to bind to MHCII molecules in vitro (87). 
Hence MHCII molecules on the surface of APCs are generally considered to be the 
primary target of GA. In addition, GA treatment did not suppress EAE in MOG35-55 TCR 
transgenic mice in this study (see figure 3.8), suggesting that expansion of GA specific 
CD4 T cells may be of crucial importance for treatment. Therefore MHCII was an 
attractive cell surface molecule for specific targeting of GA into the antigen presentation 
pathway, in order to achieve a reduction of the therapeutic dose. 
Targeting antigens to MHCII in absence of adjuvant results in increased uptake 
and presentation of antigen and the initiation of robust humoral immunity to a secondary 
challenge with the same antigen (155). This response depends on CD4 T cell help, 
suggesting the preferential induction of TH2 responses by the targeted antigen, that can 
subsequently promote humoral immunity (119). However, CFA is a strong pro-
inflammatory adjuvant (38), and its presence may substantially influence the nature of 
immune responses. Free GA can suppress EAE despite the TH1 promoting effects of CFA 
(see figure 3.3), but the M5/114-GA conjugate may be incapable of acting against the 
pro-inflammatory effects of the adjuvant. Alternatively, MHCII targeted GA may be 
sequestered by MHCIIhi cells that are irrelevant to disease suppression, thus making GA 
unavailable to its real targets. 
It is not known if GA preferentially acts on a particular type of MHCII+ cell in 
vivo. In addition, recent findings have demonstrated the induction of type II monocytes 
by GA in an MHCII independent manner (80). Hence, although MHCII-restricted 
presentation of GA epitopes is recognised to be important for the activation of anti-
inflammatory or regulatory T cells, the role of MHCII during the preceding modulation 
of APCs is rather questionable (86). The results of this study support this view, as it was 
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found that the majority of GA+ monocytes in the blood did not express MHCII (see figure 
4.4), and GA staining occurred in an MHCII independent manner (see figure 4.5). 
The in vivo binding assays suggest that monocytes may be the preferred target of 
GA (see figure 4.1). However, targeting GA to CD11b+ cells did not ameliorate EAE at 
low dose (see figure 4.18). Inadequate dosage or sequestration of the targeted drug by 
irrelevant cells (such as neutrophils that also express CD11b) are possible explanations 
for the failure of M1/70-GA to suppress EAE. However, the most likely scenario is that 
as a conjugate, M1/70-GA failed to exhibit immunomodulation on its target cells. 
Targeting antigens to CD11b can enhance proliferative responses (150), but increased 
antigen presentation alone is not sufficient for protection from EAE in absence of APC-
derived anti-inflammatory mediators (80). In addition, targeting antigens to CD11b 
results in a TH1 biased immune response (150), which may further counteract the 
suppressive potential of GA. 
CD11b and MHCII are two candidate cell surface molecules that were evaluated 
as targets for GA in this study, but amelioration of EAE was not observed using either of 
these target molecules (see figures 3.16 and 4.18). The most plausible explanation for the 
failure of GA targeting is that when conjugated, the immunomodulatory effect of GA on 
its target cells is lost. However, these findings do not imply that further attempts to target 
GA should be abandoned, but rather suggest that the choice of the cell surface target 
molecule is of crucial importance to elicit the appropriate immune response.  
The type of immune response that is initiated by targeted antigens greatly depends 
on the choice of the cell surface target (99). For example, targeting antigens to CD206 
results in MHCI-restricted antigen presentation and potent CD8 T cell mediated 
immunity (99). In contrast, targeting antigens to DEC205, a related cell surface receptor, 
results in antigen specific hyporesponsiveness of both CD8 and CD4 T cells (153, 159). 
The different outcomes for targeting CD206 and DEC205 are likely due to differential 
localisation of the two receptors after their internalisation (99). This example illustrates 
how subtle functional differences between cell surface targets can influence the immune 
response to the targeted antigen. 
Anti-inflammatory TH2 responses can be induced by targeting OVA protein to 
FcγRs (154). Immune complexes comprised of OVA and OVA-specific antibodies are 
taken up by macrophages through FcγRs. The macrophages then present OVA-derived 
peptides to CD4 T cells, which are by this way stimulated to produce IL-4 and IL-10, but 
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only low amounts of IFN-γ and IL-12 (154). The TH2 biased response is observed even 
when macrophages are pre-activated with IFN-γ prior to their exposure to the immune 
complexes. In contrast, T cells that are activated by macrophages exposed to free OVA 
produce high amounts of IFN-γ and IL-12, but low amounts of IL-4 (154).  
Targeting antigens to FcγRs using anti-FcγR-antigen conjugates may be as 
efficient in biasing T cell differentiation as the use of immune complexes. The above 
mentioned immune complexes consist of OVA protein opsonised by a 10-fold molar 
excess of Ig (154). These immune complexes may cross-link FcγRs, and cross-linking 
may also occur with antigens that are chemically conjugated to a specific antibody, as the 
reaction conditions during conjugation can be modified in favour of high molecular 
weight complexes that contain several antibody molecules interconnected by proteins or 
copolymers (see section 3.2.2.1 and figure 3.9). 
It is not known whether GA is taken up by APCs through an active or passive 
mechanism. Experimental evidence on any cell surface molecules that are possibly 
involved in this process is currently lacking as well (86). The mechanism by which GA 
induces differentiation of anti-inflammatory/type II APCs also remains to be unveiled. A 
better understanding of this process is necessary to ensure the appropriate choice of cell 
surface molecules in further approaches of targeting. The choice of a cell surface 
molecule that can be functionally involved in acquisition of the desired anti-inflammatory 
APC phenotype may prove efficient in suppression of self-reactive T cell responses, and 
hence be a plausible strategy to make GA therapy more efficient. 
 
5.3 Glatiramer Acetate: Update on Mechanism of Action 
5.3.1 How Important is Direct Binding to MHCII? 
The view that GA acts as an altered peptide ligand by blocking MHCII molecules 
and TCR antagonism to myelin-derived peptides (62, 89) has predominated for a long 
time. In addition, MHCII restricted presentation of GA epitopes to CD4 T cells and 
induction of anti-inflammatory T cells is considered to be an important part of GA 
therapy (63). However, recent findings have demonstrated that during GA treatment, 
monocytes acquire an anti-inflammatory type II phenotype independently of MHCII 
expression (80), suggesting that GA can modulate APCs in an MHCII independent 
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manner. The findings presented in this study provide additional evidence of MHCII 
independent effects of GA on monocytes. 
 Binding of fluorophor-labelled GA to MHCII expressing cells was not observed 
in vitro, and binding to monocytes was independent of MHCII in vivo (see figures 4.1 
and 4.3). While the lack of in vitro binding contradicts earlier findings (87) and may be 
attributable to differences in the experimental settings, in vivo binding of GA to any cell 
type or cell surface molecule has not been reported. It should be noted that, in vivo 
binding assays were performed by intravenous injection of fluorophor-labelled GA, and 
intravenous treatment failed to suppress EAE. However, intravenous binding assays 
better represent clinical GA therapy than in vitro binding assays using purified cell 
populations and high concentration of GA (87, 88). Hence, the results presented here 
further challenge the hypothesis that direct binding of GA to MHCII and TCR 
antagonism to myelin antigens is an important part of the mechanism of GA. 
5.3.2 Divergent T cell Mediated Mechanisms of Suppression 
Induction of TH2 cells after GA treatment is well-established in EAE and MS (68-
70). However, GA can efficiently suppress EAE in mouse strains that lack the key TH2 
cytokines IL-4 and IL-10 (81). This finding shows that, even though GA-induced TH2 
cells can counteract pathogenic cells (68, 74), this process is not essential for EAE 
suppression.  
GA can also induce Foxp3+ T-regs that contribute to suppression of EAE (77) and 
MS (79). Systemic depletion of CD25+ cells by administration of a monoclonal antibody 
(clone PC61) before EAE induction resulted in substantial loss of protection by GA (see 
A1.7). However the loss of protection was not absolute, since GA-treated mice lacking 
CD25+ cells developed less severe disease than untreated mice lacking the same cells, in 
agreement with a recent report (82). Thus the loss of Foxp3+ T-regs does not completely 
abrogate EAE suppression by GA.  
GA induces both IL-4 producing TH2 cells and Foxp3+ T-regs in mice, and these 
two populations do not overlap (80). Induction of these two T cell populations has also 
been independently observed in GA treated MS patients (69, 160). Hence, GA induced 
TH2 and T-regs may act in an additive manner, but independently of each other to control 
or suppress pathogenic T cells. Furthermore, T-regs may have the ability to compensate 
for the loss of the TH2 effector arm, whereas in the opposite scenario, TH2 cells seem to 
be less capable of compensating for the loss of T-regs (81, 82). 
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5.3.3 Possible Contribution of Multiple APC Subsets to GA Therapy 
Despite the prominent T cell mediated protective effects that are associated with 
treatment, GA does not affect T cells directly (84). The primary targets of the drug are 
considered to be cells of the innate immune system that can act as APCs (86). GA can act 
on a range of cells with the potential to present antigen to CD4 T cells in vitro, including 
DCs (85, 161), monocytes (162, 163), macrophages (125) and microglia (84).  
The significance of each individual APC subset remains poorly established in 
vivo. GA can act through monocytes to suppress EAE (80), and modulation of monocytes 
in GA treated MS patients has also been observed (84). However, in this study GA was 
found to be as efficient in suppressing EAE when monocytes were temporarily depleted 
(see figure 4.16). Because monocytes are replenished within three to four days by the 
bone marrow after their depletion (131), it is possible that a delayed monocyte-mediated 
response following reconstitution of blood monocytes is sufficient for EAE suppression.  
Alternatively, GA may be able to act on multiple subsets of innate cells that have 
the capacity of antigen presentation, such as monocytes, DCs and macrophages. 
Moreover, some types of APCs may be able to compensate for the loss or malfunction of 
others. For example, GA modulated DCs may induce protective T cell responses in the 
absence of monocytes. Consistent with this scenario, some of the CD11bhi cells that bind 
GA in the blood also expressed CD11c (see figure 4.4), suggesting that they could be 
monocyte-derived DC precursors (126). Hence it is possible that GA can also bind to and 
act through DCs. The absence of mature DCs from the blood provides a possible 
explanation for the lack of GA staining of cells that show the cell surface phenotype of 
CD11chi MHCIIhi DCs. Further studies are required to establish the significance of each 
particular APC subset in the treatment of EAE and MS.  
5.3.4 Possible Role for Suppressive Monocytes in GA Treatment 
Monocytes and macrophages are generally associated with pathogenic events 
such as the breakdown of the BBB and destruction of CNS tissue in EAE and MS (52). 
However, GA can alter these cells in vitro and in vivo, rendering them capable of 
inducing protective T cell responses (80, 125).  
Recent findings have raised the possibility that T cell independent mechanisms 
may contribute to GA’s therapeutic effect in EAE (114). Furthermore, CFA-induced 
accumulation of monocytes that inhibit T cell proliferation through the production of NO 
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has been observed in EAE (131, 133). The results presented here show for the first time 
that GA treatment can induce antigen non-specific suppression of T cell proliferation 
through modulation of monocytes (see figure 4.7). Hence, CFA and GA can induce 
suppressive monocytes independently of each other. Similar to CFA-induced monocytes, 
GA-induced monocytes may also suppress T cells through the production of NO.  
GA treatment has been shown to induce type II monocytes (80), and NO 
production is one of the characteristics of type II activation (132). Hence NO is a possible 
mediator of GA-induced T cell suppression by monocytes. However, the role of NO in 
autoimmune disorders is complex. Mice that lack iNOS develop more severe EAE than 
their wild-type counterparts (45). In contrast, treatment of mice with a selective inhibitor 
of iNOS ameliorates EAE (164), suggesting that NO plays multiple roles in the 
development and prevention of CNS autoimmunity. 
 High levels of NO produced by infiltrating macrophages are associated with 
tissue damage in the CNS and the breakdown of the BBB (52). In contrast, NO 
production in the periphery is associated with immunosuppressive effects such as 
induction of lymphocyte apoptosis (136). In addition, splenocytes from iNOS deficient 
mice show increased ex vivo proliferation in response to MOG35-55, with a negative 
correlation between NO levels and T cell proliferation in these ex vivo cultures (45).  
GA has been observed to promote lymphocyte apoptosis in MS patients (113), 
implicating a possible role for suppressive monocytes in controlling T cell proliferation in 
the periphery. Although GA treatment correlates with an overall reduction of total free 
radicals in MS patients (165), the specific effect on individual free radical species, and 
NO in particular, is unknown. Hence, the mechanism of enhanced T cell suppression may 
involve a GA-induced enhancement of NO production by monocytes. 
Antigen non-specific T cell suppression by monocytes may contribute to GA 
therapy, but the significance of this suppression remains to be established in EAE 
models. In the co-immunisation model, suppression may have been overcome or masked 
by the presence of a strong inflammatory adjuvant that promotes T cell proliferation (38). 
In addition, T cell suppression by monocytes in vitro is transient in nature (C. Slaney, 
unpublished data), suggesting that in vivo suppression may also be transitory and 
therefore escaped detection due to sustained T cell proliferation in the EAE model (82). It 
therefore remains possible that T cell suppression can be observed in other EAE models 
or in MS patients who receive daily GA treatment.  
CHAPTER 5: GENERAL DISCUSSION 
 126 
 
 
 
Figure 5.1: Proposed updates on the mechanism of action of GA in EAE. 
1: Pathogenic TH1 responses are initiated by the presentation of myelin-derived peptides 
by activated APCs. 2: The activated TH1 cells infiltrate the CNS, where they can be 
reactivated by myelin peptides presented by local APCs and create an inflammatory 
environment. 3: As a consequence, other inflammatory cell types are recruited to the 
CNS that promote demyelination and axonal damage. 4: GA is taken up by APCs in the 
periphery. It is possible that GA is able to act on multiple subsets of APCs such as 
monocytes, DCs and macrophages. 5: Upon modulation by GA, these APCs can then 
induce the expansion of T-regs, which can suppress proliferation of pathogenic T cells. 
6: The APCs also stimulate TH2 cells that are then able to cross the BBB. 7: The TH2 
cells can be reactivated by co-migrated or local APCs presenting GA-derived peptides. 
The activated TH2 cells counteract TH1 cell-mediated tissue damage by the production of 
anti-inflammatory and neuroprotective factors. 8: In addition, some DCs may have the 
ability to release active GA into the CNS environment, which may have direct protective 
effects on neurons or modulate CNS resident cells. 9: Monocyte or DC-mediated antigen 
non-specific suppression of pathogenic T cells may also occur in the periphery.  
 
In summary, monocytes, possibly along with other types of APCs, can contribute 
to GA treatment in several ways (figure 5.1). Induction of TH2 cells and T-regs by GA-
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modulated monocytes has recently been demonstrated in EAE (80). The results presented 
here suggest that GA-modulated monocytes may also suppress pathogenic T cell 
responses in an antigen non-specific manner. However, the significance of this antigen 
non-specific suppression remains to be established in EAE or GA-treated MS patients.  
 
5.4 Conclusions and Outlook 
GA is a versatile drug that affects the immune system in a plethora of ways. Most 
prominently, GA-modulated APCs are able to expand Foxp3+ T-regs that can suppress 
pathogenic T cells. Moreover, GA can modulate APCs to prime TH2 responses. These 
TH2 responses counteract pro-inflammatory cells in secondary lymphoid organs or in the 
CNS, and diminish local inflammation. However, the mechanism by which GA 
modulates APCs remains unclear. The significance of each particular APC subset also 
remains to be established.  
The results presented here show that GA binds to CD11bhi F4/80lo monocytes and 
enhances the intrinsic capacity of these monocytes to suppress T cell proliferation in an 
antigen non-specific manner. This study shows for the first time that GA can modify 
monocytes to suppress the proliferation of myelin-reactive T cells (figure 5.1; #9). This 
antigen non-specific suppression does not appear to be important in the co-immunisation 
model of EAE treatment, but it is possible that direct suppression of T cells by monocytes 
contributes to GA treatment in other EAE models and MS patients.  
The findings of this study and others also suggest that GA can act through 
multiple divergent mechanisms. GA has the potential to act on different types of APCs, 
which can in turn prime at least two different effector functions of the adaptive immune 
system (TH2 and T-reg). Both of these contribute to suppression self-reactivity and 
disease amelioration, but they can also act independently of each other. 
Further research is necessary to investigate the mechanism by which GA alters 
APC function. Better understanding of the mechanism of APC modulation may reveal 
suitable candidate cell surface molecules for targeting GA. Knowledge of the precise 
mechanism of action of GA, including T cell dependent and independent processes, will 
also pave the way for the development of superior immunomodulatory agents for the 
treatment of MS and other autoimmune disorders. 
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A1.1: GA does not protect 2D2 mice from EAE induced with 25 µg MOG35-55.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EAE was induced in 2D2 mice with 25 µg MOG35-55. Mice were either left untreated 
(EAE) or co-immunised with 500 µg GA. (p > 0.05 for EAE vs. GA; mean ± SEM of n = 
5 mice per group). † indicates that all mice in the corresponding group were euthanised 
due to severe EAE. 
  † 
 
   † 
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A1.2: Optimisation of the Conjugation of GA to Modified SAgs.  
GA was incubated with varying molar ratios of SMCCplus as described in Materials and 
Methods in detail. Excess chemical was removed and activated GA was mixed with the 
reduced SAg in different ratios, and incubated at varying conditions. Efficacy of 
conjugation was assessed by non-reducing SDS-PAGE. Representative SDS gel images 
of “poor”, “fair” and “good” conjugation reactions are shown in A1.3.   
 
Ratio SAg:GA Ratio GA:SMCCplus Incubation Outcome 
1:1 1:2 ON at 4 °C Poor conjugation 
1:1 1:2 1 h at RT Poor conjugation 
1:5 1:2 ON at 4 °C Fair conjugation 
1:5 1:2 1 h at RT Fair conjugation 
1:10 1:2 ON at 4 °C Fair conjugation 
1:20 1:2 ON at 4 °C Fair conjugation 
1:1 1:10 ON at 4° C Poor conjugation 
1:5 1:10 ON at 4° C Fair conjugation 
1:20 1:10 ON at 4° C Poor conjugation 
1:5 1:5 ON at 4 °C Good conjugation 
1:10 1:5 ON at 4 °C Good conjugation 
1:20 1:5 ON at 4 °C Fair conjugation 
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A1.3: Optimisation of the Conjugation Reaction of GA to Modified SAgs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of varying reaction conditions on the efficacy of conjugation of GA to 
modified SAg was evaluated. GA was conjugated to SAg under varying conditions (see 
A1.2), and efficiency of conjugation was assessed by non-reducing SDS-PAGE and 
Coomassie blue staining. SAg was loaded onto the gel alone before (ox) and after (red) 
reduction as control. MWM: molecular weight marker. 
 
Loading controls                  SAg (ox)             SAg (red) 
Efficacy of conjugation                                                        Fair        Good     Good       Fair      Poor 
Ratio SAg:GA                                                                      1:20        1:10        1:5          1:5       1:20 
Ratio GA:SMCCplus                                                            1:5          1:5         1:5         1:10      1:10 
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A1.4: GA does not bind to MHCII expressing cells in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Single cell suspensions were prepared from spleens, inguinal lymph nodes and blood of 
C57BL/6J mice. The cells were incubated in absence (PBS) or presence of 10 µg/ml 
Alexa488 labelled GA or OVA for one hour at 37 °C in a 96-well plate at 5 x 104 cells per 
well. The cells were then stained for cell surface markers and analysed by flow cytometry. 
Data represents one out of two independent experiments with duplicate wells. 
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A1.5: GA+ cells in the blood of MHCII deficient mice show monocyte phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C57BL/6J (WT) or B6Aa0/Aa0 (MHCII-/-) mice received intravenous injections of 50 µg 
GA-Alexa488. Blood cells were recovered one hour after the injections and analysed by flow 
cytometry. CD11bhi cells that showed GA staining (shaded histograms) were F4/80lo and 
Ly6G-. Open histograms represent CD11bhi cells that did not stain for GA (F4/80- Ly6G+ 
granulocytes). Histograms are gated on CD11bhi cells. Data represents one out of two 
independent experiments. 
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A1.6: Co-immunisation treatment with trypsinogen suppresses EAE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EAE was induced in C57BL/6J mice, and the mice were either left untreated or treated by 
co-immunisation with 500 µg trypsinogen or 500 µg OVA. (p <0.001 for EAE vs. 
Trypsinogen, p > 0.05 for EAE vs. OVA; mean ± SEM of n = 5 mice per group). Data 
represents one out of at least two independent experiments. 
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A1.7: Depletion of CD25+ cells diminishes GA treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD25+ cells were depleted in C57BL/6J mice through intraperitoneal injections of 
200 µg anti-CD25 antibody (clone PC61) in PBS three days before EAE induction. Mice 
were treated by co-immunisation with 500 µg GA. (p < 0.05 for EAE vs. PC61 + EAE, 
p < 0.001 for GA vs. PC61 + GA; mean ± SEM of n = 5 mice per group). Data represents 
one out of two independent experiments. 
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